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Abstract 
The ability to image caspase activation provides a powerful tool for the evaluation of the 
oncologic therapeutic response via the apoptotic cascade. Research efforts have focused on the 
development of radiolabelled non-peptidyl caspase inhibitors to be utilised for imaging purposes. 
Isatin sulfonamides are of particular interest because of their specificity and potency for inhibiting 
the “apoptotic executioner” caspase-3. However, imaging attempts using the radiolabelled lead 
isatin i have shown low target-to-background radiotracer uptake.  
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Figure A1: The lead isatin sulfonamide radiotracer  
The research aim was to explore alternative series of caspase-3 inhibitors as radioligands with 
optimal properties for the PET imaging of apoptosis. The series based on the pyrimidoindolone ii, 
triazoleindolone iii and imidazoleindolone iv heterocycles are structurally similar to the isatin core 
heterocycle i, with all containing the crucial ketone responsible for caspase inhibition via the 
formation of a thiohemiketal with an active site cysteine residue.  
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Figure A2: Proposed alternative heterocycles to the isatin scaffold  
Using computational modelling studies combined with UV-vis titrations, these heterocycles 
were shown to have the propensity to favourably form thiohemiketals and therefore potentially 
inhibit caspase-3. Initial target structures v - vii, modelled on the structure of the lead isatin i, were 
subsequently designed for synthesis and biological characterisation. Pyrimidoindolone target v was 
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synthesised and radiolabelled using modified literature conditions. Biological results showed the 
pyrimidoindolone to have a similar biological profile to isatin i.  
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Figure A3: Initial target pyrimidoindolone, imidazoleindolone and triazoleindolone heterocycles
 
Four different synthetic strategies were investigated for the synthesis of the 
imidazoleindolone and triazoleindolone heterocycles including, the use isatin sulfonamide 
intermediates, an intramolecular SNAr cyclisation process, Friedel-Crafts cyclisation method and 
nucleophilic addition to a benzonitrile. Preparation of imidazoleindolone vi was achieved with the 
SNAr cyclisation route. Preparation of triazoleindolone vii proved challenging with synthesis of only 
the core heterocyclic precursors, hydrazone ix and ketal vii achieved using the SNAr cyclisation route. 
Acid-sensitivity of the ring system hindered deprotection reactions and led to ring destruction.  
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Figure A4: Prepared precursors to the core triazoledindolone heterocycle  
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Abbreviations 
Å Angstrom 
A Absorption 
Ac Acetyl 
ACN Acetonitrile 
Ala    Alanine 
AMC      Aminomethylcoumarin 
Arg Arginine 
Asn    Asparagine 
Asp Aspartic acid 
β+ Positron 
Boc Di-tert-butyl dicarbonate 
BPDS Bathophenanthroline disulfonic acid 
Bq       Becquerel  
br Broad 
Bu Butyl 
CBR Caspase binding radioligand 
cf   Compare 
Ci    Curie 
CI Chemical Ionisation 
δ Chemical Shift 
CPA Cyclophosphamide 
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CT   Computerised Tomography 
Cys Cysteine 
Δ Delta / ‘change in’ 
d Doublet 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCM Dichloromethane 
dd Doublet of doublets 
ddd Doublet of doublet of doublets 
DEVD      Aspartic acid-glutamic acid-valine-aspartic acid 
DFT Density Functional Theory 
DMA Dimethylacetamide 
DMAP 4-Dimethylaminopyridine 
DME Dimethoxyethane 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribose nucleic acid 
dt Doublet of triplets 
E Energy 
ED50 Effective dose for 50% inhibition 
EI Electron ionisation  
EOB   End of Bombardment 
EOS   End of Synthesis 
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eq. Equivalent  
ES Electrospray 
Et Ethyl  
et. al And others 
Et3N Triethylamine 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
EtOH Ethanol 
g Gram(s) 
GBq Gigabecquerel  
Gln Glutamine  
Glu Glutamic acid 
Gly Glycine 
GSH Glutathione 
4-HC 4-Hydroperoxycyclophosphamide 
His    Histidine 
HMDS Hexamethylsiloxane 
HPLC High Performance Liquid Chromatography 
HRMS High Resolution Mass Spectrometry 
hrs/hr Hour(s) 
Hz Hertz 
i Iso 
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IC50    Inhibitor concentration for 50 % inhibition of an enzyme in vitro 
ID Injected dose 
IMA     Isatin Michael Acceptors 
J Coupling constant 
K Equilibrium constant  
K222 Kryptofix222 (4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane) 
kDa Kilodalton 
keV Kiloelectron volt 
KJ Kilojoules  
L Litre 
LCMS Liquid Chromatography Mass Spectrometry 
LDA Lithium diisopropylamide 
LG Leaving group 
LOR Line of response 
LR Lawesson’s Reagent 
M Molar 
m Multiplet 
µ Micro (10-6) 
mCi      Millicurie  
Me Methyl 
MeI Methyl iodide 
Met   Methionine 
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MeV Megaelectron volt 
MHz Mega Hertz  
min(s) Minute(s) 
MK Merz Kollman 
mL Millilitre  
mmol  Millimole(s) 
mol Mole(s) 
MRI   Magnetic Resonance Imaging 
MS Mass Spectrometry 
m/z Mass to charge ratio 
n Nano 
n / N Normal 
NBS N-Bromosuccinimide 
NIR Near Infrared 
nM   Nanomolar 
NMM N-methylmorpholine 
NMR Nuclear Magnetic Resonance 
Nu Nucleophile  
OMs Mesylate 
OTf triflate 
p Para 
PAC-1 First procaspase activating compound 
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PBS Phosphate buffered saline 
(p,n) (proton, neutron) 
PET Positron Emission Tomogragraphy 
PG Protecting group 
Pgp P-glycoprotein 
pH Potential hydrogen  
Ph Phenyl 
Phe     Phenylalanine 
PhMe Toluene 
pKa Acid dissociation constant  
pM Picomolar 
PMB Paramethoxy benzyl  
PMBSH Paramethoxybenzyl thiol 
ppm Parts per million 
PPTS Pyridinium p-toluenesulfonate 
pr Propyl 
prep Preparative 
Pro   Proline 
Prod. Product 
PS    Phosphatidylserine 
psi Per square inch 
PTSA Paramethoxytoluene sulfonic acid 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
12 | P a g e  
 
q Quartet 
QSAR Quantitative Structure Activity Relationship  
R Boltzmann Constant  
RC Radiochemical 
React. Reactant 
Rf Retention factor 
RIF-1 Radiation-induced murine ﬁbrosarcoma tumour cells  
rpm Rotations per minute 
rt Room temperature 
s Singlet 
SAR   Structure Activity Relationship 
SCRF Self-Consistent Reaction Field 
sec (s) Second(s) 
SEM 2-(Trimethylsilyl)ethoxymethyl 
± SEM ± Structural equation modelling  
Ser Serine 
SN2 Bimolecular nucleophilic substitution  
SNAr 
SPAAC                
Nucleophilic aromatic substitution 
Strain-promoted alkyne-azide coupling 
SPE Solid Phase Extraction 
SPECT   Single Photon emission Computed Tomography 
t Triplet 
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T Temperature 
TAC     Tumour time versus radioactivity curve 
TBAI Tetrabutylammonium iodide 
Temp. Temperature 
tert or t Tertiary  
THF Tetrahydrofuran 
Thr Threonine 
TLC Thin Layer Chromatography 
Tr Trityl 
Trp Tryptophan 
TS Transition state 
Ts/Tos Tosylate 
tt Triplet of triplets 
Tyr       Tyrosine  
UV-vis Ultraviolet-visible 
Val Valine  
Veh Vehicle or control 
Ver Verapamil 
Vs Versus 
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I. INTRODUCTION 
I.1. An Overview  
Molecular imaging is a rapidly growing research area that allows the non-invasive 
characterisation of biological processes within a living organism1 by exploiting the interaction of 
different forms of energy with tissue.2 Conventional imaging technologies are primarily based on 
imaging gross anatomy and changes in physiological features.1, 3 Today, imaging employs molecularly 
targeted contrast agents in visualising the expression and activity of biomarkers such as, growth 
factor receptors, proteases, protein kinases, as well as, detecting key biological processes including 
apoptosis.3, 4 The available imaging modalities include magnetic resonance imaging (MRI), optical 
imaging, contrast-enhanced ultrasound and radionuclide imaging encompassing, Positron Emission 
Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). The phenomenon of 
molecular imaging is poised to aid the earlier detection of cancer, personalised anticancer therapy 
and staging, and monitoring of response to therapy.4, 5  
Apoptosis or programmed cell death serves to maintain homeostasis in multicellular 
organisms. Abnormal apoptosis has been observed in a large number of pathologies but, more 
specifically, mechanisms hindering apoptosis are implicated in most malignancies.6 The induction of 
apoptosis is thus an essential part of non-surgical anticancer therapies such as, radiotherapy, 
chemotherapy and hormonal treatments. It follows that the rapid and accurate visualisation of the 
apoptotic response to therapy has a great potential in aiding diagnostic and treatment monitoring. 
Apoptosis is characterised by specific changes in the cell. These changes are exploited in the imaging 
and detection of cell death and include; membrane alterations, DNA fragmentation, enzyme 
expression/ activation and plasma membrane leakage.7 Traditional assessment of cell death involved 
the invasive removal of microscopic samples from tissues using biopsy or post-mortem.8 The fact that 
these microscopic methods are invasive limits applicability and utilisation. Molecular imaging offers 
the advantage of non-destructively imaging apoptosis in vivo.5 The cysteine-aspartyl protease, 
caspase-3 has been found to be activated in most models of apoptosis and is thus a biochemical 
target for apoptotic imaging. Current research strategies are aimed at identifying non-peptidyl, small 
molecule inhibitors of caspase-3 that can be utilised in the targeted molecular imaging of cell death. 
The imaging of apoptosis began with the nuclear magnetic resonance (NMR) characterisation 
of apoptotic cells in vitro.8 This was closely followed by MRI,9 then nuclear imaging10 together with, 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
19 | P a g e  
 
optical imaging11 and contrast-enhanced ultrasound.12 Of all the available imaging modalities, 
nuclear medicine is considered the superior technology as it is currently the most sensitive and 
specific method for studying molecular processes.13, 14 Realistic goals of nuclear medical imaging in 
oncology include: i) the early detection of molecular or physiological changes that signal the presence 
of cancer when a tumour is still at a curable stage; ii) the ability to evaluate response to therapy and 
modify treatment procedures in real time; and iii) the acceleration of the anticancer drug 
development process by allowing earlier clinical testing of new therapeutics.3, 5  In this introductory 
chapter, an overview of the available imaging modalities is provided, placing particular emphasis on 
nuclear medicine techniques and the selection of PET for the molecular imaging of apoptosis. The 
present status of research into targeted radiopharmaceutical probes for the imaging of cell death will 
be highlighted, leading to the objectives behind our proposed research, aimed at designing optimal 
caspase-3 binding probes for the PET imaging of apoptosis. In subsequent chapters, research results 
are presented and discussed, including synthesis of designed probes, computational modelling of 
properties, radiolabelling and biological characterisation. The report then concludes with an overall 
perspective from the research report and future work towards realising the research goals.    
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I.2. Molecular Imaging Modalities 
 
Figure 1.1: Timeline showing the application of the different imaging modalities at different stages of the 
apoptotic cascade, characterised by a number of biomolecular and biophysical events.  Since molecular events 
precede the biophysical changes, nuclear imaging techniques are more sensitive at the early phases of 
apoptosis. Figure adapted from Hakumaki et al.8  
Figure 1.1 shows the biomolecular and biophysical events that characterise the onset of 
apoptosis which can be exploited by the different imaging modalities in the detection of apoptosis. 
The concept of targeted imaging is illustrated in Figure 1.2: specific biomarkers such as, enzymes and 
receptors involved in biological activities such as, apoptosis are identified and targeted using 
chemicals or biomolecules that selectively bind to the chosen biomarker. These targeting moieties 
are labelled with signalling agents used to ‘visualise’ the biomarkers and therefore the biological 
activity being imaged.15  The signalling agents are designed for use in specific imaging modalities 
including, ultrasound, optical imaging, MRI and nuclear medicine techniques comprising, PET and 
SPECT.  
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Figure 1.2: Targeted Biomarker imaging. Figure taken from Fass et al.15 
Ultrasound employs high frequency sound waves (> 20 kHz) to produce images of structures 
within the body.8 The technique is regularly used to guide biopsies and is one of the most common 
methods used in the diagnosis of tumours in the thyroid, breast, prostate, liver and kidneys.15 It has 
been shown that ultrasound may be able to detect the biophysical effects of apoptosis such as the 
subcellular nuclear chromatin condensation and DNA fragmentation which signal the onset of 
apoptosis.8, 16 However, deep-seated tumours can prove difficult to image.8 Notable advantages of 
ultrasound imaging in comparison to other modalities include, its low cost, easy availability and 
portability. A key disadvantage of the technique in the field of apoptosis is its inability differentiate 
apoptosis from necrosis (uncontrolled cell death).8  
Optical imaging is an imaging modality that relies on radiation penetrating the body for image 
construction using high-speed and often sensitive detection of fluorescent tracers. However, photons 
of the UV-vis range are absorbed by tissue chromophores and hence cannot penetrate more than 1-
2 mm into tissues. This has limited the use of optical imaging to millimetre-scale resolution, largely 
restricting the method to the planar imaging of small animals.1, 13  
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MRI is the modality of choice for the evaluation of tumour size, shape and anatomical 
appearance in many areas of the body.17 The technique is based on the magnetic relaxation of water 
protons contained in different tissue types, and therefore benefits from the high concentration of 
water in living organisms. Excellent spatial resolution and tissue contrast are achieved by the 
enhancement of local water proton relaxation in the presence of an exogenous contrast agent, 
usually a paramagnetic gadolinium(III) complex.18 MRI is however limited by low sensitivity, requiring 
the use of relatively large concentrations of tracers for imaging purposes, which can potentially have 
toxic side effects. Thus, difficulties lie in the design and development of MR contrast agents that can 
increase sensitivity without compromising the safety. Despite the sensitivity issues, MRI has been 
successfully applied in research to the molecular imaging of apoptotic cell membranes using the 
endogenous protein, Annexin-V as the probe.19, 20 
Nuclear medicine imaging can be regarded as the non-invasive monitoring of biological 
processes using trace amounts of positron-emitting and gamma-emitting radiopharmaceuticals for 
PET and SPECT respectively. Nuclear imaging techniques cannot match the spatial resolution of MRI 
or ultrasound due to the nature of the physics involved. However, this technique maintains a position 
of prominence in molecular imaging because of the extreme sensitivity the technique is capable of. 
Very high sensitivities mean that in vivo imaging by both SPECT and PET can be performed at sub-
pharmacological tracer doses.13, 21 This makes it possible to label and administer even highly potent 
or toxic compounds without the manifestation of pharmacological or toxicological effects.21 We were 
particularly interested in molecular imaging using PET which is further described in the subsequent 
sections.  
Figure 1.3 below summarises the advantages and disadvantages of the available molecular 
imaging modalities. Despite the obvious trade-offs between all the imaging modalities, the advent of 
molecular imaging has contributed to the great progress observed in the understanding of apoptosis 
in cancer.8 
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Figure 1.3: A summary of the advantages and disadvantages of different molecular imaging modalities. 
Image taken from Willmann et al.22 
I.2.1. The Basic Principles of PET  
Since positron-emitting atoms are not naturally occurring, the radionuclides used in PET are 
produced by a cyclotron. In a cyclotron, high power electric and magnetic fields are used to accelerate 
charged particles (e.g. protons, deuterons or alpha particles) to high energies which then bombard 
stable atoms in a target to give rise to radioactive isotopes. Table 1.1 gives a brief summary of the 
nuclear reactions used to produce the principal radionuclides used in PET (11C, 15O, 18F, and 13N).14, 23 
As shown in Table 1.1, there are generally more protons than neutrons in each radionuclide. The 
excess positive charge is released during nuclear disintegration by the emission of a positron.17 The 
emitted positron travels a short distance and is annihilated by colliding with an electron, producing 
two 511 keV photons.17 Simultaneous detection of the annihilation photons along a line of response 
(LOR) between two detectors provides a distribution summation of the radiotracer which is 
computed into PET images of the process under investigation.14, 17, 23, 24  
Table 1.1: Production and characteristics of the principal PET radionuclides14 
Positron 
emitting 
radionuclide 
Stable  
element 
Nuclear 
Reaction 
No. of protons 
(p) and neutrons 
(n) in the product 
nucleus 
Half-life  
(mins) 
Stable 
nucleus after 
positron 
emission 
11C Nitrogen (14N) 14N(p,α)11C 6p, 5n 20.4 11B 
13N Carbon (12C) 12C(d,n)13N 7p, 6n 10.0 13C 
15O Nitrogen (14N) 14N(d,n)15O 8p, 7n 2.03 15N 
18F Oxygen (18O) 18O(p,n)18F 9p, 9n 109.8 18O 
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In oncology, functional information from PET provides advantages over anatomic information 
from ultrasound and MRI. Whole body PET imaging allows the early identification of disease, 
differentiation between benign and malignant lesions, examinations of all organs for metastases, and 
the determination of therapeutic effectiveness.23 PET has also been shown to have 8 - 43 % higher 
diagnostic accuracy than conventional procedures in trials for lung and colorectal cancers.23, 25  Of the 
two nuclear imaging techniques available (PET and SPECT), PET is considered superior for a number 
of reasons.13 Firstly, the principal PET radionuclides (11C, 15O, 13N and 18F) are physiologically 
important elements and their biogenicity makes it possible to directly label organic molecules of 
interest without altering their biological activities.18 Common SPECT nuclei include 99mTc and 123I 
which are not biologically important elments.13 Secondly, the spatial resolution of PET clinical 
cameras is in the range of 1 - 2 mm compared to the 6 - 7 mm of SPECT clinical cameras13 i.e. PET 
acquires data with higher spatial resolution than SPECT.  
However, PET is not without limitations. The requirement for an in-house cyclotron to 
produce the short-lived isotopes used in PET limits the application of the technique. This is more 
problematic with 11C which has a short half-life of 20.4 mins. The second limitation of PET is also 
imposed by the short half-lives of the principal positron emitters, forcing the synthesis, purification, 
analysis and formulation of radiolabelled probes to occur within the order of minutes. The larger 
positron emitting isotopes such as, 64Cu, 89Zr and 124I with longer half-lives of 12.7 hours, 78.4 hours, 
and 4.17 days respectively, could be used.26 However, the longer half-lives of these radionuclides 
would prolong exposure of the subject (patient or laboratory animal) to ionising radiation, resulting 
in significantly higher radiation doses. Nonetheless, the limitations imposed by the short half-lives of 
the principal PET radionuclides are compensated for by the advantages they offer to their use as 
tracers. In addition to being physiologically important elements, the principal PET radionuclides allow 
the possibility of repeating studies in the same subject within a short time interval,21 which is 
beneficial in reducing the number of animals required for an experiment without compromising 
statistical significance. 
In addition, PET has the ability to measure chemical changes that occur before the 
macroscopic anatomical signs of a disease can be observed.27 Despite the challenges imposed by the 
short-lived positron emitters, a wide variety of selective PET radiotracers have been developed 
including, enzyme substrates and inhibitors, receptor ligands, amino acids and markers of blood flow 
and blood volume.23 PET is the preferred method for imaging receptor/enzyme function and 
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biochemical mechanisms, since its high sensitivity makes it possible to visualise biomolecules 
typically present in the nanomolar range.8, 28  In oncology, conventional methods may be insensitive 
to assessing therapeutic response where tumour shrinkage is not anticipated, but where functional 
changes may be marked. It is here that PET imaging can particularly play an important role using 
targeted radiopharmaceutical probes.   
I.2.1.1. Radiotracer/ Probe Design for PET Imaging 
PET imaging requires specific molecules labelled with a positron-emitting radionuclide which 
can be quantified in vivo by the detection of photons emitted as a result of positron annihilation. In 
a typical PET imaging assay, a radiotracer is injected intravenously and scanned to measure the tracer 
concentration in tissues and plasma over time. The development of new PET imaging probes is a 
multidisciplinary area consisting of biological target selection, organic synthesis, radiosynthesis and 
the in vitro and in vivo evaluation of the radiopharmaceutical. The main challenge in oncological PET 
imaging is the design and development of targeted radiopharmaceuticals with high affinity and high 
specificity that can allow the quantitation of molecular processes in a reproducible and repeatable 
manner. In targeted imaging, the radionuclide or the signalling moiety is attached to a molecule that 
binds to a specific biological target, such as an enzyme of interest (Figure 1.2). The ideal radiotracer 
agent binds only to the biological target of interest so that little or no non-specific interactions are 
observed. In order to obtain images with high target-to-background ratio, a number of prerequisites 
for the development of imaging probes must be met. These are extensively reviewed in the published 
literature.29, 30 Some common criteria, applicable to PET as well as to other imaging modalities 
include: 
I. High Sensitivity – biomarkers or targets such as receptors and proteins are commonly 
expressed at very low concentrations. Hence, the ability of imaging techniques to detect 
concentrations in the sub-micromolar or often, sub-nanomolar scale is crucial. 
II. High Specificity and Affinity – a high affinity of a probe for its biological target ensures the 
probe accumulation in the target tissue, resulting in high-contrast images. The affinity of the 
radiotracer should also be compatible with the concentration of the molecular target of 
interest i.e. molecular targets present in high concentrations can be imaged using radiotracers 
with a relatively low affinity  (10 - 30 nM), compared to the sub-nanomolar radiotracer affinity 
required for a target which is expressed in lower concentrations.31 In other words, the lower 
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the concentration of a molecular target, the higher the affinity requirement of a radiotracer 
to provide sufficient specific binding signals.  
III. Favourable pharmacokinetics – low peripheral metabolism and plasma clearance times of 
minutes to hours are desirable. Labelled metabolites can undergo non-specific binding or take 
part in other biological processes, reducing target-to-background ratio. Hence, where the 
radiotracer is extensively metabolised in vivo, the preference is for the compound to be 
labelled in a position which produces labelled metabolites that are least likely to interfere 
with the process under investigation.  
IV. Lipophilicity – the lipophilicity of a probe is an important factor since it determines the 
aqueous solubility of the probe for intravenous administration or the ability of the probe to 
permeate barriers such as membrane bilayers and the blood brain barrier. Highly lipophilic 
tracers often exhibit non-specific binding interactions. In general, successful radiotracers have 
sufficient lipophilicity that they are able to diffuse across cell membranes but not so lipophilic 
that their concentration in lipid-rich tissues hinders their binding at the molecular target of 
interest.  
V. Ease of Radiolabelling – the molecular structure of a radiotracer precursor should allow rapid 
labelling with the appropriate radionuclide, given the restriction imposed by the short half-
lives of PET nuclides and the limited scope of available radiolabelling methods.  
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I.2.1.2. [18F] - Ideal PET Radionuclide 
Table 1.2: Positron ranges in soft tissues for selected positron emitters.32 
Positron 
emitting 
radionuclide 
Half-
life 
(mins) 
Theoretical 
specific 
activity 
(Ci/ µmol) 
Decay 
% β+ 
Positron Energy 
(MeV) 
Positron range in 
soft tissue (mm) 
Maximum 
(Emax) 
Mean Maximum Mean 
11C 20.4 9220 99.77 0.970 0.386 4.2 1.23 
18F 109.8 1710 96.7 0.635 0.250 2.6 0.61 
124I 6048 31 11.0 1.532 0.686 6.3 2.3 
12.0 2.135 0.974 8.7 3.5 
68Ga 68.3 2766 87.7 1.899 0.836 8.2 2.9 
64Cu 768 245 17.87 0.653 0.278 2.9 0.64 
Table 1.2 shows a number of PET radionuclides that can be used in the development of 
radiopharmaceuticals.32 The biogenicity and high specific activity (the concentration of cold, 
unradiolabelled material present in a formulated dose) of 11C make it ideal for labelling biological or 
organic molecules of interest. However, the physical half-life of 20.4 mins is too short for extensive 
application in terms of commercialisation and distribution. The radiometals are appropriate for 
labelling peptides and proteins via chelation chemistry, and the availability of 68Ga via generator 
production is advantageous. 124I can also be used for radiolabelling peptides and proteins, but its low 
specific activity is far from ideal and the much longer half-life is unfavourable with respect to 
radiation dose to a subject. With 124I, the very high energy positron emissions also results in blurry 
images and imaging is further complicated by a second gamma emission. 18F is generally the preferred 
PET radionuclide for the development of radiopharmaceuticals for a number of reasons:32 
I. It has the lowest positron energy (0.635 MeV) which limits the distance travelled by the emitted 
positron before annihilation, restricting the tissue range to a maximum of 2.6 mm. The result is 
high resolution images compared to PET images obtained with other PET radionuclides 
II. 18F can be produced in high specific activity and is readily available from small medical 
cyclotrons 
III. 18F decays with almost 100 % positron efficiency 
IV. 18F-PET tracers typically have well established radiochemistry for synthesis in relatively high 
yields 
V. The physical half-life of 109.8 mins allows the possibility of distribution to clinics without access 
to a cyclotron 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
28 | P a g e  
 
VI. The combination of intermediate half-life and medium energy photo emission provides an 
acceptable radiation dosimetry profile to allow repeated studies in patients.  
I.2.1.3. Radiosynthesis of PET Tracers  
PET radiosynthesis involves the radiolabelling of a drug molecule by the incorporation of a 
cyclotron-produced radionuclide. The radionuclides obtained from a cyclotron are sometimes used 
directly but are often converted into more reactive chemical species to allow their facile 
incorporation into the molecules of interest.  
Fluorine can react with a range of organic and inorganic molecules both as a nucleophile and 
as an electrophile. For the production of 18F, two types of targets are used in a cyclotron; a liquid 
target for the production of nucleophilic 18F- and a gas target for the production of electrophilic 
fluorine gas, [18F]F2. Typically the nuclear reactions involve the  proton bombardment of 18O-enriched 
water and deuteron bombardment of 20Ne atoms for the production of 18F- and [18F]F2 respectively.14, 
32 Cyclotron produced electrophilic [18F]F2 is diluted with carrier (cold) fluorine gas, leading to low 
specific activity not optimal for the synthesis of high specific activity radiopharmaceuticals. In 
addition, in electrophilic radio-fluorination reactions, the labelling reaction yield is limited to a 
maximum of 50 % because the [18F]F2 precursor has only one atom as 18F and the other atom as the 
stable 19F.  
In contrast to the carrier added [18F]F2, non-carrier added 18F- can be produced in high specific 
activity (2 - 10 Ci/µmol) and is therefore usually preferred for radiolabelling reactions.32, 33 The 
synthesis of radiopharmaceuticals using [18F]fluoride are typically achieved via the nucleophilic 
substitution of the corresponding mesylate, tosylate or a triflate precursor (SN2), or by nucleophilic 
aromatic substitution (SNAr).32, 34 These labelling reactions differ from normal organic synthesis, 
owing to the short half-lives of the radionuclides requiring fast reaction times and simple procedures. 
Trace amounts of the radioactive isotope are usually reacted with relatively large amounts of a 
substrate. Typically, aqueous [18F]fluoride delivered from a cyclotron is dried in the presence of 
Kryptofix-222 (K222) and potassium carbonate via azeotropic distillation with successive additions of 
acetonitrile to give the ‘naked’ [18F]fluoride, a very reactive nucleophile. Nucleophilic fluorination is 
then carried out in an aprotic solvent (e.g. DMSO, DMF or ACN) under basic conditions, with 
conventional heating or microwave irradiation.35, 36 
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With a growing interest to widen the reaction scope and therefore the radiochemistry 
precursor compounds that can be used, new radiosynthetic strategies have been developed. 
Traditionally, radiolabelling with [18F]fluoride focused on nucleophilic substitution reactions.37 
Recently, the copper(I) catalysed 1,3-dipolar cycloaddition of terminal alkynes with substituted 
azides, the so-called ‘click’ reaction has been widely employed.37 An example of the application of 
the click reaction in the radiosynthesis of a PET radiotracer is discussed in Section I.4. The ‘click’ 
radiolabelling technique has been recently expanded to a copper-free reaction, where the alkyne-
azide coupling is promoted by strain without the need to use the cytotoxic copper catalyst.38, 39 The 
reaction of a strained cyclooctyne and an azide in strain-promoted alkyne-azide coupling (SPAAC) 
reaction has shown greatly improved kinetics. The ring strain of a substituted cyclooctyne and 
electron-withdrawing ﬂuorine substituents promote the [3 + 2] dipolar cycloaddition with azides. 
Recently, a number of groups have reported the use of copper-free click reaction for [18F] 
radiolabelling reactions.38, 40-43 
I.3. Apoptotic Imaging Markers and Biological Targets 
Apoptosis is a cell suicide mechanism which contributes to normal physiology and pathology. 
Beyond cancer, apoptosis plays a key role in several other pathologies, including stroke, ischemia, 
osteoarthritis and neurodegenerative disorders.44, 45 Several features of apoptotic cells differentiate 
them from their healthy counterparts, marking them for rapid engulfment by phagocytes and 
subsequent recycling of their cellular constituents.46 One of the most distinctive features of apoptosis 
is condensation of the nucleus and its fragmentation into smaller pieces. Indeed, in the absence of a 
specific molecular target, early studies identified apoptotic cells using this characteristic.47-49  
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Figure 1.4: Caspase activation pathways, initiating of apoptosis. Image taken from Taylor et al.46 
The evasion of apoptosis is one of the six hallmarks of cancer and the induction of cell death 
is thought to be an essential part of the successful treatment of tumours.50 It is generally believed 
that molecular imaging will enable the implementation of personalised treatment, rapid assessment 
to therapy and optimisation of treatment strategies in real time. Early imaging of apoptosis used the 
radiolabelled protein, Annexin-V51 and more recently, the Aposense family of molecules have been 
developed for apoptotic PET imaging.52-55 Both Annexin-V and the Aposense tracers target the 
apoptotic cell membranes. Of late, inhibitors targeting the caspase enzymes in the early stages of 
apoptosis have received much attention.56-58 These 3 classes of apoptotic imaging agents are 
described in the following sections.  
 
 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
31 | P a g e  
 
I.3.1. Imaging Phosphatidylserine (PS) Reorganisation using Annexin-V 
The terminal stage in the apoptotic cascade is phagocytosis, the consumption of the dead 
cells by phagocytes.46 Phagocytes recognise and coordinate to specific sites on the cell membrane of 
the dead cells. Phosphatidylserine (PS) which is the most characterised phagocytic ligand is confined 
to the inner cell membrane in healthy cells, but is externalised to the outer membrane in response 
to pro-apoptotic stimuli where it serves as a signal for cell ingestion by phagocytes without 
inflammation.59, 60 This translocation of PS has been exploited in the molecular imaging of 
apoptosis.46 
Annexin-V, a 36 kDa human protein which undergoes Ca2+ dependent binding to negatively 
charged phospholipid surfaces, was initially discovered as an anticoagulant protein, where the 
anticoagulant mechanism is based on the protein’s high affinity for PS.61 Blankenberg et al. first 
demonstrated the feasibility of SPECT imaging of apoptosis in tumours using 99mTc-labelled Annexin-
V.51 Though 99mTc-Annexin-V was able to predict tumour response in cancer patients, the target-to-
background ratio was low as a result of high uptake in the liver and kidneys and comparatively low 
uptake in tumours. The strong affinity of Annexin-V for the intact renal cortex has been attributed to 
the high concentration of PS in the kidneys.51 Annexin-V binding also occurs non-specifically during 
necrosis, a process also characterised by PS exposure.51 In contrast to apoptosis, necrosis is 
accompanied by the release of cellular contents into the extracellular space, triggering an 
inflammatory response.46 But similarly to apoptosis, necrosis is characterised by rapid loss of 
membrane integrity and the externalisation of PS. This has implications in the molecular imaging of 
apoptosis using PS as a biomarker. The use of Annexin-V is also limited by relatively slow clearance 
from non-targeted tissues, attributed to its large protein structure.62 As a result, Annexin-V probes 
are not considered optimal for apoptotic imaging.   
I.3.2. Imaging Apoptotic Cell Membranes using the Aposense Family  
Aposense is a family of low molecular weight amphipathic molecular probes that detect and 
accumulate within cells undergoing apoptosis.52-55 This class of probes recognise the apoptotic cell 
membrane and undergo a process that enables them to cross the membrane and accumulate within 
the cytoplasm in the early stages of the cell death process. Studies have shown that the uptake of 
these probes correlates with Annexin-V binding, loss of mitochondrial membrane potential and 
caspase activation, which are all associated with apoptosis.55 The Aposense probes are particularly 
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notable for their excellent clearance profiles and favourable biodistribution. Intracellular 
accumulation, as opposed to Annexin-V binding to the cell surface, means that Aposense probes can 
potentially exhibit increased signal-to-noise ratio.  
HO OH
18F
O O
N
S OO
N
F
O
HO
1 2  
Figure 1.5: Members of the Aposense family of apoptotic probes  
 A member of the Aposense family, the dansyl derivative 1 (Figure 1.5), comprising of a 
fluorophore and a fluorine atom was developed for both fluorescence and potential PET imaging 
using 18F.55 In vitro fluorescence imaging has shown the irreversible, selective and rapid accumulation 
of dansyl 1 in various cell types undergoing apoptosis. Similar results were also observed in in vivo 
studies of tumour models. In subsequent studies, 18F-labelled 5-fluoropentyl-2-methyl-malonic acid 
2 (Figure 1.5), was designed as a radiotracer for the clinical evaluation of apoptosis by PET imaging. 
This probe was also found to selectively accumulate in apoptotic but not in necrotic cells, 
demonstrating utility for selective imaging of tumour-induced apoptosis.52, 53, 63 However, the 
biomarker targeting mechanism of the Aposense family of radiotracers is yet to be fully defined; 
though it is believed that the amphipathic tracers function through the electrostatic attraction of 
their anionic carboxylate ‘head’ groups to the positively charged PS residues on the surface of the 
apoptotic cells, followed by the attachment of their lipophilic ‘tail’ inside the phospholipid cell 
membrane.52  
The radiolabelled malonic acid species 2 has proceeded to clinical trials with phase 1 
completed in healthy volunteers and phase 2 reportedly underway. Results of the phase 1 clinical 
trials showed favourable attributes for a PET apoptotic tracer including, favourable dosimetry, 
biodistribution, stability and safety profile, encouraging further development of the Aposense probe 
for the clinical PET imaging of apoptosis.64 However, further studies are required to elucidate the cell 
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membrane target of the amphipathic probes and the exact mechanism of translocation from the cell 
membrane to the cytoplasm. 
I.3.3. Imaging Early Apoptotic Events by Targeting Caspase-3(7) 
With regards to the initiation of apoptosis, numerous proteins are released from the 
mitochondrial intermembrane space. One of these proteins, cytochrome c, triggers the assembly of 
a caspase-activating complex called the apoptosome (Figure 1.4). Many of the apoptotic events are 
then initiated as a result of caspase-mediated cleavage of substrate proteins. The caspases represent 
an exclusive intracellular target for the development of new apoptotic imaging agents. This class of 
cysteine-aspartyl proteases are receiving increasing attention as targets for therapeutic assessment 
and drug development, owing to their central role in mediating the initiation and propagation of the 
apoptotic cascade.44, 45 Of the fourteen known human caspases, the functions of caspase-2 and 
caspases 11 to 14 are unclear. The remainder have been characterised and can be divided into 3 
functional groups: i) caspases-1, 4, and 5 which are associated with inflammation, ii) the initiator 
caspases-8, 9 and 10 and, iii) the effector caspases-3, 6 and 7. The initiator caspases are activated at 
the top of the apoptotic signalling cascade and then proceed to activate the effector caspases. Three 
main routes have been proposed for the induction of apoptosis; an extrinsic or receptor mediated 
pathway, an intrinsic or mitochondrial pathway and the granzyme B pathway (Figure 1.4).46, 65 All 
three routes lead to the activation of the effector caspases-3, 6 and 7 which then carry out the 
proteolysis associated with the propagation of apoptosis.46, 66-68 Studies have shown that the effector 
caspase-3 is particularly activated in virtually every model of apoptosis.66 Thus, the ability to image 
caspase-3 activation non-invasively provides a unique tool for diagnosis and evaluation of therapeutic 
response via the apoptotic cascade. To realise this aim, radioligands based on small molecule 
inhibitors of caspase-3 (and the structurally similar caspase-7 enzyme) must be identified and 
demonstrated to be efficacious. The section that follows reviews the recent history in the 
development of radiotracers based on caspase-3(7) inhibitors. 
 
 
 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
34 | P a g e  
 
Table 1.3: The effect of stereochemistry, pyrrolidine substituents and isatin N-alkylation on caspase-3 
inhibition potency.56, 69 
Pyrrolidine ring substitution Isatin N-alkylation 
No. Structure Casp-3 
IC50 (nM)  
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Table 1.4: The importance of ring size on casp-3 potency56 
No. Structure Casp-3 IC50 (nM) 
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I.4. Design and Development of Radiotracers Targeting Caspase-3/7 
Peptide-based compounds were amongst the first compounds reported to be potent 
inhibitors of caspase-3.70, 71 However, these compounds were found to possess poor cell permeability 
due to their high polarity, preventing in vivo applications. The peptidyl inhibitors were also shown to 
be moderately selective with poor metabolic stability. To overcome this problem, much effort has 
been devoted to developing non-peptidyl, small molecule inhibitors. Several classes of caspase-3/7 
inhibitors have been reported including, the pyrroloquinoline-1,3-diones series,72 isatin Michael 
acceptors (IMA) and isatin sulfonamides.73 The isatin sulfonamide series have been extensively 
studied due to their high potency and selectivity for caspase-3/7.  
I.4.1. Isatin Sulfonamides as Potent and Selective Inhibitors of Caspase-3/7: SAR 
Following high throughput screening aimed at discovering caspase-3 inhibitors, Lee et al. 
identified the hit, 5-nitroisatin 3 (Table 1.3) as a caspase-3/7 inhibitor.56, 69 With the goal of optimising 
the initial hit, in order to avoid the metabolic liabilities of nitro aromatics, and integrate a chemical 
functionality with appropriate electronic properties that would also allow the incorporation of 
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molecular diversity, a variety of derivatives were evaluated. This resulted in the identification of 5-
N,N-dialkylisatin sulfonamides as caspase-3 inhibitors (Table 1.3).56 The isatin sulfonamides also 
possessed much improved selectivity for caspase-3/7 inhibition compared to nitroisatin 3. Initial 
studies demonstrated the importance of stereochemistry on the 5-N,N-dialkylisatin sulfonamides, 
where the S-configuration at the chiral pyrrolidine or azetidine carbon atom was crucial for potency 
(Table 1.3, isatin 4 and 5).56, 72  
During the initial hit optimisation, Lee et al. found that increasing the ring size from 5 to 7 or 
replacing the pyrrolidine ring with an azetidine led to decreased potency for caspase-3 (Table 1.4, 
isatins 13 - 16). The increase in potency from isatin 6 to 8 (Table 1.3), as the pyrrolidine ring is 
substituted with larger alkyl/aryl groups, suggested hydrophobic binding interactions in the enzyme 
active site. Similarly, alkylating the isatin nitrogen with larger hydrophobic groups led to further 
increase in inhibitory activity, though polar moieties could also be accommodated as shown by the 
retained potency of the 4-pyridlymethyl derivative (Table 1.3 isatins 9 - 12). Introduction of a phenyl 
group on both the left side ether and the isatin nitrogen resulted in a dramatic increase in potency, 
giving the isatin sulfonamide 11 as the lead compound.  
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Figure 1.6: Similar potencies were reported for the pyrrolidine analogues 17 and their azetidine equivalents 
18, but replacing the phenyl ring with a pyridine 19 or a pyrimidinyl ring 20 resulted in higher potencies. The 
unalkylated prolinol derivative 21 showed the importance of the left side ether for caspase-3 inhibition 
potency.57, 73 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
37 | P a g e  
 
 
In subsequent studies by Chu et al., aimed at optimising the lead compound 11, the group 
showed that para substituents on the N-benzyl had no appreciable effect on caspase-3 inhibition 
potency (Figure 1.6, isatin series 17).73 This correlated with the earlier observations by Lee et al., 
regarding the alkylation of the isatin nitrogen with hydrophobic groups (Table 1.3). That is, both sets 
of SAR studies suggested that hydrophobic groups are preferred to the N1-Me or the unalkylated 
isatin-N1. However, there was no strong preference between different hydrophobic groups. This was 
accounted for using molecular field maps (Figure 1.8)74 of isatin sulfonamide binding interactions 
with caspase-3. The molecular field maps denoted the binding pocket around the isatin nitrogen as 
hydrophobic, where both aliphatic and aromatic rings at the isatin N-1 would create desirable close 
contacts with amino acid residues in the active site (Figures 1.7).  
Chu et al. reported similar potencies between the pyrrolidine analogues 17 and their azetidine 
equivalents 18 (Figure 1.6), despite the difference in potency reported by Lee et al. for compounds 
13 and 14 (Table 1.4).73 Interestingly, replacing the benzene ring of the 2-(phenoxymethyl) 
pyrrolidine with a pyridine ring resulted in higher potencies (Figure 1.6, isatin 19). In further SAR 
studies by Smith et al., it was found that, similarly to the results reported by Chu et al., increases in 
potency was observed when the benzene ring of the 2-(phenoxymethyl)pyrrolidine was replaced 
with polar moieties bearing H-bond acceptors such as, a pyrimidinyl ring (Figure 1.6, isatin 20).57 In 
addition, the isatin sulfonamide 21 demonstrated the importance of the left side ether in bonding 
interactions with the enzyme (Figure 1.6).  
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Figure 1.7: Binding interactions of a) isatin sulfonamide analogue 11 (ligand 3 in the image), and b) 
its azetidine equivalent (ligand 34 in image). Figure taken from Wang et al.74 
 
The basis of the SAR observations was revealed from sequence alignements69 and docking 
studies.74 It was found that the three hydrophobic residues (Tyr204, Trp206 and Phe256) in the S2 
pocket of caspase enzymes are unique to caspases-3 and 7.69 A superimposition of 59 derivatives 
from the pyrrolidine (17) and azetidine (18) series showed that the isatin core and the flexible 
pyrrolidine or azetidine ring make extensive hydrophobic contacts with these residues in the S2 
pocket, thus conferring binding specificity to the isatin sulfonamides (Figure 1.7).74 In addition to the 
key π-π interactions in the S2 pocket, the molecular field maps (Figure 1.8) showed that groups 
containing hydrogen bond acceptors were accommodated due to the presence of Ser381 residue 
within hydrogen bonding distance of this region, as well as the partial exposure of this region to 
solvent.73, 74 This accounted for the retained or increased potencies of inhibitors where the benzene 
ring of the phenoxymethyl moiety was replaced with a heteroaromatic ring such as a pyridine or 
pyrimidyl ring (Figure 1.6, isatins 19 and 20).56, 57, 73 
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Figure 1.8: Molecular field maps derived from a model with isatin 11 and its azetidine equivalent; a) steric 
map, b) electrostatic map, c) hydrophobic map, d) hydrogen bond donor map, e) hydrogen bond acceptor 
map. Figure taken from Wang et al.74 
Aside from the hydrophobic interactions at the S2 subsite, the essential binding modes also 
include, electrostatic interactions formed between the sulfonamide group and Arg207 backbone 
amide or its guanidino group (Figures 1.7, 1.8). Importantly, an X-ray co-crystal structure of a complex 
between caspase-3 and isatin sulfonamide 9 revealed a binding model involving the reversible 
addition of an active site cysteine residue to the isatin C-3 carbonyl carbon, forming a tetrahedral 
thiohemiketal intermediate.69 Thus, it was expected that isatin sulfonamides would distribute 
reversibly into cells but would only be trapped specifically within cells with active caspase-3/7. The 
inhibitor-enzyme covalent bond formation consequently inhibits caspases-3/7. 
 X-ray crystallography has also shown that the substrate preferences for caspase-3 and 7 are 
identical, since they are structurally and functionally very similar.75, 76 These two caspases differ only 
in the composition of their S4 subsite where the chemical content of caspase-3 is predominantly 
hydrophobic while caspase-7 is more hydrophilic.76 Hence, selectivity between caspases-3 and 7 may 
be obtainable by designing inhibitors with extended binding in the S4 subsite. However, given that 
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both caspase-3 and 7 are effector caspases with similar roles in the propagation of the apoptotic 
cascade,44, 45 the simultaneous inhibition of the two caspases has not been shown to be problematic.  
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Figure 1.9: From the initial hit 356, 69 to lead structure 1173 and the current lead 2257  
SAR studies by different groups in the past decade led to the current lead caspase-3 inhibitor, 
isatin sulfonamide 22 (Figure 1.9).57 The studies established isatin sulfonamides as potent and 
selective inhibitors of caspase-3/7. Although a good correlation was found between the cell-based 
and the in vitro caspase-3 activities of the compounds, a significant shift in activity was observed 
when comparing in vitro activities to the corresponding potencies in intact cells.57, 69, 77 The observed 
activity shift has been attributed to non-specific inhibitor interactions with nucleophilic moieties in 
the cytosol.56, 69 Studies are ongoing to optimise the specific binding properties of the isatin 
sulfonamides with progression of lead compounds to radiolabelling and in vivo PET imaging in animal 
models.   
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I.4.2. Development of Radiolabelled Isatin Sulfonamides 
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Figure 1.10: Developed Caspase Binding Isatin Radioligands.57, 78, 79 
Following the establishment of isatin sulfonamides as putative inhibitors of caspase-3/7, 
Kopka et al. proposed these inhibitors as caspase binding radioligands (CBRs) for the in vivo imaging 
of apoptosis.77 The group synthesised a number of  isatin sulfonamide precursors for radiolabelling, 
incorporating structural modifications at the N-1 position which was proven to tolerate a wide range 
of chemical groups without the loss of caspase-3/7 inhibition potency.56, 73 The suitability of the isatin 
sulfonamides for development as CBRs commenced with the radiosynthesis of the first isatin 
radiotracer [125I]23 (Figure 1.10) for SPECT imaging.77 However, in later studies by Smith et al., this 
radioligand was reported  to have poor biological stability, attributed to a rapid in vivo aromatic 
hydroxylation of the phenyl ether, with the possibility of the majority of the detected radioactivity 
originating from the metabolic product.57 
Taking advantage of the metabolic-blocking effect of electron-withdrawing fluorine 
substituents and the metabolic stability of 1,2,3-triazole groups, Smith et al. designed a library of 
isatin sulfonamides incorporating the triazole heterocycle and fluorine substituted aromatic 
groups.57 The lead compound, [18F]22 was subsequently selected on the basis of subnanomolar 
affinity for activated caspase-3, high selectivity for the target enzyme, moderate lipophilicity and high 
metabolic stability with no evidence of in vivo defluorination. Isatin sulfonamide 22 was 
demonstrated to bind to a range of drug-induced apoptotic cancer cells in vitro and in vivo, by up to 
2-fold and as early as 24 hrs post-treatment, compared to control treatment.57 Whole body in vivo 
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microPET in mice detected an increased signal intensity in tumours after drug treatment which was 
associated with drug-induced apoptosis and caspase-3 activation (Figure 1.11).57 
 
 
 
 
 
Figure 1.11: Figure taken from Smith et al.57, 80 
[18F]22 PET imaging analysis. 38C13 xenografts 
bearing mice were treated with 100 mg/kg 
cyclophosphamide CPA (n = 3) or vehicle (n = 3) for 24 
hrs and subsequently subjected to 60 min dynamic 
PET imaging. (a) [18F]22 PET images of CPA-treated, 
38C13 xenograft bearing mice and the 
vehicle/control mice. White arrowheads indicate the 
tumour position. (b) [18F]22 tissue uptake in tumour 
and blood samples removed after PET scan. (c) The 
tumour time versus radioactivity curve (TAC).  
[18F]22 binding and active caspase-3/7 content 
analysis in cancer cells undergoing drug-induced 
apoptosis. Left panel: the effect of cisplatin (100 
µM; 24 hrs) or etoposide (100 µM; 24 hrs) 
treatment on [18F]22 uptake. Right panel:  
caspase-3/7 activity in RIF-1 fibrosarcoma and 
LNM35 lung carcinoma cells, correlating with 
[18F]22 uptake and showing that radiotracer 
uptake was due to caspase-3 activation. For each 
set of treated and control samples, radioactivity 
data was expressed as decay-corrected counts per 
milligram of total cellular protein. 
The results obtained demonstrated [18F]22 as a caspase-3 targeted PET radiotracer with 
potential utility in the evaluation of oncologic therapeutic response.57 Notably however, low baseline 
uptake of [18F]22 in tumours was observed. PET images also showed a high retention of the 
radiotracer in the liver and intestines. Thus, the use of an anatomical imaging modality such as MRI 
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for the localisation of the tumour may be necessary in the translation of this tracer into clinical 
practice, with limited application in the abdominal region.  
 
Figure 1.12: Whole-body microPET image of [18F]24 distribution in a control rat (left) and cycloheximide-
treated rat (right). Images summed from 10 to 60 mins after intravenous injection of ~150 μCi [18F]24. Figure 
taken from Zhou et al.78 
Table 1.5: Inhibitor profile of the leading caspase-binding isatin radioligands 
Compound Casp-1 
(nM) 
Casp-3 
(nM) 
Casp-6 
(nM) 
Casp-7 
(nM) 
Casp-8 
(nM) 
Log P Specific activity 
(mCi/μM) 
[18F]2478 >50000 9.7 3700 23.5 >50000 4.19 1500 
[18F]2579 >20000 8.6 4930 26.1 >25000 3.65 2280 
[11C]2679 >20000 14.5 10000 21.8 >2500 3.97 1400 
[18F]2257 >5000 0.5 >5000 2.2 >5000 1.61 32.34* 
[18F]2281 >5000 0.5 >5000 2.2 >5000 1.61 18513** 
*Specific activity from click radiolabelled [18F]22, calculated from the reported value of 1.2 GBq/μM 
** Specific activity from the direct radiolabelling of [18F]22 by automated SN2 [18F]fluoride displacement of a 
tosylate precursor, calculated from the reported value of 685 GBq/μM 
Zhou and Chu et al. also demonstrated the feasibility of apoptotic PET imaging using the 
radiolabelled isatin sulfonamides [18F]24, [18F]25 and [11C]26 (Figure 1.10, page 41).78, 82 The inhibition 
potencies of these inhibitors are shown in Table 1.5 above. In all cases, results of microPET studies 
using a cycloheximide-induced liver model of apoptosis revealed an increased uptake of the inhibitor 
in treated versus control animals (Figure 1.12), with slower washout of radioactivity from the liver 
and spleen in the treated animals. The levels of uptake were shown to be consistent with chemically 
induced apoptosis and caspase-3 activation. However, the liver model used in the microPET studies 
was limited by the induction of a high level of apoptosis which is not representative of the levels that 
are typically observed clinically. Similarly to [18F]22, biodistribution studies of these tracers showed 
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the retention of inhibitor-derived radioactivity in the liver, attributed to a rapid hepatic clearance, 
therefore precluding the use of these tracers in the abdominal region. 
Of the four caspase binding radioligands reported to date (Table 1.5), [18F]22 incorporating 
1,2,3-triazole and 2,4-difluorophenyl moieties is the most potent. However, the initial modest 
specific activity of 1.2 GBq/μM (32.4 mCi/μM),57 though sufficient for initial evaluation, was not 
optimal for more complex in vivo models or clinical development. Thus, ongoing optimisation of the 
probe continues, with improved radiosynthesis to increase the specific activity as briefly described 
below.81 
I.4.2.1. Radiochemistry of Caspase-3 PET Imaging Agents  
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Scheme 1.1: The process of 18F-labelling by the displacement of a leaving group.83 
Research efforts have focused on utilising radiopharmaceuticals labelled with 18F because, as 
discussed in section I.2, its properties make it ideal for clinical imaging purposes. It is worth 
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considering the essential radiolabelling methods employed in the radiosynthesis of caspase binding 
isatin radioligands. The reactive isatin ring has proven problematic for radiolabelling with 
[18F]fluoride, owing to nucleophilic attack on the C-3 carbonyl carbon (Scheme 1.1).83, 84 It was found 
that attempts to radiolabel isatin sulfonamide derivatives by the displacement of a leaving group led 
the trapping of the [18F]fluoride nucleophile by the C-3 carbonyl of the isatin scaffold, giving the 
species 29, instead of the desired radiolabelled derivative [18F]24 (Scheme 1.1).83  
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Scheme 1.2: 11C-labelling of isatin sulfonamides.83 
Zhou et al. subsequently demonstrated that the radiolabelling reaction proceeded efficiently 
via the acid-base ring opening/recyclisation procedure shown in Scheme 1.1.83 The precursor (27/28) 
was initially treated with a strong base (e.g. Bu4NOH) which resulted in ring opening to give the 
intermediate 31. [18F]Fluoride could then undergo the intended nucleophilic substitution to displace 
the tosylate or mesylate leaving group of intermediate 31, before converting the resulting 
radiolabeled product 32 to the desired radioligand, [18F]24 under acidic conditions (Scheme 1.1). This 
ring-opening-reclosure method was also utilised in 11C-labeling of isatin sulfonamides (Scheme 1.2). 
An alternative route avoiding the trapping effect of the C-3 carbonyl involved protection of the 
ketone as a 1,3-dioxane, followed by radiolabelling under standard conditions and subsequent 
hydrolysis of the protecting group (Scheme 1.2). Both reaction routes reportedly afforded the isatin 
probes [18F]24 and [11C]26 in high yields and high specific activities (Figure 1.10, Table 1.5).  
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Scheme 1.3: 18F-labelling of isatin sulfonamide 22 by copper catalysed click chemistry.57 
Isatin sulfonamides can also be radiolabelled via the copper catalysed cycloaddition of 2-
[18F]fluoroethylazide 37 to an alkyne precursor, commonly called ‘click’ radiolabelling (Scheme 1.3).57 
This reaction can be carried out without the need for protecting groups with the procedure shown 
to be highly regioselective for the 1,4-disubstituted 1,2,3-triazoles.85 However, the click reaction gave 
the radiolabelled lead isatin [18F]22, in poor specific activity; Table 1.5 shows that the specific activity 
at the end of synthesis is lowest for the click-labelled [18F]22. In successive studies, direct 
radiolabelling by the SN2 displacement of a tosylate precursor with [18F]fluoride, gave isatin [18F]22 
in significantly increased specific activity (Scheme 1.4).81 An automated procedure for the SN2 
method has been developed and validated to clinically acceptable standards.81 This improved specific 
activity combined with increased purity, synthesis time and automation have projected the 
radiotracer [18F]22 to the early stages of clinical development.86 
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Scheme 1.4: 18F-labelling of isatin sulfonamide 22 by direct displacement of a tosylate leaving group.81 
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I.4.3. Pyrimidoindolones: A New Class of Caspase-3/7 Inhibitors 
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Figure 1.13: Core isatin heterocycle 41, the pyrimidoindolone heterocycle 42 and the sulfonamide-
substituted pyrimidoindolones 43 and 44.58 
While radioligands based on isatin sulfonamides were demonstrated to be sensitive and 
selective radiotracers of in vivo apoptosis, imaging results of the developed tracers, including the lead 
compound [18F]22, have shown low target-to-background activities. For clinical imaging purposes, 
improvements in the signal-to-noise ratio is crucial. Hence, studies are ongoing to further optimise 
this class of inhibitors in clinically relevant models. Nevertheless, the structurally similar 
pyrimidoindolones have emerged as a new class of caspase-3/7 inhibitors.58 Probes based on the 
pyrimidoindolone heterocycle have the potential to decrease non-specific in vivo binding activities, 
by modulating the reactivity of the ketone carbonyl responsible for caspase inhibition through the 
formation of a thiohemiketal in the enzyme active site (Figure 1.13).  
Active caspases have been shown to be homodimers with two identical active sites.87 A recent 
study showed that isatin sulfonamides bind to a single domain of the enzyme, distorting the second 
active site and dramatically reducing the binding affinity to this site.87 Enzyme activity is abolished 
upon binding of an isatin sulfonamide to only one active site of the caspase homodimer, resulting in 
half-site reactivity.87 In contrast, the pyrimidoindolones (Figure 1.13) have been shown to inhibit 
caspase-3 by binding to both active sites with equal affinity. Thus, the stoichiometry of inhibitor to 
dimeric caspase-3 is 1/1 and 0.5/1 for the pyrimidoindolones and the isatins respectively. However, 
consideration of the enthalpies, free energies and entropies of pyrimidoindolone and isatin binding 
to caspase-3 showed similar affinities for the two heterocycles, despite the different 
stoichiometries.87  
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Table 1.6: A selection of the pyrimidoindolone derivatives prepared by Havran et al.58 
Compound  
No. 
R Caspase-3 
IC50 (nM) 
Solubility @ pH 
7.4 (μg/mL) 
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Figure 1.14: X-ray co-crystal structure of pyrimidoindolone 44 with human caspase-3 (left) and with the 
residues illustrated on the right, showing similar binding interactions observed with isatin sulfonamides. 
Figure taken from Havran et al.58 
An X-ray co-crystal structure of caspase-3/inhibitor 44 (Figure 1.14) revealed that the 
inhibition of caspase-3 involved the formation of a covalent bond between the electrophilic C-10 
carbonyl and an active site cysteine residue. That is, similarly to the isatins, an electrophilic carbonyl 
carbon in the correct position is crucial for the inhibitory activity of the pyrimidoindolones. The initial 
SAR studies by Havran et al. revealed similarities with the isatin sulfonamides, showing analogous 
hydrophobic and hydrophilic binding interactions with caspase-3/7.58 As with the isatin SAR studies, 
a 2-(phenoxymethyl)pyrrolidine substituent on the pyrimidoindolone heterocycle gave a potent 
inhibitor, but the replacement of the benzene ring with a pyridine ring further increased potency, 
with the added advantage of increased solubility (Table 1.6, 44 vs. 45).  
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Scheme 1.5: Reported hydration of the pyrimidoindolone scaffold leading to the formation of the 9-
membered ring, 51 under standard aqueous conditions.58 
 Interestingly, studies showed a decrease in the potency of the pyrimidoindolones in aqueous 
solution over time.58 Using NMR studies, this decrease was attributed to hydration of the parent 
inhibitor under neutral conditions (Scheme 1.5). Addition of two molecules of water to the 
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pyrimidoindolone ring gave a dihydrate intermediate 50, with subsequent expulsion of water and 
ring opening to give the nine-membered keto-amide 51 (Scheme 1.5).58 As trace amounts of a 
radiotracer are typically administered intravenously during imaging, the poor aqueous stability may 
prove problematic in potential clinical applications of this class of caspase-3/7 inhibitors. 
Nonetheless, hydration of the pyrimidoindolone scaffold was only significant after 24 hours, and 
since 18F-PET imaging is typically performed on very short time scales, within the order of minutes, 
the limited aqueous stability may not preclude the use of pyrimidoindolones as apoptotic imaging 
agents.  
Further biological evaluation using experimental models of apoptosis is required to assess the 
extent of this low aqueous stability. However, attempts have been made to improve such aqueous 
stability.58 With the goal of improving solubility, Havran et al. investigated the effect of replacing the 
phenoxy ether moiety with simple amines. Morpholine proved to be the optimal amino substituent, 
retaining inhibitory activity but with no improvement on aqueous solubility (Table 1.6, 46). The 
reverse sulfonamides were subsequently proposed, aiming to improve stability by reducing the 
electrophilicity of the C-10 carbonyl group, minimising nucleophilic attack by water whilst retaining 
an ability to form a covalent bond with the active-site cysteine. Unfortunately, the reverse 
sulfonamides resulted in significantly decreased potency and poorer aqueous stability (Table 1.6, 47). 
Based on the group’s earlier observation that compounds with an unsubstituted dihydropyrimido 
ring such as the 2-(methoxymethyl)pyrrolidine derivative 43 (Figure 1.13) were extremely unstable 
in aqueous solution compared to ones incorporating a gem-dimethyl group in the 3-position, 
spiroannulated structures were proposed. The aim was to improve stability whilst avoiding the 
metabolic liabilities of the ‘free’ methyl groups. The spirocyclobutyl derivative proved to be very 
potent but without improved aqueous stability (Table 1.6, 48). In contrast, the spirocyclopentyl 
analogue (Table 1.6, 49) showed an improved stability profile whilst maintaining nanomolar affinity 
for caspase-3. The reason for this improved stability is not yet known. Nevertheless, the results of 
the SAR studies, in addition to the ability to improve aqueous stability demonstrated that the 
pyrimidoindolones could potentially find utility as radiotracers for the imaging of apoptosis.58 
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I.5. Proposed Research  
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Figure 1.15: From the isatin radiotracer to pyrimidoindolone based caspase inhibitors and the newly 
proposed imidazoleindolone and triazoleindolone heterocycles.  
Based on the observations that PET imaging using isatin sulfonamides is hampered by low 
target-to-background activities, we aimed to design and develop alternative heterocycles with the 
potential to increase the signal-to-noise ratio of apoptotic PET images through specific caspase-3 
binding interactions. We were particularly interested in further investigating the pyrimidoindolone 
heterocycle as a caspase-binding radioligand. Although in vitro models had shown the 
pyrimidoindolones as relatively potent caspase-3 inhibitors,58 there were no reported radiolabelled 
pyrimidoindolone-based radiotracers for the PET imaging of apoptosis.  The selection of a potential 
pyrimidoindolone radiotracer for further studies was based on the hypothesis that: 
i) Their dual binding mode to the caspase-3 dimer compared to the half-site activity of 
the isatin sulfonamides87 would provide greater scope for specific binding interactions and reduce in 
vivo background uptake of the radioligand and;  
ii) The conversion of the isatin C-2 carbonyl to an amidine in the equivalent position of 
the pyrimidoindolone ring would modulate the electrophilicity of the ketone carbonyl, thereby 
minimising non-specific interactions with nucleophilic moieties (e.g. thiols) of cytosolic proteins 
(Figure 1.15). 
Our initial strategy therefore involved the preparation of a model pyrimidoindolone 
radiotracer for preliminary biological characterisation as a potential caspase-3 binding apoptotic PET 
probe. Chapter III covers the design, synthesis, radiolabelling and biological characterisation of the 
initial pyrimidoindolone radiotracer, with comparisons to the lead isatin sulfonamide 22.  
Given the problems reported with aqueous stability of the pyrimidoindolone scaffold,58 a 
‘back-up’ strategy was implemented, involving the exploration of novel heterocycles as potential 
caspase-3 inhibitors. The proposed heterocycles were based on the imidazoleindolone 52 and 
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triazoleindolone 53 heterocycles (Figure 1.15). Both these heterocycles possess the crucial ketone 
carbonyl responsible for caspase inhibition. Similarly to the pyrimidoindolone, it was hoped that the 
replacement of the isatin C-2 carbonyl with an electron rich imidazole and triazole ring in the 
imidazoleindolone and triazoleindolone heterocycles respectively would favourably modify the 
ketone reactivity and thiohemiketal stability. To our knowledge, there were no reported information 
on the synthesis and biological properties of the imidazoleindolone and triazoleindolone 
heterocycles, unlike the previously described pyrimidoindolone heterocycle. Thus, initial research on 
these heterocycles focused on computational modelling in order to validate their potential as caspase 
inhibitors compared to the known isatin and pyrimidoindolone systems.  
 
Scheme 1.6: Computational calculations of the favourability of thiohemiketal formation for all four 
heterocycles shown in Figure 1.15 are descried in Chapter II  
Chapter II describes the initial computational studies combined with UV-vis experimental 
titrations employed for modelling the relative thiohemiketal formation properties of the 
imidazoleindolone and triazoleindolone heterocycles, alongside the pyrimidoindolone and the isatin 
ring systems. The aim was to study the kinetics and thermodynamics of thiol addition to the ketone 
groups of the different heterocycles as an indication of their propensity to inhibit caspase-3. (Scheme 
1.6). Chapter IV details the design and synthesis of the initial imidazoleindolone and triazoleindolone 
target heterocycles.  
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CHAPTER II: 
INITIAL COMPUTATIONAL 
MODELLING & UV-VIS 
TITRATIONS  
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II. INITIAL COMPUTATIONAL MODELLING & UV-VIS TITRATIONS  
II.1 Introduction 
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Figure 2.1: The core isatin heterocycle 41 and the heterocycles under study as caspase-3 inhibitors 
As discussed in Chapter I, the inhibition of caspase-3 stems from the formation of a covalent 
bond between the enzyme and the ketone carbonyl of a substrate, resulting in a tetrahedral 
thiohemiketal intermediate.69 As a result of this inhibition mechanism, an electrophilic carbonyl 
carbon in the correct position is crucial for inhibitory activity. However, a highly electrophilic or 
reactive carbonyl may result in non-specific interactions with nucleophilic moieties in biological 
systems. Indeed, the isatin sulfonamides are suboptimal as caspase-3 binding apoptotic imaging 
probes due to poor signal-to-noise ratio of PET images, attributed to background interactions of the 
highly electrophilic isatin ketone (Chapter I).57, 80  
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Scheme 2.1: Electron density delocalisation of the isatin 41, pyrimidoindolone 42, imidazoleindolone 52 and 
triazoleindolone 53 heterocycles 
    Like the pyrimidoindolone 42, the triazoleindolone 53 and imidazoleindolone 52 are 
structurally similar to the isatin heterocycle 41, with all being aromatic heterocycles bearing the 
crucial ketone carbonyl in analogous positions. Scheme 2.1 shows that direct delocalisation onto the 
ketone carbonyl can occur with the imidazoleindolone and triazoleindolone heterocycles, but not 
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with the pyrimidoindolone and isatin structures. This is expected to impact on the overall reactivity 
of the ketone carbonyls. It was hoped that the presence of an imidazole and triazole rings in the 
imidazoleindolone and triazoleindolone heterocycles would give extended aromatic systems that 
would favourably modulate the ketone reactivity, limiting unwanted interactions with nucleophiles 
in the cytosol of biological systems. 
II.2. Computational Analysis of the Heterocycles  
Molecular properties and mechanisms involved in the biological actions of molecules are 
generally too complex to be described by a detailed computational model for the design of new 
biologically active compounds.88 Nevertheless, by means of statistical treatment of a set of 
molecules, qualitative properties of molecular structures may be determined for various descriptors 
such as, octanol-water partition coefficient,89 Van der Waals interactions,90, 91 
electronegativity/electropositivity, molecular dipole moment92 and bond distances or connectivity.93  
Unlike experimental measurements, there is no statistical error in quantum-chemical 
calculations but there are inherent accuracy issues associated with the derived assumptions required 
to facilitate the calculations.94 In calculations of properties in a series of related compounds, the 
computational error is considered to be approximately constant throughout the series.88, 94 Thus, 
relative values are calculated, which can be meaningful in revealing characteristic trends even though 
the absolute values may not be quantitatively correct.88, 94 
Computational studies are considered of vast importance in modern drug design and have 
been successfully used to predict or account for correlations between structure and activity.94 As 
such, computational calculations have been effectively used to predict hemiacetalisation equilibrium 
constants with clear correlations with experimental data.95 To assess, and attempt to predict the 
potential potencies of the imidazoleindolone and triazoleindolone structures, as well as the 
pyrimidoindolone heterocycle in comparison to the isatin ring, computational studies were initially 
employed. That is, by using computational studies to analyse the relative favourability of thiol 
addition to the heterocycles’ ketone groups, we aimed to deduce the likelihood of the heterocycles 
acting as effective caspase-3 inhibitors.  
As shown in Figure 2.1, the core heterocycles were used for the computational calculations 
as we aimed to examine the relative properties of the pharmacophores, excluding the added effects 
of substituents. The N-methyl substituted isatin 41 was chosen instead of the unsubstituted 
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equivalent in order to avoid any complexities of the amide tautomer. For the pyrimidoindolone 
heterocycle, the spirocyclopently substituted structure 57 was used as this was shown to be the ideal 
substituent in SAR studies conducted by Havran et al., with regards to aqueous stability (Chapter I).58 
As we intended to incorporate the spirocyclopently substituent in the initial radiolabelled 
pyrimidoindolone target to be synthesised for biological characterisation, we chose to also employ 
this substituent for computational studies, though it was not expected to have a major impact on the 
results obtained.  
II.2.1. Computational Methods 
Density Functional Theory (DFT) is employed as a quantum mechanical modelling method 
with which to investigate the electronic structure in realistic models of atoms, molecules and their 
surfaces.96 DFT predicts a variety of molecular properties ranging from molecular structures, 
vibrational frequencies, atomisation energies to ionization energies, electric & magnetic properties 
and reaction pathways.96 Specific DFT functionals are used when calculating the properties of many-
electron systems, with the reliability of computational calculations depending on the functional 
chosen for the studies. There are various types of DFT functionals designed for use in various areas 
of computational chemistry calculations.97 An extensive list of density functionals developed for 
calculations can be found in the cited review.97 For the purpose of our calculation, two different 
functionals were employed: 
a) wB97xD - a functional that includes dispersive non-covalent interactions, optimised for van 
der waals long-range corrected interactions for empirical atom–atom dispersion. This 
functional has been reported to be signiﬁcantly superior for non-bonded interactions, with 
satisfactory performance for covalently bonded interactions.98 This functional was therefore 
ideal for predicting transition state energies involved in thiohemiketal formation, where long 
range interactions, such as weak S…C and H…O bonds are important. Since this functional is 
used for predicting non-covalent as well as covalent interactions, it was expected to produce 
adequate results relating to the ground state energies of the reactants and products involved 
in the thiohemiketal formation.  
b) M062X - a functional that considers charge transfer between bonds as well as 
thermochemistry properties.97 As thermochemistry combines thermodynamics with bond 
energies in the calculation of quantities such as enthalpy, entropy and free energy, this 
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functional was expected to give an efficient model for the equilibrium constant of 
thiohemiketal formation derived from free energy calculations.  
In computational chemistry calculations, functionals are combined with a relevant basis set. 
In the present study, calculations were performed using the wB97xD and M062X functionals with the 
commonly used ‘6-31G (2d,2p)’ basis set, which adds the polarisability function of molecular orbitals 
including s, p and d orbitals, denoted by “(2d,2p)”.99-102 For ‘heavy atoms’ (defined as atoms heavier 
than hydrogen), up to 2 d orbitals are added, while up to 2 p orbitals are added for the hydrogen 
atom. In cases where transition metals are involved, 2 f orbitals are added to the basis set.99-102  
In addition, all calculations were simulated in DMSO, employing the self-consistent reaction 
field method (SCRF)103 to account for solute-solvent interactions, described in terms of a dipole 
moment.104 Water was not used as the ‘solvent’ to avoid hydration and strong hydrogen-bonding 
effects interfering with results.  
All calculations were performed with the Gaussian 09 software for the ground states of the 
molecules with values directly extracted from the Gaussian output file.105 
II.2.2. Calculation of Ketone Partial Chargesa  
Using the 6-31G (2d,2p) basis set combined with the chosen functionals wB9xD and M062X, 
two types of partial charges were calculated for the heterocycles; the MK (Merz Kollman)106, 107 and 
Mulliken108 charges, which use electrostatic potential and normal electron population respectively. 
These are the two most commonly used methods for determining atomic charges.109 While Mulliken 
analysis divides electronic population equally between the two atoms of a bond (the so called 
Mulliken population analysis) using linear combinations of atomic and molecular charges to 
determine partial charges,108 the MK or electrostatic approach assigns point charges to atomic 
centres in order to best reproduce the electrostatic potential. 106, 107 
 
 
 
                                                          
a Computational calculations of partial charges were carried out by the computational chemist, Alexandra Simperler, 
Imperial College London 
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Table 2.1: Calculated partial charges on the ketone carbon atom of the heterocycles 
Heterocycle 
wB97xD M062X 
MK Charges Mulliken Charges MK Charges Mulliken Charges 
Isatin (a) +0.48 +0.26 +0.46 +0.29 
Pyrimidoindolone (b) +0.47 +0.27 +0.41 +0.30 
Imidazoleindolone (c) +0.51 +0.28 +0.49 +0.31 
Triazoleindolone (d) +0.52 +0.29 +0.51 +0.33 
 
Results obtained from the computational calculation of the two types of partial charges are 
listed in Table 2.1. In general, there were very little differences in partial charges across the four 
different heterocycles, with both sets of data for each functional in agreement. That is, MK charges 
obtained with wB97xD functional correlates in trend with those obtained with the M062X functional 
and the same goes for the Mulliken charges. However, the figures obtained for MK charges were 
generally larger than those obtained for Mulliken charges. The computational definition of atomic 
charge is arbitrary and typically do not correspond to direct experimentally measurable quantities.94 
In addition, the methods are mostly defined to reproduce heats of formation, ionization potentials, 
and/or geometric characteristics of molecules.94 In spite of this, obtained numerical quantities can 
give at least a qualitative picture of the charge distribution in a molecule.94, 110 
 The ketone carbon partial charges for the different heterocycles suggested that, the 
electrophilicity of their ketone groups are similar and may therefore have a similar reactivity with 
thiol nucleophiles. From the small differences in the data obtained, it would appear that the partial 
charges of the triazoleindolone and the imidazoleindolone heterocycles are similar and slightly more 
electrophilic than the pyrimidoindolone and isatin heterocycles which are in turn also similar. 
Nonetheless, the Mulliken and MK partial charges only considered the charge distribution within the 
carbonyl bond of the heterocycles, in the absence of the thiol nucleophile and therefore did consider 
the effect of a dipole induced when the ketone is in close proximity with a thiol, as shown by the 
schematic below (Figure 2.2). The error margins in computational studies make it unfeasible for small 
differences to be analysed. It was therefore concluded that the electrophilicities of the heterocycles 
are likely to be similar.  
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Figure 2.2: Ketone carbon partial charges Vs the dipole induced when a ketone is in close proximity to a thiol 
nucleophile 
II.2.3. Transition States and Gibbs Free Energiesb  
Following the partial charge measurements, the activation energy and Gibbs free energy 
influencing the likelihood of the forward and back reactions were calculated. These were expected 
to better represent the reaction profile of thiohemiketal formation. Unlike the MK and Mulliken 
charges, the use of functionals such as M062X and wB97xD, and basis sets such as 6-31G (2d,2p) have 
been shown to successfully predict chemical properties that were directly supported by experimental 
results.94, 110 
N
O
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54 56
 
Scheme 2.2: The equilibria between the ketone heterocycles and their thiohemiketal products 
The simple methylthiol was used as the model thiol for the computational calculations in 
order to avoid potential non-nucleophilic effects of more complex thiols (Scheme 2.2). The flexibility 
of larger or more complex thiols would result in a number of conformations with different energies, 
while the presence of aryl groups in thiols was shown to lead to intramolecular π-π stacking which 
may enhance the stability of the transition states, influencing observed results. This is exemplified 
with paramethoxybenzylthiol in Figure 2.3 whose flexible Ar-CH2-SH moiety gave a thiohemiketal 
product with two different conformations and one conformer showing π-π stacking.   
                                                          
b Gibbs free energies and hydrogen bonding distances were calculated by the computational chemist, Alexandra 
Simperler, Imperial College London 
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Figure 2.3: Parallel (left) and perpendicular (right) approach of PMBSH resulting in π-π stacking or vertical 
alignment of the thiol with the imidazoleindolone heterocycle 52 
Table 2.2: Computational results of thiol addition to the heterocycles calculated using wB97xD and M062X 
functionals with the 631G (2d,2p) basis set, including intramolecular hydrogen bonding distances and 
equilibrium constants calculated from free energy values 
wB97xD Energies298K [kJ/mol] 
 
H-bonding 
distance (Å) 
 
K 
Ketone GTS-GReact GProd-GReact GTS-GProd  
Isatin (a) 151 -3.69 155 2.67 4.43 
Pyrimidoindolone (b) 163 +7.25 155 2.33 0.05 
Imidazoleindolone (c) 162 +7.83 154 2.86 0.04 
Triazoleindolone (d) 171 +1.02 171 3.10 0.66 
For the free energy ΔG, wB97xD: a < d < b ≤ c; for the equilibrium constant, K: a > d > b ≥ c 
For the activation energy, wB97xD: a < c ≤ b < d 
Intramolecular hydrogen bonding distance, wB97xD: b < a < c < d 
M062X Energies [kJ/mol] 
H-bonding 
distance (Å) 
 
K Ketone GTS-GReact GProd-GReact GTS-GProd 
Isatin (a) 141 -18.73 160 2.51 1920 
Pyrimidoindolone (b) 139 -9.74 149 2.32 51 
Imidazoleindolone (c) 154 -4.71 159 3.03 7 
Triazoleindolone (d) 163 -12.41 175 3.13 150 
For the free energy ΔG, M062X: a < d < b < c; for the equilibrium constant, K: a > d > b > c 
For the activation energy, M062X: b ≤ a < c < d 
Intramolecular hydrogen bonding distance, M062X: b ≤ a < c ≤ d 
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The relative activation energies, Gibbs free energies and equilibrium constants obtained using 
the functionals wB97xD and M062X, combined with the 6-31G (2d,2p) basis set are shown in Table 2.2.  
 
Figure 2.4: Plots of the calculated reaction pathway energies 
Analysis of the wB97xD data suggested that the free energy, ΔG of thiol addition increases in 
the order; isatin < triazoleindolone < pyrimidoindolone ≤ imidazoleindolone. That is, the 
favourability of thiohemiketal formation decreases in the same order with thiol addition to the isatin 
shown to be the most favourable, followed by the triazoleindolone and then the pyrimidoindolone 
and the imidazoleindolone heterocycles. Reactions with negative ΔG values are favourable because 
a high energy compound reacts to give a lower energy product, while reactions with positive ΔG 
values are not favoured. In the data calculated using the wB97xD functional, only the isatin 
heterocycle has a negative free energy and is apparently the only heterocycle that would favourably 
react with a thiol to form a thiohemiketal. Computational data are however qualitative results, 
showing predicted relative free energies of thiol addition to the heterocycles and hence the positive 
free energies were not taken as indications that thiohemiketal formation from the other heterocycles 
are unfavourable.  
Unlike the results obtained with the wB97xD functional, negative ΔG values were obtained 
for all four heterocycles using the M062X functional. Despite the quantitative differences, both the 
wB97xD and the M062X functionals showed the same order of thiol addition favourability according 
to the obtained ΔG values: isatin > triazoleindolone > pyrimidoindolone > imidazoleindolone.  
For both functionals, the lowest activation energy was obtained for the isatin ring, indicating 
that thiol addition may also be fastest with the isatin heterocycle. The pyrimidoindolone and the 
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imidazoleindolone structures were shown to have comparatively lower activation energies compared 
to the triazoleindolone heterocycle, suggesting that, though thiohemiketal formation may be more 
favourable for the triazoleindolone heterocycle, the rate of thiol addition to the pyrimidoindolone 
and imidazoleindolone heterocycles would be faster. Nevertheless, the lower free energy for the 
triazoleindolone heterocycle would result in a high proportion of the triazoleindolone-thiohemiketal 
product at equilibrium.  
N
Me
S O H
O
2.5A
Isatin 41 - thiohemiketal
N
N
S O H 2.3A
Pyrimidoindolone 57 - thiohemiketal  
Figure 2.5: Intramolecular hydrogen bonding, forming a 5-membered ring in the isatin 41 and 
pyrimidoindolone 57 thiohemiketal products 
Intramolecular hydrogen bonding distances, shown for the isatin and pyrimidoindolone 
thiohemiketal products in Figure 2.5, were measured in attempt to account for the trends observed. 
From the M062X data, the pyrimidoindolone and isatin ring systems have the shortest hydrogen 
bonding distances of 2.32 Å and 2.51 Å respectively, a distance range that is reported to result in 
‘strong, mostly covalent’ hydrogen bonding.111, 112 Hydrogen bonding distances of 3.03 Å and 3.13 Å 
were obtained for the triazoleindolone and imidazoleindolone heterocycles respectively, a range 
reported to form hydrogen bonds that are ‘mostly electrostatic’.111, 112 Intramolecular hydrogen 
bonding was expected to favourably impact the stability of the thiohemiketal products. However, the 
obtained hydrogen bonding distances for the thiohemiketal products did not directly correlate with 
ΔG values. 
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Using the obtained ΔG values, the equilibrium constants for thiol addition were calculated, 
using Equation 2.3, derived from Equations 2.1. The equilibrium constant is directly related to, and 
inversely proportional to free energy; the lower the free energy the higher the equilibrium constant 
and the more favourable the forward reaction. A K value of above 1 was obtained for all heterocycles 
using the M062X functional, indicating that that the reaction with a thiol lies on the thiohemiketal 
product side at equilibrium, albeit to different extents for the different heterocycles. The two 
functionals showed the isatin to have the highest K value by a significant margin.  
Both the wB97xD and M062X functionals are regularly used in computational calculations 
with the two functionals considering such a wide spectrum of properties that it cannot be 
conclusively determined which functional gave the most accurate representation of the favourability 
of thiohemiketal formation. Both functionals however, are in agreement with the obtained trend in 
the free energy of thiol addition to the heterocycles; isatin > triazoleindolone > pyrimidoindolone > 
imidazoleindolone. 
II.3. Experimental UV-Vis Analysis of the Heterocycles 
Initial computational analysis of the three heterocycles in comparison to the isatin ring 
suggested that all three heterocycles under study have the propensity to inhibit caspase-3 through 
the favourable addition of a cysteine thiol group to the ketone carbonyls. The next step was to 
experimentally study the heterocycles in order to validate these predictions. For initial experimental 
studies, UV-vis absorption spectroscopy was employed for the determination of thiohemiketal 
equilibria. The experimental values were then compared to the relative trend in the values calculated 
from the computational model.  
N
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Figure 2.6: Unsubstituted and substituted imidazoleindolone heterocycles 
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In order to carry out the UV-vis titrations, the first step was to synthesise the core 
heterocycles. For the purpose of not diverting beyond the scope of this chapter, the synthesis of the 
pyrimidoindolone, imidazoleindolone and triazoleindolone heterocycles are described in subsequent 
Chapters III and IV. The pyrimidoindolone heterocycle 57 and imidazoleindolone heterocycle 52 were 
successfully synthesised. Isatin 41 is commercially available and was purchased from Sigma-Aldrich. 
Unfortunately, the synthesis of the novel triazoleindolone heterocycle proved very problematic and 
was ultimately not achieved.  
Additionally, the bromide and sulfonamide-substituted imidazoleindolone heterocycle 58, 59 
and 60 were prepared and used to analyse substituent effects on thiohemiketal formation (Figure 
2.6). The bromide substituent was chosen due to facile synthesis of this derivative while the 
sulfonamide substituent was included to closely resemble the isatin sulfonamides. 
II.3.1. UV-Vis Spectroscopic Titrations of Thiohemiketal Formation  
The interaction of the relevant ketone with a thiol was monitored from the decrease in the 
ketone absorption at the maximum absorption wavelength. A similar experiment was successfully 
conducted by Aulabaugh et al. who employed UV-vis spectroscopy to monitor the interaction of isatin 
with caspase-3 resulting from thiohemiketal formation in the enzyme active site.87 The formation of 
a thiohemiketal results in the reduction of the ketone absorption. As a result, the concentration of 
the thiohemiketal formed is proportional to the difference in the UV-vis absorption before and after 
thiol addition to the ketone solution.  
To experimentally determine the equilibria between the ketone derivatives and their 
thiohemiketal products, anhydrous DMSO was used as the solvent, in order to limit the possible 
ketone hydration by residual water. Aiming to closely emulate the cysteine thiol residue found in the 
caspase-3 active site, the tripeptide, glutathione was initially employed as the thiol for the study but 
this was insoluble in DMSO. As a result, the simple thiol, PMBSH was used instead. Methanethiol, 
which was employed in the computational studies was not used in order to avoid problems with 
handling this toxic gaseous compound. The use of different thiols should not restrict comparisons of 
the computational data with the experimental results, since relative trends, rather than absolute 
figures were to be compared for the two sets of data, each with the thiol nucleophile kept constant. 
Given the sensitivity of thiols to oxidation in air, solutions were degassed and stoppered UV cuvettes 
under argon were used for all experiments.   
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 The UV-vis absorption of all the heterocycles under study were measured in DMSO over the 
course of 24 hours to ascertain the stability of the ketone substrates in DMSO. All heterocycles were 
proven to remain stable in DMSO with no signs of decomposition after 24 hours. The UV-vis 
absorption of mixtures of PMBSH were shown to be constant for 15 minutes after which the solutions 
were assumed to have reached equilibrium. Prolonged measurements for up to 12 hours showed 
that the absorption spectra of the ketone/PMBSH mixtures remained unchanged. The UV-vis 
absorption spectra and the resulting plots of absorption at varying thiol concentration are shown 
below in Figures 2.7 to 2.9. The table of absorption data for all heterocycles can be found in the 
appendix. The more favourable thiol addition to the isatin ring is evident from the UV-vis absorption 
spectra of thiol addition to the isatin ring (Figure 2.7), showing significant decreases in the ketone 
absorption with increasing thiol concentration. By contrast, the UV-vis absorption spectra of the 
imidazoleindolone and pyrimidoindolone heterocycles only show small decreases in ketone 
absorption for the same ketone/thiol concentrations (Figures 2.8 – 2.9).  
         
Figure 2.7: The UV-vis absorption spectra (left); and a plot of absorption (A) and ΔA Vs [thiol] for 2mM isatin 
41 solution titrated with 0 – 10 equivalents of PMBSH. For details of the absorption values at the different 
concentrations, see the Appendix (page 240). 
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Figure 2.8: The UV-vis spectra and a plot of absorption Vs [thiol] for 2mM imidazoleindolone 52 titrated with 
0 – 10 equivalents of PMBSH 
 
            
Figure 2.9: The UV-vis spectra and a plot of absorption Vs [thiol] for 2mM pyrimidoindolone 57 titrated with 
0 – 10 equivalents of PMBSH 
 
II.3.2. Calculating Equilibrium Constants using Benesi-Hildebrand Plots 
The Benesi-Hildebrand plot113, 114 is a convenient and widely used method for calculating 
binding constants and reaction equilibria when one-to-one conjugates are formed. The method relies 
on the measurement of characteristic electronic absorptions before and after the formation of an 
adduct.114 The mathematical derivation of the Benesi-Hildebrand equation is summarised below. 
Modification of the equation allows equilibrium constants to be calculated from plots showing the 
relationship between the UV-vis absorption and the concentration of one reaction component that 
was varied and used in excess amounts, without the need to determine the absorption coefficient of 
the reaction species.  
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where ΔA is the change in absorption at a particular wavelength, ε is the absorption coefficient, [kt]o 
is the initial ketone concentration and [th] is the thiol concentration. 
Modification of the equation to a double reciprocal plot gives:  
 
Hence, from a plot of the reciprocal of the change in absorption (1/ ΔA) versus the reciprocal 
of the thiol concentration (1/[th]), where the ketone concentration is kept constant and the thiol 
concentration is varied, K =  intercept/slope . The Benesi-Hildebrand plots of 1/ ΔA against 1/[th] for 
the heterocycles are shown below in Figures 2.10 - 2.12.   
 
 
 
Figure 2.10: The Benesi-Hildebrand plot for thiol addition to isatin 41, giving a K value of 0.19 mM-1 
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Figure 2.11: The Benesi-Hildebrand plot for thiol addition to imidazoleindolone 52, giving a K value of 5.85 x 
10-4 mM-1 
 
Figure 2.12: The Benesi-Hildebrand plot for thiol addition to the pyrimidoindolone 57, giving a K value of 
0.03 mM-1 
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II.3.3. Experimental Results  
Table 2.3: Calculated K values for thiol addition 
Ketone Thiohemiketal K / mM-1 
Isatin 41 0.19 
Pyrimidoindolone 57 0.03 
Imidazoleindolone 52 0.0005 
The equilibrium constants calculated from the Benesi-Hildebrand plots in Figures 2.10 – 2.12 
are summarised in Table 2.3. In contrast to the computational results (using the M062X functional), 
all the experimental K values are less than 1, suggesting that the ketone dominates over the 
thiohemiketal product at equilibrium for all the heterocycles. This was apparent from the UV-vis 
absorption spectra of the pyrimidoindolone and imidazoleindolone heterocycles where small 
changes in the ketone absorption were observed upon thiol addition (Figures 2.8 and 2.9). However, 
the trend in experimental K values and therefore the favourability of thiol addition reflects the trend 
obtained from computational studies:   
Isatin 41 > Pyrimidoindolone 57 > Imidazoleindolone 52 
Experimentally, isatin thiohemiketal formation is approximately 6-fold and 380-fold more 
favourable than thiol addition to the pyrimidoindolone and imidazoleindolone heterocycles 
respectively. 
It is worth noting that thiohemiketal formation was confirmed from the 1H NMR of isatin 41 
and PMBSH mixture in deuterated DMSO (Figures 2.13 – 2.16). The signal intensity of the 
thiohemiketal increases upon increasing the ratio of thiol to isatin from 1:1 to 3:1 in order to push 
equilibrium further towards thiohemiketal formation. A clear NMR could not be obtained for the 
other heterocycles due to their low K values for thiohemiketal formation.  
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Figure 2.13: 1H NMR of the isatin 41 in DMSO (aromatic region only), measured with a 400 MHz 
spectrometer 
 
Figure 2.14: 1H NMR of PMBSH in DMSO (aromatic region only), measured with a 400 MHz spectrometer 
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Figure 2.15: 1H NMR of a 1:1 mixture of isatin 41 and PMBSH in DMSO (aromatic region only), measured with 
a 400 MHz spectrometer 
 
 
Figure 2.16: 1H NMR of a 1:3 mixture of isatin 41 and PMBSH in DMSO (aromatic region only), measured with 
a 400 MHz spectrometer 
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II.3.3.1. The Substituent Effect 
The UV-vis absorption spectra and the resulting plots of absorption versus thiol concentration 
for the bromide- and sulfonamide-substituted imidazoleindolone heterocycles 58, 59 and 60 are 
shown below in Figures 2.17 – 2.19. The corresponding Benesi-Hildebrand plots are shown in Figures 
2.20 – 2.22.  
      
Figure 2.17: The UV-vis spectra and a plot of absorption Vs [thiol] for 2mM imidazoleindolone 58 titrated 
with 0 – 10 equivalents of PMBSH 
 
           
Figure 2.18: The UV-vis spectra and a plot of absorption Vs [thiol] for 2mM imidazoleindolone 59 titrated 
with 0 – 10 equivalents of PMBSH 
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Figure 2.19: The UV-vis spectra and a plot of absorption Vs [thiol] for 1mM imidazoleindolone 60 titrated 
with 0 – 10 equivalents of PMBSH 
 
 
Figure 2.20: The Benesi-Hildebrand plot for thiol addition to the bromo-substituted imidazoleindolone 58, 
giving a K value of 0.006 mM-1 
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Figure 2.21: The Benesi-Hildebrand Plot for thiol addition to the bromo-substituted imidazoleindolone 59, 
giving a K value of 0.006 mM-1 
 
Figure 2.22: The Benesi-Hildebrand plot for thiol addition to the sulfonamide-substituted imidazoleindolone 
60, giving a K value of 0.03 mM-1 
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Table 2.4: Calculated thiohemiketal K values of substituted imidazoleindolone heterocycles 
                        Ketone                                        Thiohemiketal K /mM-1 
Imidazoleindolone 52 0.0005 
Br-Imidazoleindolone 58 0.006 
Br’-Imidazoleindolone 59 0.006 
Sulfonamide-imidazoleindolone 60 0.03 
As shown in Table 2.4, the imidazoleindolone heterocycle becomes more susceptible to 
thiohemiketal formation when substituted with an electron withdrawing group. The favourability of 
thiohemiketal formation increases by approximately 12-fold with a bromide substituent on the 
phenyl ring (58) or on the imidazole ring (59), and by 60-fold when substituted with the more electron 
withdrawing sulfonamide group. The favourability of thiol addition to the sulfonamide substituted 
imidazoleindolone 60 was shown to be similar to that of thiol addition to the pyrimidoindolone 57, 
but still less than the formation of a thiohemiketal from the unsubstituted isatin 41.  
Further computational analysis using the bromide substituted imidazoleindolone 58 was 
obtained and compared with the results obtained for the unsubstituted imidazoleindolone 52 using 
the M062X functional. We found that the equilibrium constant for thiohemiketal formation increased 
by 12-fold with the bromide substituted heterocycle 58; the exact increase observed experimentally 
(Table 2.5).  
Table 2.5: The computational results of unsubstituted imidazoleindolone 52 compared to the bromo-
substituted imidazoleindolone 58 
M062X Energies298K [kJ/mol] H-bonding 
distance (Å) 
K 
Ketone GTS-GReact GProd-GReact GTS-GProd 
Imidazoleindolone 52 154 -4.71 159 3.03 7 
Br-Imidazoleindolone 58 153 -11.02 164 3.04 85 
For the free energy ΔG: 58 < 52 and the resulting K: 58 > 52 
For the barrier between the transition state and reactant (activation energy): 52 ≤ 58 
For the intramolecular hydrogen bonding distance: 52 ≤ 58 
 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
76 | P a g e  
 
II.4. Conclusion 
In the present study, the favourability of thiol addition to the ketone group of the four 
heterocycles under study was established through the computational calculation of Gibbs free 
energy, in addition to other potentially contributing factors such as intramolecular hydrogen bonding 
and ketone partial charges. The predicted trend in the computationally derived favourability of 
thiohemiketal formation was supported by the results obtained from UV-vis titration of the ketone 
substrates with PMBSH.  
The trend in the calculated and experimentally determined thiohemiketal equilibria may not 
be reflected in biological binding affinities, where the overall structure of a ketone substrate has a 
substantial effect on caspase-3 binding and subsequent inhibitory activity. Nevertheless, by 
comparing the determined properties of the three heterocycles under investigation to the 
extensively studied isatin sulfonamide, their relative caspase-3 inhibition potency may be predicted.  
Though the computational and experimental data gave different absolute values, both sets of 
results showed the same trend in equilibrium constant (K) values and therefore the favourability of 
thiohemiketal addition: Isatin 41 > Pyrimidoindolone 57 > Imidazoleindolone 52. Both sets of results 
are in agreement in suggesting that the isatin heterocycle is much more favourable towards 
thiohemiketal formation, followed by the pyrimidoindolone 57, with the imidazoleindolone 52 being 
the least favourable. While the triazoleindolone heterocycle 53 was not used the in UV-vis equilibria 
calculations due to synthetic difficulties, the agreement of the computational results with the 
experimental data for the other three heterocycles gives us the confidence to conclude the 
favourability of thiohemiketal formation from the triazoleindolone heterocycle 53 is second only to 
the isatin ring, and more favourable than the pyrimidoindolone 57 and imidazoleindolone 52 
heterocycles.  
Additionally, the influence of substituents on thiohemiketal formation was shown by the 
experimental K values of the bromide and sulfonamide substituted imidazoleindolone heterocycles, 
58, 59 and 60. As expected, the presence of electron withdrawing substituents increased the 
favourability of thiohemiketal formation, likely due to increased electron deficiency of the ketone 
carbonyl.  
The model of a ketone reacting with a simple thiol represents the formation of a 
thiohemiketal in an intermolecular reaction, whereas the intracellular formation of a thiohemiketal 
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resulting from a ketone-substrate binding to an enzyme active site cavity is comparable to an 
intramolecular reaction as the reacting groups are brought together in very close proximity.115, 116 It 
has been reported that such intracellular reactions can be favoured over intermolecular reactions by 
a factor of 103-108 M, depending on the extent to which optimal substrate orientation in the enzyme 
active site is achieved, and the reduction of conformational degrees of freedom.115, 116 With this in 
mind, the favourable results obtained from computational and UV-vis studies are sufficiently 
encouraging to warrant further study, progressing to the synthesis and biological characterisation of 
caspase-3 binding apoptotic PET probes based on the imidazoleindolone 52, pyrimidoindolone 57 
and triazoleindolone 53 pharmacophores. 
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III. [18F]-Fluorinated Pyrimidoindolone to Image Caspase-3  
III.1. Introduction: Target Structure Design  
While the isatin sulfonamides are the current state-of-art of caspase-binding radioligands, 
PET imaging of apoptosis using these inhibitors is hampered by low target-to-background ratio 
(Chapter I.4.2). The pyrimidoindolones (Figure 3.1) subsequently emerged as potential alternatives 
to the isatin sulfonamides with initial SAR studies reported by Havran et al. (Chapter I.4.3).58 As 
previously discussed (Chapter I.4.3), a recent study showed that isatin sulfonamides bind to a single 
domain of the dimeric caspase-3 enzyme while the pyrimidoindolones bind to both domains with 
equal affinity.87 It was hoped that the dual binding of pyrimidoindolones to the caspase active site 
compared to the half-site activity of the isatin sulfonamide would lead to increased specific binding 
activities, reducing non-specific background signals when used for PET imaging.  
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Figure 3.1: The pyrimidoindolone heterocycle and the structurally similar to isatins 
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Figure 3.2: The current isatin lead compound [18F]22, a previously tested isatin sulfonamide 55, and the 
proposed initial pyrimidoindolone structure [18F]62 
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Figure 3.3: The designed pyrimidoindolone target structure 62 to be synthesised, radiolabelled and 
characterised for capsase-3 imaging was modelled on the structure of the lead isatin 22. 
Results of the SAR studies reported by Havran et al. revealed similarities to the isatin 
sulfonamides in terms of hydrophobic and hydrogen binding interactions with the caspase-3/7 
binding cleft.58  To allow direct comparisons with isatin sulfonamide 22, the target pyrimidoindolone 
was designed with the same triazole ring substituent found in the lead isatin probe. SAR studies of 
the isatin sulfonamides have shown that triazole substituents are well tolerated on both the 
sulfonamide and amide sides of the isatin ring while maintaining high potency and selectivity as 
shown in Figure 3.2. For ease of synthesis, the triazole ring was positioned on the sulfonamide side 
of the pyrimidoindolone ring (Figure 3.2). On the amidine side of the pyrimidoindolone, substitution 
can only occur on the unfunctionalised aliphatic carbon atoms. Hence, to allow facile synthesis, 
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reagents for the construction of the pyrimidoindolone ring which already contain the planned 
substituent were preferred. For optimal aqueous stability with high potency, based on results 
reported by Havran et al. (Chapter I.4.3),58  the spirocyclopentyl substituent was selected (Figure 3.3). 
III.2. Target Pyrimidoindolone Synthesis  
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Scheme 3.1: Retrosynthetic analysis showing the route employed for the target pyrimidoindolone synthesis 
The retrosynthetic analysis, summarising the route employed for the target pyrimidoindolone is 
shown in scheme 3.1 and detailed in this section. The core pyrimidoindolone ring differs from that of the 
core isatin ring by the substitution of an amide group for an amidine group. Hence, similar reactions 
used to prepare the isatin sulfonamide were used for the initial steps. The synthesis of the 
pyrimidoindolone target 62 started with the treatment of sodium 5-isatin sulfonate 63 with 
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phosphorus oxychloride in sulfolane at 60 ᴼC, converting the sulfonate group into the sulfonyl 
chloride 64 in 43 % yield (Scheme 3.2).58 
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Scheme 3.2: Preparation of the (S)-2-(benzyloxymethyl)pyrrolidine hydrochloride 68 in 79 % yield over 3 
steps and the isatin sulfonyl chloride 64.57, 58 
Reaction of sulfonyl chloride 64 with the required amine, (S)-2-(benzyloxymethyl)pyrrolidine 
68 would then give the isatin sulfonamide intermediate 69. The amine 68 was prepared from 
commercially available (S)-prolinol with an overall yield of 79 % (Scheme 3.2). First, the amine moiety 
of (S)-prolinol 65 was protected with a Boc group to give the N-protected prolinol 66, which was 
treated with NaH and benzyl bromide to give the intermediate 67 in 92 % yield. Subsequent 
deprotection of the Boc group then gave (S)-2-(benzyloxymethyl) pyrrolidine 68 as an HCl salt in 
quantitative yield (Scheme 3.2).  
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Scheme 3.3: Preparation of isatin sulfonamide 69 and ketal protected derivative 70 
Following the preparation of the amine 68, isatin sulfonamide 69 was prepared in 83 % yield 
by treatment of sulfonyl chloride 64 with amine 68 in the presence of triethylamine. To avoid possible 
side reactions involving the reactive ketone centre in subsequent steps, it was necessary to protect 
ketone 69 as ketal 70, obtained in 87 % yield from the condensation of ketone 69 with 1,3-
propanediol in the presence of catalytic TsOH (Scheme 3.3).  
III.2.1. Halomethylation of Cyclopentylcarbonitrile  
CN
Cl
CN
X Cl
Base
71 72  
Scheme 3.4: Attempted halomethylation of cyclopentylcarbonitrile 71.117 
Table 3.1: Unsuccessful reaction conditions for the preparation of nitrile 72 
Entry X Base Solvent Temp (ᴼC) Yield (%) 
1 I LDA THF -78 0 
2 I LDA THF -60 0 
3 I NaH THF 0 0 
4 I LDA THF 0 to -78 0 
5 Br LDA THF -78 0 
6 Br LDA THF 0 0 
7 Br LDA PhMe 0 0 
 
2,2-Dialkyl-3-halopropanenitriles are frequent intermediates in the synthesis of 
pyrimidoindolones to construct the amidine functional group. However, the preparation of these 
intermediates is hampered by the formation of polymeric by-products.117 Cliffe et al. reported a route 
towards these compounds via nitrile-stabilised carbanions.117 This involved the deprotonation of the 
nitrile α-proton at -65 ᴼC using LDA as the base, followed by the addition of the anion to a mixture 
containing excess dihalomethane in THF.  
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Despite the reported high-yielding preparation of 2-cyclopentyl-3-chloropropanenitrile,117 we 
encountered problems when preparing the compound 72, the intermediate in the synthesis of our 
pyrimidoindolone target (Scheme 3.4). As shown in Table 3.1, no reaction was observed using either 
THF or toluene as the solvent, bromochloromethane or chloroiodomethane as the alkylating agent, 
LDA as the base with temperatures ranging from -78 ᴼC to 0 ᴼC and reaction times of 1 – 18 hours.  
Sodium hydride (pKa = 35 in water), which has a pKa comparable to LDA (pKa = 35 in THF) was also 
used as the base in a large excess at 0 ᴼC overnight (Table 3.1, Entry 3). Unfortunately, only unreacted 
nitrile 71 was isolated from the reaction mixture. Dihalomethanes are known to form carbenoid 
species by the displacement of a halide following deprotonation by a strong base, which may 
compete with nucleophilic attack by nitrile carbanion.118 The lack of reaction was initially attributed 
to dihalomethane alkylating agents undergoing deprotonation by the 1-
lithiocyclopentanecarbonitrile anion or LDA under the reaction conditions, a process reported to 
occur readily with hindered amide bases in THF at -90 oC.119, 120 
 
 
 
 
 
 
 
 
 
 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
85 | P a g e  
 
D CN
CN
i. Base
ii. D2O/MeOD/MeI
(Me)
71 76  
Scheme 3.5: Attempted deuteration/methylation of nitrile 71  
Table 3.2: Unsuccessful reaction conditions for the deuteration/methylation of nitrile 71 
Entry Base Base eq. Solvent Temp (ᴼC) Time* % D/Me 
incorporation 
1 LDA 1 THF -78 1-2 hrs 0 
2 LDA 1 PhMe -78 1-2 hrs 0 
3 LDA 1 THF -60 1-2 hrs 0 
4 LDA 1 THF 0 1-6 hrs 0 
5 LDA 1 THF rt 1 to 18hrs 0 
6 LDA 3.5 THF rt 1 to 18hrs 0 
7 NaH 1 THF 0 2 hrs 0 
8 NaHMDS 1 THF 0 1 to 3hrs 0 
9 NaHMDS 1 THF rt 2 days 0 
10 NaHMDS 3.5 THF rt 3 days 0 
11 NaNH2 3 THF rt 18 hrs 0 
*Stirring time of a solution of the appropriate base and nitrile 71 at the stated temperature, prior to 
quenching with D2O, methanol-D4 or Me-I. 
Subsequent reactions (Table 3.2, Scheme 3.5), designed to investigate the efficiency of nitrile 
deprotonation at various temperatures by treatment with a base prior to quenching with deuterium 
oxide, deuterated methanol or methyl iodide were undertaken.  Both 1H NMR and mass spectrometry 
of reaction samples after quenching showed no incorporation of deuterium or the methyl group to 
give the species 76 (Scheme 3.5). No reaction was observed using LDA, followed by quenching at 
either -78 ᴼC, -60 ᴼC, 0 ᴼC or room temperature, where the base-nitrile mixture was stirred for 1 - 18 
hours in THF before quenching (Table 3.2, Entries 1, 3, 4, 5). Using excess LDA made no difference to 
the reaction outcome (Table 3.2, Entry 6). Cliffe et al. reported toluene as a superior solvent to THF 
for the reaction.117 This was attributed to toluene reducing the basicity of the carbanion so that the 
possible carbenoid formation from the dihaloalkane and consequent side-reactions are less likely. 
The reaction was consequently repeated in toluene; however no incorporation of either deuterium 
or a methyl group (from MeI) was observed (Table 3.2, Entry 2).  
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It became apparent that problems with the deprotonation of nitrile 71 accounted for the 
unsuccessful halomethylation reactions. As nitrile α-protons are known to be sufficiently acidic to be 
deprotonated by LDA, it was thought that the synthetic problem could stem from the stability of the 
carbanion formed following deprotonation of the nitrile 71. In order to trap the apparently unstable 
carbanion immediately after deprotonation, a reaction was carried out in which a precooled solution 
of LDA was added to a solution containing both the cyclopentylcarbonitrile and excess electrophile 
(bromochloromethane) at -78 ᴼC. This procedure successfully gave the desired halomethylated 
product 72, though with a low yield of 24 %. 1H NMR and mass spectrometry of the mixture of by-
products indicated polymeric species containing several chlorine atoms, a problem reported to occur 
in the photochemical preparation of 2,2-dialkylethanenitrile and in the reaction of dihalomethanes 
with 2-arylethanenitriles.117 A sufficient amount of the desired intermediate 72 was obtained to 
proceed with the synthesis of the target pyrimidoindolone probe. However, in order to prepare a 
library for future SAR studies of the pyrimidoindolone heterocycles, it would be necessary to improve 
the efficiency and yield of the 2,2-dialkyl-3-halopropanenitrile preparation.  
III.2.2. Pyrimidoindolone Target Probe Synthesis; Part 2 
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Scheme 3.6: Synthesis of Pyrimidoindolone target continued.58 
Following the successful synthesis of the alkylating agent, 2-cyclopentyl-3-
chloropropanenitrile 72, the previously prepared ketal-protected isatin sulfonamide 70 was 
successfully alkylated by SN2 nucleophilic substitution to give the corresponding nitrile 77 in 71 % 
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yield (Scheme 3.6). The next step involved the reduction of the nitrile group to a primary amine which 
would then undergo intramolecular dehydration/cyclisation to give the amidine ring 79. An initial 
reduction attempt using catalytic Raney Ni at atmospheric pressure for up to 2 days was unsuccessful. 
Nitrile reduction was ultimately achieved using an autoclave at a pressure of ~70 psi and a very dilute 
solution. An autoclave was required to increase pressure and therefore concentration of hydrogen 
gas in the reaction mixture, while a dilute solution prevented intermolecular reactions which may 
compete with the subsequent desired intramolecular cyclisation. Amidine 79, was isolated from the 
hydrogenation reaction mixture as the major product and the intermediate primary amine 78 as the 
minor product. Filtration to remove the Raney Ni catalyst and heating the reduction reaction mixture 
fully converted primary amine 78 to amidine 79, with a total yield of 83 % (Scheme 3.6).  
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Scheme 3.7: Full deprotection reaction of amidine 79.58 
In the next step, the fully deprotected structure 80 was obtained in 81 % yield by the 
treatment of amidine 79 with methanesulfonic acid, resulting in the acid-catalysed removal of the 
benzyl ether and ketal hydrolysis (Scheme 3.7). Introduction of a propargyl group by the O-alkylation 
of alcohol 80 would have then completed the synthesis of the radiochemistry alkyne precursor 81 
(Scheme 3.8). However, attempts to O-alkylate alcohol 80 using propargyl bromide 74 under several 
reaction conditions failed to give the desired alkyne precursor 81 (Scheme 3.8, Table 3.3).  
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Scheme 3.8: Attempted alkylation of alcohol 80 with propargyl bromide 
Table 3.3: Attempts at the preparation of alkyne 81 
Entry Base/ Catalyst Solvent Temp (ᴼC) Time Observation 
1 KOH THF rt 5-18 hrs No reaction 
2 KOH DMF rt 10 mins Decomposition 
3 NaH THF rt 4-12 hrs No reaction 
4 NaH DMF rt 5-10 mins Decomposition 
5 K2CO3 Acetone reflux 12 hrs Unknown product 
6 NaH / Bu4NI THF rt 18 hrs No reaction 
7 NaH / Bu4NI THF reflux 2 hrs Decomposition 
8 K2CO3/ Bu4NI THF rt 3 days No reaction 
9 Cs2CO3 Propargyl bromide/ 
Acetone 
reflux 18 hrs Decomposition 
As shown on Table 3.3, in general, no reaction was observed when the alcohol 80 was treated 
with base (KOH, NaH, or NaH/Bu4NI, K2CO3/ Bu4NI) in THF at room temperature which was attributed 
to the limited solubility of the various bases in THF (Table 3.3, Entries 1, 3, 6, 8). However, heating 
the THF reaction mixture to reflux led to the decomposition of the starting material (Table 3.3, Entry 
7). The use of catalytic amounts of Bu4NI in an attempt to improve the reactivity of the electrophile 
was unsuccessful (Table 3.3, Entry 3 Vs 6). Reactions in DMF at room temperature quickly led to the 
decomposition of the starting material with either KOH or NaH as the base (Table 3.3, Entries 2, 4). 
Repeating the reaction in acetone using K2CO3 and heating to reflux for 12 hours gave an unknown 
product (Table 3.3, Entry 5), while the use of Cs2CO3, a more soluble base than K2CO3 in acetone, and 
a large excess of propargyl bromide led to complete decomposition (Table 3.3, Entry 9).  
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Scheme 3.9: Successful alkylation of ketal 82 to yield alkyne 83 
The unsuccessful reactions were attributed to the presence of a reactive electrophilic ketone 
in the pyrimidoindolone ring system of intermediate 80. It was possible that the anion produced upon 
deprotonation of the alcohol group of 80 reacted faster with the highly electrophilic ketone than with 
propargyl bromide, ultimately resulting in decomposition. On the basis of this, we felt that that 
alkylation with propargyl bromide would be successful if the ketone was protected. Hence the alcohol 
82 was prepared from the fully protected intermediate 79 using transfer hydrogenation with 
palladium in the presence of 1,4-cyclohexadiene to achieve the selective deprotection of the benzyl 
group (Scheme 3.9). Ketal-protected alcohol 82 was successfully alkylated in THF at room 
temperature using NaH to give the desired alkyne 83 in 60 % yield (Scheme 3.9).  
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Scheme 3.10: Preparation of the precursor alkyne 81 for radiolabelling by click reaction 
Subsequent ketal deprotection of alkyne 83 by treatment with methanesulfonic acid gave the 
radiochemistry precursor, as well as the unradiolabelled pyrimidoindolone reference precursor 81 in 
58 % yield (Scheme 3.10).  
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Scheme 3.11: Preparation of the pyrimidoindolone 62 cold reference by click chemistry 
To synthesise the target pyrimidoindolone cold reference, alkyne 81 was used in a ‘click’ 
reaction, a copper catalysed azide-alkyne cycloaddition between an azide and a terminal alkyne to 
give a 1,2,3-triazole (Scheme 3.11).121 The unradiolabelled target compound 62 was obtained in the 
moderate yield of 50 %. For radiolabelling, alkyne 81 would be used along with [18F]-fluoroethylazide 
37 to give the radiolabelled target pyrimidoindolone probe [18F]62, as described in the next section.  
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Scheme 3.12: Preparation of tosyl radiochemistry precursor 84 
We also intended to explore radiolabelling by direct nucleophilic displacement with 
[18F]fluoride. The tosyl triazole precursor 84 to be radiolabelled by nucleophilic displacement using 
[18F]fluoride was therefore prepared from the copper catalysed click reaction with tosylethylazide 36 
and ketal-protected alkyne 83 (Scheme 3.12). This precursor 84 was used to obtain the radiolabelled 
target compound 62, as described below in section III.3.  
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III.2.2.1. Exploring a Different Route to the Pyrimidoindolone Target   
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Scheme 3.13: Target pyrimidoindolone synthesis via an alternative route 
In an attempt to improve the efficiency and yield of the target pyrimidoindolone synthesis, 
the developed route was approached in a different order but using identical reagents and reactions. 
This alternative route involved incorporation of the alkyne group earlier in the sequence (Scheme 
3.13). Starting from N-Boc-prolinol 66, the alcohol moiety was alkylated with propargyl bromide 74 
in 65 % yield, followed by Boc deprotection to give the desired amine 86 in quantitative yield. 
Coupling of amine 86 with sulfonyl chloride 64 led to isatin sulfonamide 87 in 86 % yield. Subsequent 
ketone protection as ketal 88 in 64 % yield, and amide alkylation with carbonitrile 72 using the same 
reactions described above for the preparation of intermediate 77 gave the amide alkylated isatin 
sulfonamide 89 in 59 % yield.  
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Scheme 3.14: Raney Ni reduction of intermediate 89 
Unfortunately, attempts to selectively reduce nitrile 89 in the presence of the alkyne group, 
using Raney Ni resulted in the full reduction of both the alkyne and nitrile group, giving the ether 90 
(Scheme 3.14).  
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Scheme 3.15: Click reaction of intermediate 89 prior to Raney Ni reduction 
To avoid the problem of non-selective reduction, a click reaction was carried out with alkyne 
89 prior to nitrile reduction (Scheme 3.15). The copper-catalysed click reaction of alkyne 89 with 
tosylazide 36 successfully gave 1,2,3-triazole 91 in 50 % yield. Unfortunately, Raney Ni reduction gave 
a mixture containing unreacted tosylate 91, as the minor component and an unknown by-product 
with the tosylate group displaced according to a 1H NMR spectrum (Scheme 3.15).  
In addition to problems encountered with nitrile reduction in the presence of other functional 
groups, the successful steps did not show any improvements on yields and reaction efficiency. As a 
result, pyrimidoindolone target synthesis via this alternative route was terminated, progressing with 
the original route described above.  
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III.2.2.2. Synthesis of the Pyrimidoindolone Core Heterocycle / Pharmacophore 
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Scheme 3.16: Preparation of the pyrimidoindolone 57 
Pyrimidoindolone heterocycle 57, used in the UV-vis experiment described in Chapter II was 
prepared simultaneously with the target pyrimidoindolone probe 62, in five steps starting with the 
commercially available isatin ring 61. Isatin 61 was protected as a 1,3-dioxolane using 1,3-
propanediol and toluenesulfonic acid in toluene to give the ketal 92 in 50 % yield. The ketal 92 was 
then alkylated with chloromethyl cyclopentanecarbonitrile 72 using tBuOK as a base to give nitrile 93 
in 14 % yield and with less than 80 % purity. This reaction step failed to reach completion, with both 
the starting amide 92 and alkylating agent 72 isolated from the reaction mixture despite prolonged 
heating for up to three days, and using excess amounts of the base and alkylating agent. Unlike the 
facile amide-alkylation of the sulfonamide substituted isatin ring 70, alkylation of the unsubstituted 
ring 92 proved challenging. It was likely that the presence of an electron withdrawing substituent on 
the phenyl ring, such as a sulfonamide was required to activate the ring towards electrophilic 
substitution. Reduction of the crude nitrile 93 using Raney Ni as a catalyst and methalonic ammonia 
as the solvent gave the primary amine which was subsequently heated to drive 
cyclisation/dehydration to give the amidine 94 in 55 % yield. Ketal deprotection using 
methanesulfonic acid then gave the pyrimidoindolone heterocycle 57 in 89 % yield (Scheme 3.16).  
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III.3. Radiochemistry of the Pyrimidoindolone Target  
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Figure 3.4: Pyrimidoindolone radiochemistry precursors (81, 83 and 84) and the cold reference (62) 
In a direct attempt to mimic the original isatin radiochemistry reported by Smith et al. 
(Scheme 2.17),57 radiolabelling using the copper catalysed click reaction of an alkyne precursor with 
[18F]fluoroethylazide 37, was initially employed for the pyrimidoindolone radiosynthesis. 
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Scheme 2.17: Reported click radiolabelling of the lead isatin sulfonamide 2257 
The first stage in the click radiosynthesis of pyrimidoindolone 62 (Scheme 3.18) was aimed at 
exploring a range of reaction conditions in attempts to find the optimum condition for the 
radiolabelling procedure. The radiolabelling agent, [18F]fluoroethylazide 37 was prepared from 
tosylethylazide 36 using Kryptofix-222 as a phase transfer agent and K2CO3 as the base (Scheme 
3.18). The reaction mixture was purified by distillation using a thermospray with varying and 
inconsistent radiochemical yields obtained, likely due to inconsistencies in cleaning the thermospray. 
The possible effects of the solvent used, reaction temperature, reaction time and the presence of a 
ligand were investigated, monitoring the reactions by reverse-phase HPLC. The observed results are 
summarised in Table 3.4. 
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Scheme 3.18: Click radiolabelling with precursor alkyne 81 
Table 3.4: Click radiolabelling reaction results observed by analytical HPLC 
Entry Time (mins) Temp ᴼC  % [18F] (RC) incorporation* 
   DMF DMSO 
1 5 rt - 10 
2 10 rt 34 17 
3 15 rt 32 29 
4 5   rt + BPDS** 49 4 
5 10 rt + BPDS 51 24 
6 15 rt + BPDS 48 33 
7 30 rt + BPDS 60 28 
8 5 50 65 78 
9 10 50 58 64 
10 15 50 56 46 
11 30 50 46 51 
12 5 84 74 39 
13 10 84 52 54 
14 15 84 36 49 
15 36 84 19 34 
*% of total radioactivity incorporated to give the radioactive product [18F]62, determined by analytical 
reverse-phase HPLC. **BPDS ligand (Figure 3.5) added to the reaction mixture. 
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N
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Figure 3.5: The Structure of bathophenanthroline disulfonate (BPDS), a Cu(I) stabilising ligand 
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Slow reactions were observed at room temperature with modest amounts of [18F]fluoride 
incorporation (Table 3.4, Entries 1 – 3). Although the starting copper reagent was Cu(II) sulfate, the 
active metal catalyst in a click reaction is known to be Cu(I) formed from in situ reduction of Cu(II) by 
ascorbic acid. Any oxygen in the reaction mixture would act to oxidise Cu(I) back to Cu(II), hindering 
the reaction. In attempts to enhance the click reaction, the Cu(I) stabilising ligand, BPDS (Figure 3.5) 
was employed.122 However, the addition of BPDS had no effect on the reactions carried out at room 
temperature in DMSO (Table 3.4, Entries 4 – 7). BPDS addition initially enhanced the DMF reaction 
but negligible increases in the percentage of [18F]fluoride incorporation were observed with time 
(Table 3.4, Entries 4 – 7). When heated to 50 ᴼC, both solvents showed initial fast reaction followed 
by the gradual decomposition of both the radiolabelled product [18F]62 and the alkyne precursor 81 
(Table 3.4, Entries 8 – 11). At 84 ᴼC, faster reaction was observed in DMF within the first five minutes 
(Table 3.4, Entry 12). However, faster decomposition in DMF gave lower overall yield over time (Table 
3.4, Entries 12 – 15). It was clear from the radiochemical chromatograms that the radioactive product 
decomposes to give an unknown radioactive compound. This decomposition became more 
significant at higher temperatures where the product peak area decreases as the peak for the 
unknown compound increases. Of the results summarised in Table 3.4, the highest yield was 
observed in DMSO at 50 ᴼC for five minutes (Entry 8). These conditions were adopted for the 
preparation and isolation of the radiolabelled product by preparative reverse-phase HPLC (Table 3.5). 
Table 3.5: Click reaction results observed by prep HPLC 
Entry Time 
(mins) 
Solvent (50 µL) Temp  
ᴼC 
% [18F] (RC) 
incorporation* 
1 5 DMSO 50 8 
2 7 DMSO 50 6 
3 17 DMSO 50 6 
4 10 DMF 50 21 
5 5.5 DMF 80 29 
6** 5 DMF 80 42 
* % of total radioactivity incorporated to give the radioactive product [18F]62, determined by preparative 
reverse-phase HPLC 
** With the ketal-protected alkyne 83 used as the precursor i.e. the reaction shown in Scheme 3.19 
However, the high incorporation of radioactivity observed could not be replicated on a larger 
scale for the isolation of the radiolabelled product (Table 3.5, Entries 1 – 3). The same disappointing 
result was observed in DMF at 50 ᴼC and 80 ᴼC (Table 3.5, Entries 4 - 5). In addition to the poor 
radiochemical incorporation, product [18F]62 co-eluted with a stable but unknown by-product, giving 
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the probe in a crude mixture that could not be purified by prep HPLC. A similar problem with isatin 
sulfonamide ‘click’ radiolabelling was reported by Glaser & Co, where the desired product also co-
eluted with a by-product that had an almost identical retention time.123 The amount of impurity 
observed in the isolated radio-product mixture was especially significant with low levels of 
radiochemical incorporation. We observed from the synthesis of the pyrimidoindolone cold 
reference that the ketone moiety, when not protected had the propensity to react to give unwanted 
products. Hence, we proceeded to use the ketal-protected alkyne precursor 83 in click radiolabelling 
with the hope of improving the purity profile of the pyrimidoindolone radio-probe (Scheme 3.19).  
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Scheme 3.19: Click radiolabelling with ketal-protected precursor alkyne 83 
Consequently, click radiolabelling reaction was attempted with ketal-protected alkyne 83 as 
the precursor (Scheme 3.19). While a comparatively better result was observed (Table 3.5, Entry 6), 
a modest radiochemical incorporation of 42 % was obtained. This modest yield, combined with 
incomplete ketal deprotection upon treatment of the reaction mixture with sulfuric acid, resulted in 
a poor overall yield. Increasing the reaction time in order to achieve complete ketal deprotection 
resulted in radiochemical decomposition, further decreasing the overall yield. Although improved, 
co-eluting impurities remained problematic. In addition, the click reaction proved irreproducible with 
yields ranging from 0 % to 42 % radiochemical incorporation under analogous conditions. 
Following the irreproducible results and impurities observed for the click process, 
radiolabelling by direct 18F- SN2 displacement of a tosylate was examined, adopting the reaction 
shown in Scheme 3.20. The results observed under different reaction conditions by analytical HPLC 
are summarised in Table 3.6 below. 
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Scheme 3.20: Radiolabelling by 18F- displacement of a tosyl leaving group 
Table 3.6: 18F- tosyl displacement radiolabelling results observed by analytical HPLC 
Entry Time Solvent  
(µL) 
Temp 
(ᴼC) 
Base % [18F] (RC) 
incorporation* 
1 5 DMF (100) 80 K2CO3 14 
2 10 DMF (100) 80 K2CO3 29 
3 15 DMF (100) 80 K2CO3 30 
4 20 DMF (100) 80 K2CO3 40 
5 5 DMF (100) 110 KHCO3 22 
6 10 DMF (100) 110 KHCO3 26 
7 15 DMF (100) 110 KHCO3 36 
8 20 DMF (100) 110 KHCO3 37 
9 5 DMF (100) 110 K2CO3 63 
10 10 DMF (100) 110 K2CO3 76 
11 10 DMF (150) 110 K2CO3 36 
*% of total radioactivity incorporated to give intermediate ketal [18F]97 as determined by analytical HPLC 
Table 3.6 shows the percentage radiochemical incorporation giving the intermediate ketal-
protected intermediate, [18F]97. Again the effects of reaction time and temperature, as well as 
concentration were examined. As shown in Table 3.6, increasing the reaction temperature from 80 
ᴼC to 110 ᴼC significantly increased the radiochemical yield when K2CO3 was used as the base (Table 
3.6, Entries 2 and 10). The precursor tosylate was consumed via the desired reaction as well as by 
decomposition within ten minutes at all temperatures examined. The observed decomposition was 
likely due to side reactions with residual water or chloride from the [18F]fluoride mixture generated 
from a cyclotron, or tosyl elimination to give the corresponding alkene which was reportedly 
observed during the radiosynthesis of [18F]isatin 22.123 
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At 80 ᴼC, precursor decomposition was faster than the desired reaction, while using KHCO3 as 
the base resulted in both faster radiochemical and precursor decomposition. KHCO3 (pKa = 6.37) 
being much less basic than K2CO3 (pKa = 10.25) may have been less efficient at neutralising the 
reaction, leading to increased side reactions. Aiming to examine the effect of concentration on the 
reaction, where the solvent volume was increased from 100 µL to 150 µL, the obtained radiochemical 
incorporation suggested that decomposition of the precursor tosylate 84 was faster with a more 
dilute reaction mixture (Table 3.6, Entries 10 and 11). The possible consumption of the precursor 
tosylate 84 by side reactions with other nucleophiles such as water and chloride was counteracted 
by the use of a large excess of the precursor. The procedure of radiolabelling by SN2 [18F]fluoride 
displacement of the tosylate group generally gave significantly improved purity profile (95 – 100 %), 
compared to the click labelling process as there was no co-eluting by-product.  
 
Figure 3.6: Radiolabelling reactions with KHCO3 as the base in DMF at reaction times of 10 mins (left), 15 mins 
(middle) and 20 mins (right), showing increased decomposition with time (Table 3.6, Entries 6, 7 and 8). The 
radiolabelled ketal-protected intermediate [18F]97 is shown on the chromatograms at 3:52 to 3:57 mm:ss. 
Chromatograms were obtained by reverse-phase HPLC elution. 
 
Figure 3.7: Radiolabelling reactions with K2CO3 as the base in DMF at reaction times of 5 mins (left) and 10 
mins (middle), showing increased radiochemical yield of [18F]97 shown on the chromatograms at around 4 
minutes (Table 3.6, Entries 9 and 10). The chromatogram on the right shows the result of a diluted mixture 
with a reaction time of 10 mins, showing poor radiochemical yield of [18F]97 (Table 3.6, Entry 11). 
Chromatograms were obtained by reverse-phase HPLC elution. 
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Scheme 3.21: Acid catalysed ketal deprotection following radiolabelling by tosyl displacement  
Hydrochloric acid was initially employed for ketal deprotection of the radioactive 
intermediate [18F]97 to give the target probe [18F]62, monitoring the disappearance of the ketal 
intermediate by analytical HPLC. The deprotection reaction involved diluting the [18F]fluoride 
displacement reaction mixture with a 3M HCl solution and heating to 110 ᴼC. In this case, slow and 
incomplete deprotection was observed despite increasing the HCl concentration to 5M and the 
reaction time to 30 mins. A moderate 50 % deprotection was obtained using 5M HCl and heating at 
110 ᴼC for 30 mins. Diluting with sulfuric acid drove ketal deprotection to completion within 10 mins 
at the same temperature. Unfortunately, problems with product isolation were encountered during 
neutralisation of the sulfuric acid mixture with 3N to 6N NaOH solution. The semi-prep HPLC 18F 
chromatogram of the mixture showed broad, unseparated peaks. Solid-phase extraction, where the 
product was immobilised on a C-18 cartridge and eluted with ACN, then with 5 mM HCl in EtOH, gave 
a much improved semi-prep HPLC profile with product isolation. However, this method resulted in 
poor radiochemical yield due to incomplete elution of the lipophilic product, and/or loss of the 
protonated product in acidic aqueous mixture, given that the pH of the reaction mixture was 4 or 
less. Attempts to quench the reaction mixture to a more basic pH resulted in decomposition of the 
product probe. Isatin sulfonamides demonstrated similar instability under basic conditions owing to 
the reaction of a base with the electrophilic ketone group (Chapter I.4.2).83 Gradual addition of the 
base to the acidic mixture to obtain the ideal pH of 5-6 was unsuccessful because of the large and 
rapid pH change encountered at the equivalence point when adding a strong base to a strong acid.  
As a result of the problems encountered with product isolation from the sulfuric acid mixture, 
deprotection using HCl was re-visited, because neutralisation of the weaker HCl acid could be more 
easily controlled to reach an ideal pH of 5/6. The slow rate of deprotection with HCl was addressed 
by investigating the effect of changing the reaction solvent from DMF or DMSO to ACN. Using ACN, 
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low to moderate radiochemical incorporation of 10 – 45 % was observed. Again, similarly to reactions 
in DMF/DMSO, the degree of ketal deprotection in a one-pot reaction using 4M – 5M HCl and heating 
for 15 mins at 100 – 120 ᴼC was disappointing, consistently giving less than 50 % conversion of the 
ketal intermediate [18F]97 to target probe [18F]62 after 30 minutes. In successive reactions, it was 
found that the deprotection rate was significantly increased by removing ACN solvent by distillation 
prior to the addition of HCl.  This resulted in a deprotection yield of 70 – 85 % within 15 minutes at 
110 ᴼC (Figure 3.9). Similarly to deprotection reactions using sulfuric acid, lack of HPLC peak 
separation was observed, though this problem was solved by phase separation. Immobilisation of 
the NaOAc neutralised HCl reaction mixture on a C-18 cartridge, washing with water and then eluting 
the product probe with ethanol gave a sample that was successfully separated by prep HPLC to give 
the target probe in high purity (Figure 3.9). A radiochemical yield of 22 % (decay-corrected, 130 mins 
reaction time) was obtained for biological characterisation. The chromatograms of the reaction 
conditions used for radiosynthesis prior to biological characterisation are shown in Figures 3.8 and 
3.9 with the reaction conditions summarised in the Experimental chapter.  
  
Figure 3.8: Left - semi-prep HPLC chromatogram of the cold reference of the target probe 62. Right – analytical 
HPLC chromatogram showing the reaction mixture in ACN, 110 ᴼC, 15 mins reaction time with 29% 
radiochemical incorporation to give the intermediate [18F]97 (at 4:32 mm:ss) 
     
Figure 3.9: Semi-prep HPLC chromatograms of ACN reaction mixtures following acid deprotection and 
neutralisation. Left – chromatogram of the ketal deprotection reaction mixture without phase separation 
using a C-18 cartridge, showing broad peaks. Right – a prep HPLC chromatogram of the ketal deprotection 
reaction mixture with clear peak separation following phase separation with a C18 cartridge - with 85 % 
conversion of the ketal intermediate [18F]97 (at 18:20 mm:ss) to the target probe [18F]62 at 10:21 mm:ss.  
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III.4. Biological Characterisation of the Pyrimidoindolone Target   
III.4.1. In vitro Caspase Enzyme Inhibition Assay 
Table 3.7: Pyrimidoindolone Caspase IC50 Datac 
Incubation 
Time (mins) 
Caspase-3 IC50 (nM) Caspase-8 IC50 (nM) 
Pyrimido 62 Isatin 22 Pyrimido 62 Isatin 22 
15 108.90 13.43 >5000 >5000 
30 78.19 1.86 >5000 >5000 
60 118.80 5.72 >5000 >5000 
90 95.83 3.98 >5000 >5000 
Mean ± SEM 100.43 ± 8.78 6.25 ± 2.52 - - 
 
The potency of pyrimidoindolone 62 for caspase-3 and control caspase-8 was determined by 
measuring the substrate concentration required to inhibit each enzyme activity by 50 % (IC50). For 
IC50 determination of pyrimidoindolone 62 Vs lead isatin 22, nine substrate concentrations ranging 
from 5 pM to 500 µM were used, measuring the accumulation of the fluorogenic product 7-amino-
4-methylcoumarin (7-AMC) resulting from cleavage of caspase enzyme substrate Ac-DEVD-AMC by 
uninhibited activated caspase. 7-AMC production was measured by a fluorimetric method following 
incubation at 15, 30, 60 and 90 mins. The results are summarised above in Table 3.7. Isatin 22 shows 
an average of 16-fold more affinity for caspase-3 than the pyrimidoindolone 62. Both probes were 
shown to be poor substrates for caspase 8, showing selectivity for caspase-3.  
III.4.2. In Vitro Cell Uptake Studiesd 
Cell uptake studies of the pyrimidoindolone tracer 62 was also carried out in control, PAC-1 
(first procaspase activating compound) and 4-HC (4-hydroperoxycyclophosphamide) treated cells. 
The studies involved inducing apoptosis in cancer cells by treatment with anticancer agents prior to 
measuring cell uptake of the pyrimidoindolone probe resulting from the tracer binding to activated 
caspase-3. Like isatin sulfonamides, the probe was designed to be taken up by intact cells, but only 
retained in cells with activated caspase-3. Without the induction of caspase-3 (and therefore 
apoptosis), pyrimidoindolone tracer retention in cells would not be observed. It also follows that the 
observation of pyrimidoindolone uptake following the induction of apoptosis would successfully 
indicate that the probe is a caspase-binding ligand. The aim of the cell uptake studies was to first 
                                                          
cData reported by Dr. Quang-De Nguyen who carried out the in vitro caspase inhibition experiment 
d The cell uptake experiment was conducted by Dr Quang-De Nguyen, Imperial College London. 
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assess the caspase-binding properties of the synthesised pyrimidoindolone probe 62 before 
proceeding to in vivo studies.  
The uptake of pyrimidoindolone 62 was measured approximately 24 hours after the 
treatment of cells with PAC-1 and 4-HC. PAC-1 is a compound (Figure 3.10) that induces apoptosis 
via the selective and direct activation of the executioner caspase-3.124 Caspase-3 is stored in cells as 
the inactive procaspase-3 which is inhibited by low levels of zinc. PAC-1 has been shown to activate 
procaspase-3 by chelating zinc and therefore releasing the zinc-mediated inhibition, converting 
inactive procaspase-3 to the active caspase-3, which then induces a cascade of events that lead to 
cell death.124  
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Figure 3.10: The chemical structure of PAC-1, anticancer caspase-activating agent 
Whereas PAC-1 is a direct activator of caspase-3, 4-HC indirectly activates caspase-3 through 
the formation of metabolites that cause DNA damage, thus inducing cell death.125 4-HC 99, a pre-
activated form of cyclophosphamide is an anticancer agent which converts to 4-
hydroxycyclophosphamide 100, which is at equilibrium with the open-ring aldophosphamide 101 
when in solution.126, 127 Aldophosphamide 101 then generates the active alkylating metabolite, 
phosphoramide mustard 102 which alkylates DNA strands (Scheme 3.22).126, 127 The resulting DNA 
interstrand crosslinks and DNA damage then triggers apoptotic cell death involving prolonged cell-
cycle arrest.125 
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Scheme 3.22: The formation of DNA chelating mustard from 4-HC126 
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In contrast to PAC-1 which has a more immediate effect on apoptotic induction through the 
direct activation of caspase-3, 4-HC indirectly induces apoptosis via a prolonged cell-cycle dependent 
pathway which means it activates caspase-3 at a much slower rate. It has been reported that 
maximum DNA crosslinking was observed at about 4 hrs following a brief exposure to DNA alkylating 
agents such as phosphoramide mustard.128 The different rates of caspase-3 activation impacts on the 
rate of cell death and hence the rate of tracer uptake when PAC-1 is used for cell treatment compared 
to 4-HC treatment.  
 
Figure 3.11: 38C13 lymphoma cell uptake of [18F]-pyrimidoindolone 62 in; untreated control cells (0.1 % DMSO, 
24 hrs); 4-HC treated cells (3 µg/mL, 24 hrs) and; PAC-1 treated cells (10 µM, 24 hrs) - showing a 1.5-fold 
uptake in 4-HC treated cells and decreased uptake in PAC-1 treated cells compared to control cells, 24 hours 
after treatment. For all treated and control samples, radioactivity data are expressed as decay-corrected 
counts per milligram of total cellular protein. 
Figure 3.11 shows increased pyrimidoindolone radiotracer uptake in 4-HC treated cells 
compared with the control cells, measured 24 hours after treatment. The apparent low uptake 
observed with PAC-1 treated cells was attributed to the faster induction of apoptosis leading to faster 
cell death, prior to the measurement of tracer uptake. It was believed that at 24 hours after 
treatment with PAC-1, the majority of cells would have undergone the complete apoptotic cycle (cell 
death) when caspase-3 is no longer active and therefore cannot bind the radiotracer. In contrast, 
given the prolonged process of apoptotic induction by 4-HC, uptake measurement at 24 hours 
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appears to be an ideal time point with 4-HC treatment for detecting ‘dying’ cells still undergoing the 
apoptotic cycle with activated caspase-3 still present (rather than ‘dead’ cells). In order to detect 
apoptosis and the resulting pyrimidoindolone uptake with PAC-1 treatment, it would be necessary to 
measure radiotracer uptake at an earlier time point or at time intervals to show the process from 
apoptotic/caspase-3 activity to cell death.  
Nevertheless, the increased radiotracer uptake of 4-HC treated cells compared with the 
control cells (Figure 3.11) suggested the pyrimidoindolone 62 to be a caspase-binding ligand. Similar 
results were observed with the [18F]-isatin radiotracer 22 which also showed increased uptake in 4-
HC treated cells compared to control cells (Figure 3.12), 24 hours after treatment.80 A 2-fold uptake 
and 1.5-fold uptake of 4-HC treated cells compared with control cells were observed with the isatin 
and pyrimidoindolone tracers respectively, indicating that the isatin is a slightly more potent caspase 
substrate.  
 
Figure 3.12. Uptake of [18F]-isatin 22 in 38C13 lymphoma cells treated with 4-HC to induce apoptosis (4-HC; 1 
µg/mL; 24 hrs) and in control/ untreated cells (control: 50 % DMSO, 24 hrs), showing a 2-fold uptake in treated 
cells compared to control cells, 24 hrs after treatment. For treated and control samples, radioactivity data 
were expressed as decay-corrected counts per milligram of total cellular protein. Figure taken from Nguyen et 
al.80 
III.4.3. In vivo Tissue Biodistribution & Metabolic Profiles   
Following the in vitro cell uptake measurements which showed the pyrimidoindolone 62 to 
be a caspase-3 substrate, in vivo biodistribution studies were carried out, aiming to assess the 
distribution of the probe in major organs. The tissue distribution studies involved intravenous 
injection of the pyrimidoindolone radiotracer into tumour-bearing untreated mice followed by 
biodistribution measurement in major organs, 60 mins after injection. At 60 mins after injection, high 
localization of [18F]62-derived radioactivity was seen in the kidneys, urine and liver, suggesting the 
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importance of both renal and hepatic routes of elimination (Figure 3.13). The radiotracer was 
completely eliminated from the plasma within 60 mins. Future work would involve assessing in vivo 
biodistribution in tumour-bearing treated mice in order to compare the distribution of the 
radiotracer in the tumour of treated mice compared to that of untreated or control mice. Data shown 
in Figure 3.13 shows the absence of pyrimidoindolone probe binding or distribution in untreated 
tumour, which should facilitate the measurement of tumour tracer-binding associated with caspase 
activation in treated mice.  
 
Figure 3.13: [18F]62 biodistribution in untreated RIF-1 tumour bearing mice at 60 mins after 
injection. Data are ± SEM; n = 3 mice 
A comparison of the obtained pyrimidoindolone data with the biodistribution data reported 
for the isatin sulfonamide [18F]22 showed that the pyrimidoindolone probe has a similar 
biodistribution profile as the isatin (Figure 3.14).57 Both radiotracers showed elimination in the 
liver/gallbladder, intestines, kidneys and urine.   
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Figure 3.14: Biodistribution of [18F]-Isatin 22 in untreated RIF-1 tumour bearing mice between 2 and 60 mins 
reported by Smith et al.57  
 
 
Figure 3.15: In vivo metabolism of [18F]22 assessed in plasma by radio-HPLC. Top left, [18F]22 standard; top 
right, 2 min plasma; bottom left, 15 min plasma; bottom right, 60 min plasma. Data reported by Smith et 
al.57 
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In vivo metabolic stability of the pyrimidoindolone radiotracer was also determined in liver, 
plasma and urine samples. Similarly to the metabolic data reported for isatin 22 (Figure 3.15),57 radio-
HPLC analysis showed that the pyrimidoindolone radiotracer 62 produces a single polar metabolite 
in the plasma, urine and liver. At 60 mins after injection, traces of the unmetabolised parent 
pyrimidoindolone tracer was present in plasma (14 %) and in the liver (10 %), while the urine sample 
contained only the metabolite for elimination (Figure 3.16).  
  
 
Figure 3.16: In vivo metabolism of [18F]-pyrimidoindolone 62 in untreated RIF-1 tumour bearing mice 
measured in plasma, liver and urine, 60 minutes after injection. Top left - [18F]62 standard; Top right 
– urine; bottom left - plasma; bottom right – liver. 
 
The results suggested that the isatin scaffold is relatively more stable than the 
pyrimidoindolone; although for both [18F]-isatin-22 and [18F]-pyrimidoindolone-62, the presence of 
the parent tracer after 60 min is apparent in certain tissues, [18F]-isatin-22 showed a higher presence 
of the unmetabolised parent tracer. In the plasma for example, 14 % and 50 % of the radioactivity 
was due to unmetabolised parent tracer for the pyrimidoindolone and isatin probes respectively 
(Figures 3.15 and 3.16). 
While no attempts were made to identify the nature of the metabolites, possible metabolic 
pathways of the pyrimidoindolone radiotracer include glutathione conjugation129 and 
glucuronidation,130 two classic metabolic pathways for drugs to form more readily 
excreted hydrophilic products. Given that both the pyrimidoindolone 62 and the isatin 22 were 
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designed as substrates for caspase-3, binding by the addition of a thiol residue in the caspase-3 active 
site, possible in vivo metabolism of the heterocycles could be through the incorporation of 
glutathione (GSH) to give polar metabolites for elimination. Alternatively, metabolism of the 
heterocycles could occur by the reduction of the ketone to alcohol, followed by glucuronidation 
where glucuronic acid is added to the probe via the alcohol or possibly the amidine group in the case 
of the pyrimidoindolone, giving polar metabolites for excretion.130 Metabolism of isatin sulfonamide 
22 may also occur through aromatic hydroxylation.131-133 However, it is well documented that the 
fluoro-substituted phenyl rings hinder in vivo P450-catalysed ring hydroxylation due to the electron 
withdrawing effect of the fluoride.132, 133 
 
  
Time = 0 hrs (after formulation) Time = 2 hrs Time = 4 hrs 
Figure 3.17: [18F]-pyrimidoindolone 62 stability study with samples taken from a solution of the radiotracer 
in aqueous PBS buffer 
Metabolism may also compete with in vivo aqueous decomposition for the breakdown of the 
pyrimidoindolone probe. As reported by Havran et al.,58 the pyrimidoindolone ring may undergo 
hydrolysis by the addition of two molecules of water to give the multiple hydroxyl compound 50 
(Chapter I.4.4, Scheme 1.5, page 49) which could then undergo further metabolism such as by 
glucuronidation.130 Aqueous stability may account for the apparent lower metabolic stability of the 
pyrimidoindolone compared with the isatin sulfonamide.  
Given the reported limited aqueous stability of the pyrimidoindolone scaffold,58 radio-HPLC 
was used to monitor the stability of pyrimidoindolone radiotracer 62 in aqueous solution, in order to 
assess stability in the timeline of a radiotracer biological use (Figure 3.17). The resulting 
chromatograms showed that the radio-product in aqueous solution remained stable for at least 3 
hours, with over 95 % of the parent radiotracer still present after 4 hours (Figure 3.17). The apparent 
minimal aqueous decomposition 3 hours after formulation in aqueous solution is not expected to 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
110 | P a g e  
 
present a problem for possible clinical use of the pyrimidoindolone. The short half-life of 18F PET 
radionuclide means that the use of freshly synthesised radio tracers are typically conducted at short 
time spans, typically less than 4 hours. To reduce costs and allow off-site use with transportation of 
a radiotracer in clinics, a probe is typically expected to remain stable for up to 4 hours from 
formulation to injection.  
III.4.4. Transwell / Efflux Ratio Assaye 
When developing optimal caspase-3 binding apoptotic imaging probes, as well as considering 
the potency for caspase-3, it is important to assess tracer cell permeability which would impact on 
the ability of the probe to access the tumour being imaged. Cellular efflux is considered to be a major 
cause of resistance to chemotherapy in cancer patients.134, 135 A principal cause of drug resistance in 
tumour cells is the active efflux of exogenous compounds affecting their concentration in tumours.134-
136 The transwell efflux assay calculates tracer properties in terms of cell permeability and extrusion 
from cells which is expressed as a ratio.  
The ATP binding ABC transporters, P-glycoprotein (P-gp) and breast cancer resistant protein 
ABCG2 have been identified to play major roles in the active efflux of various exogenous and 
endogenous substrates across the extra- and intracellular membranes.137 A substrate of the ABC 
transporters passing the membrane by passive diffusion is recognised by the transporter and through 
hydrolysis of ATP, is extruded out of the cell, thus limiting its intracellular concentration.138  
The ability of Pgp-2 and ABCG2 to actively efflux molecules from cells is implicated in the 
tumour resistance to treatment.134, 135 ABC transporters have been shown to be over-expressed in 
many tumour types, leading to increased resistance to exogenous compounds. Minimising the 
interaction of drugs with ABC transporters in order to increase intracellular concentrations and 
therefore biological effects is a key part of the tracer design and the development process. Given the 
significance of active drug efflux in oncology, an experiment to study the cell efflux ratio of the 
pyrimidoindolone probe 62 compared with the isatin lead 22 was conducted.  
The transwell efflux assay involved studying the interaction of the caspase-binding probes 
with ABC transporters. Tracer binding to the Pgp and/or ABCG2 transporters would result in active 
efflux of the probes across tumour cells.  
                                                          
e Transwell/ Efflux Assay was conducted by Dr. Maciej Kaliszczak, Imperial College London  
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Figure 3.18: The set-up of a transwell assay experiment to assess the transport of compounds across the 
apical (A) and basal (B) side of a caco-2 monolayer, a cell based model for studying drug permeability. The 
apical side represents the extracellular surroundings while the basal side models the intracellular system.  
The direct impact of the transporters on the intracellular concentration of the probes was 
assessed by measuring the permeability of the isatin lead and pyrimidoindolone probe across a 
monolayer of differentiated caco-2 cells, the most extensively characterised cell-based model for 
studying the cell permeability of compounds. Permeability was measured from the apical (A) to the 
basal (B) side (Papp A→B), and extrusion or efflux was measured from the basal to the apical side 
(Papp B→A), for both isatin 22 and pyrimidoindolone 62. The experimental set up is shown in Figure 
3.18.  
Table 3.8: Permeability of the probes across the caco-2 cells from the apical to the basal side, measured by 
LCMS (for details see experimental page 226). 2 hour incubation with results mean of n = 3. 
Papp A-B (x10-6 cm/sec) 
 Average (n = 3) Standard Deviation 
Pyrimido Probe 62 11 0.6 
Isatin Lead 22 36 2.2 
Vinblastine (negative control) 10 0.4 
 
The permeability of isatin 22 and pyrimidoindolone 62 across the caco-2 cells from the apical 
to the basal side is shown in Table 3.8. The isatin 22 was shown to be absorbed into the cell through 
the membrane by more than 3 times the absorption rate of the pyrimidoindolone 62. However, the 
standard deviation of 0.6 and 2.2 for the pyrimidoindolone and isatin respectively suggested that the 
results obtained for the pyrimidoindolone were more reproducible, while the isatin data showed 
more variation across the three runs of the experiment (n = 3). Vinblastine, a known Pgp-substrate139 
which is actively effluxed from cells following absorption was added as a control compound. The data 
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shown in Table 3.8 show that both the isatin and pyrimidoindolone are absorbed into the cell. 
However, if the compounds are secreted faster than they are absorbed, their intracellular 
concentrations would be altered despite possible high absorption rates.  
 
Figure 3.19: Efflux ratio in caco-2 transwell assay as expressed by the ratio between the permeability from the 
basal to the apical side (Papp A-B) and the permeability from the apical to the basal side (Papp B-A). Results 
are mean of n = 3. Verapamil was incubated for 1 hour before incubation with the different compounds at 50 
µM. The results are mean of n = 3. 
It has been established that if a compound exerts a ratio between the secretion (permeability 
from the basal to the apical side) and the absorption (permeability from the apical to the basal side) 
of ≥ 3, it can be considered as being actively efﬂuxed.140 ‘Normal’ diffusion, where the compound is 
at equilibrium between the apical and basal side gives a secretion/absorption ratio of approximately 
one. The isatin sulfonamide 22 and the pyrimidoindolone 62 show an efflux ratio (Papp B→A / Papp 
A→B) of 3 and 3.74 respectively (Figure 3.19). This indicated that both the isatin and 
pyrimidoindolone were actively effluxed, with the pyrimidoindolone effluxed at a higher rate than 
the isatin. To ascertain that the observed active efflux was due to transport by the ABC transporters, 
the secretion/absorption ratio was also measured in the presence of the Pgp inhibitor, verapamil 
(Ver). Upon addition of verapamil, the efflux ratios of the pyrimidoindolone and the isatin were 
reduced to 1.19 and 1.94 respectively. The efflux ratio of vinblastine139 which is known to be actively 
effluxed by the Pgp transporter was also reduced. Efflux of the compounds was not completely 
blocked because verapamil only blocks the Pgp transporter and not ABCG2 or any other ABC 
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transporters. It is worth noting that, as indicated by the three ‘stars’ above the plot in Figure 3.19, a 
P-value of <0.0001 statistically indicated that the results obtained were significant and the 
observation were highly unlikely to be the result of random chance.  
Table 3.9: The physicochemical properties of isatin 22 and pyrimidoindolone 62 responsible for Pgp binding 
 MW No. of N+O atoms Acid pKa* 
Isatin 22 549.5 10 > 4 
Pyrimido 62 530.6 10 > 4 
*Acid pKa values of isatin 22 and pyrimidoindolone 62 assumed to be > 4 
The Pgp transport is associated with a single ﬂexible binding site that can accommodate 
several substrates, with substrate specificity shown to be conformation-independent.141 Pgp 
substrate specificity is instead defined by a set of simple rules: typical Pgp substrates are large 
molecules with high H-bond accepting capability, whereas small molecules with low H-bond 
accepting capability are likely to be non-substrates.141 Acids are unlikely Pgp substrates but bases 
have higher chances of being substrates. Pgp substrate specificity has been defined by a set of 
physicochemical properties estimated by the "rule of fours": compounds with (N + O) ≥ 8; MW > 400; 
and acid pKa > 4 are likely to be Pgp substrates. Conversely, compounds with (N + O) ≤ 4; MW < 400; 
and base pKB < 8 are likely to be non-substrates. Molecular weight was found to play a particularly 
key role in determining substrate affinity for Pgp.141 Table 3.9 shows that both the isatin 22 and 
pyrimidoindolone 62 have the physicochemical properties of typical Pgp substrates (MW > 400 and 
N+O of > 8), accounting for the fact that both are actively effluxed. Given the presence of the basic 
amidine group in the pyrimidoindolone structure and a keto-amide group in the isatin heterocycle, 
the tracers are not considered acidic and are highly likely to have acid pKa values of > 4.  
As tumours are known to over-express the ABC transporters, the fact that both the 
pyrimidoindolone 62 and the isatin 22 appear to be substrates for the transporters would impact on 
the ability of the probes to permeate and sufficiently accumulate in tumour cells to bind to 
intracellular caspase-3. It would therefore be necessary to optimise the probes to be poor substrates 
for the ABC transporters before potential clinical use. Although it is possible to block active efflux by 
administering substrates that block the transporters alongside the drug molecules, known 
transporter inhibitors have been shown to be toxic.142 The inhibitors do not only block the ABC 
transporters found on tumour cells, they also block those found in cells throughout the body.142 
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Hence, the preferred solution to active efflux of compounds such as the isatin and pyrimidoindolone 
is optimisation and development of structures that do not bind to the transporters and are specific 
to caspase-3. This is a key consideration for future work on the continued search for an optimal 
caspae-3 binding apoptotic PET imaging probe.  
III.5. Conclusion 
Based on the observations that PET imaging using isatin sulfonamides is hampered by low 
target-to-background activity,57 we set out to prepare and investigate the properties of a 
pyrimidoindolone-based probe with the initial structure modelled on the lead isatin sulfonamide 22. 
The initial results reported here show that the pyrimidoindolone 62 and isatin sulfonamide 22 share 
similar biological characteristics. Despite the reported dual binding of the pyrimidoindolone87 and 
the expected reduced electrophilicity of the C-10 carbonyl, the pyrimidoindolone heterocycle 62 
generally showed no significant differences from the isatin sulfonamide with regards to caspase-3 
potency and selectivity.  
Future work on the study of pyrimidoindolones as caspase-3 binding apoptotic radioligands 
would involve the preparation of a library of derivatives for SAR studies. Similarly to the design of the 
initial pyrimidoindolone probe 62, the library compounds would be modelled on the extensively 
studied isatin sulfonamides. Further studies to optimise the preparation of the pyrimidoindolone 
scaffold, and the efficiency and yield of radiosynthesis would also be required.  
For the purpose of the reported studies, we achieved the aim of synthesising and 
radiolabelling an initial pyrimidoindolone target for biological evaluation of the heterocycle’s utility 
as a caspase-biding radioligand. As well as the cold, unradiolabelled reference compound, precursors 
for radiolabelling by both click reaction and direct displacement by [18F]fluoride were prepared and 
used in the successful radiosynthesis of the pyrimidoindolone target [18F]62. 
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CHAPTER IV: 
IMIDAZOLEINDOLONE AND 
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IV. IMIDAZOLEINDOLONE AND TRIAZOLEINDOLONE SYNTHESIS 
IV.1. Introduction 
We sought to develop a new class of potent caspase-3 binding radioligands with increased 
specificity and reduced non-specific binding interactions relative to the isatin series for use in the PET 
imaging of apoptosis. With the aim of investigating new heterocycles with structural similarities to 
the extensively studied isatin sulfonamides, we proposed the unexplored imidazoleindolone (52) and 
triazoleindolone (53) heterocycles (Figure 4.1). Like the isatin sulfonamides, these heterocycles 
possess an electrophilic ketone carbonyl essential for caspase-3 inhibition through the formation of 
a thiohemiketal with a cysteine residue in the caspase-3 active site (Chapter I.4).69, 74 
N
N
N
N
N
O O
Imidazoleindolone 52 Triazoleindolone 53
Ketone carbonyl essential for
thiohemiketal inhibition
N
N
N
N
N
HO
S(Cys) HO S(Cys)
52b 53b  
Figure 4.1: Imidazoleindolone and the triazoleindolone heterocycles containing the ketone carbonyl 
essential for caspase-3 inhibition through the formation of a thiohemiketal with a thiol residue 
It was hoped that the extended aromatic system of the imidazoleindolone and 
triazoleindolone heterocycles would favourably modulate the reactivity of the ketone carbonyl, 
reducing non-specific interactions in the cytosol which is believed to be responsible for the low 
target-to-background ratio of PET images using the isatin sulfonamides (Chapter I.4).57, 69, 77 As 
previously discussed, computational studies were initially employed to model the favourability of 
thiol addition to the imidazoleindolone 52 and triazoleindolone 53 scaffolds in order to gain a 
preliminary insight into their potential caspase-3 inhibitory potencies (Chapter II). The computational 
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results suggested that, like the isatin ring, the two heterocycles would favourably react with a thiol 
group to give the corresponding thiohemiketal products. The order of thiohemiketal formation 
favourability according to the obtained free energy of reactions was shown to be isatin > 
triazoleindolone > imidazoleindolone. This suggested that the imidazoleindolone 52 and 
triazoleindolone 53 heterocycles would form a thiohemiketal less readily than the isatin. It is worth 
noting that the computational calculations using the unsubstituted heterocycles did not consider the 
spatial distribution of a radiotracer within the target active site cavity. As such, the calculated 
favourability may not reflect biological binding affinities where the binding interaction of an inhibitor 
as a whole has a substantial effect on inhibitory activity. 
This chapter describes the results of the synthetic routes explored for the preparation of the 
novel triazoleindolone and imidazoleindolone structures. As well as preparing the core heterocycles, 
we aimed to synthesise target substituted structures to be used in preliminary experimental 
characterisations. Similarly to the pyrimidoindolone target 62 (Chapter III), these target heterocycles 
were designed to emulate the structure of the lead isatin sulfonamide 22 (Figure 4.2). SAR studies of 
the isatin series showed that a sulfonamide bearing a pyrrolidine ring was highly preferable for 
potency (Chapter I.4). Additionally, the importance of stereochemistry with the (S)-configuration at 
the chiral pyrrolidine was demonstrated by prior SAR studies (Chapter I.4).56 72 As a result, the 
designed substituted imidazoleindolone and triazoleindolone structures to be synthesised contained 
the same sulfonyl pyrrolidine moiety as the isatin sulfonamide 22 with the (S)-configuration at the 
chiral pyrrolidine (Figure 4.2).  
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
118 | P a g e  
 
N
O
O
S
N
O O
O
F
F
N N
N
F
N
O
S
N
O O
O
N
O
S
N
O O
O
N
N
N
F
F
F
F
The Isatin Sulfonamide Lead Compound
The Initial Imidazoleindolone Target The Initial Triazoleindolone Target
22
60 104
 
Figure 4.2: Imidazoleindolone and Triazoleindolone target structures, 60 and 104, modelled on the lead 
isatin sulfonamide structure 
 The first set of structures selected were imidazoleindolone 60 and triazoleindolone 104, 
substituted with the same sulfonamide group found in the lead isatin structure 22 (Figure 4.2). The 
aim was to optimise the synthetic routes to these heterocycles before proceeding to the addition of 
substituents on the azole side of the heterocycles.  
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IV.2. Imidazoleindolone and Triazoleindolone Synthesis via Isatin Sulfonamide 
Intermediates  
Synthesis of the sulfonamide substituted imidazoleindolone and triazoleindolone 
heterocycles from the isatin sulfonamide 109 was initially explored (Figure 4.3). From the isatin 
intermediate 109, functional group interconversion of the isatin amide group to an imidazole or a 
triazole ring would then give the desired imidazoleindolone and triazoleindolone heterocycle 
respectively (Figure 4.3).  
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Figure 4.3: Imidazoleindolone and triazoleindolone synthesis via an isatin intermediate 
To obtain the target structures 60 and 104, the sulfonamide substituted isatin 109 was first 
synthesised, following reported literature procedures and similar steps utilised for the 
pyrimidoindolone synthesis described in Chapter III.57 Starting from the Boc-protected (S)-prolinol 
66, the alcohol group was converted into tosylate 105 in 84 % yield, which was subsequently 
displaced with 2,4-difluorophenol 106 under basic conditions to give phenoxy ether 107 in 62 % yield. 
Boc deprotection of ether 107 gave the amine 108 in 95 % yield, followed by the amine coupling with 
isatin sulfonyl chloride 64 to give the sulfonamide 109 in 70 % yield (Scheme 4.1).  
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Scheme 4.1: Preparation of the isatin sulfonamide 109 as a starting material in imidazoleindolone 60 and 
triazoleindolone 104 synthesis.57 
After facile preparation of isatin sulfonamide 109, a number of synthetic strategies designed 
to incorporate the imidazole and triazole rings were explored. Firstly, it was hoped that the 
triazoleindolone target 104 could be achieved through the reaction of formic hydrazide 112 with 
reactive intermediates of isatin sulfonamide 109. Such intermediates included the thioamide, imidoyl 
chloride, carbamate and methyl imidate derivatives of the isatin sulfonamide 109. 
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Scheme 4.2: Intended formation of the triazoleindolone heterocycle from thioamide intermediate 111.143-146 
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The first isatin sulfonamide intermediate explored was the thioamide species 111 (Scheme 
4.2). Preparation of the thioamide 111 involved treatment with Lawesson’s reagent (LR) 110 (Scheme 
4.2), a thionating agent used to convert C=O bonds to C=S bonds.147 In solution, LR is at equilibrium 
with the more reactive dithiophosphine ylide 113 which reacts with a carbonyl to give rise to a 
thiaoxaphosphetane intermediate 115 (Scheme 4.3). The driving force is the formation of a stable 
P=O bond in a cyclo-reversion step that gives the C=S bond.147  
P
S
P
S S
S
MeO OMe MeO P
S
S
MeO P
S
S
R R'
O
MeO P
O
S
S
R
R'
MeO P
S
S
O
R'
R
MeO P
O
S
R
S
R'
+
Thioamide
product
dithiophosphine ylide
Thiaoxaphosphetane intermediate
110
2 2
113
114115116
111 109
Scheme 4.3: Thionating mechanism of the Lawesson’s reagent147 
Thioamides (C=S bonds) are known to be much less stable than amides (C=O bonds) and are 
therefore more reactive.148 While the incorporation of a triazole ring is not known to occur through 
the reaction of formic hydrazide with an amide group, formic hydrazide 112 has been reported to 
successfully react with the more reactive thioamide group to give a 1,2,4-triazole ring (Schemes 4.2, 
4.4).143-146   
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Scheme 4.4: Proposed mechanism of formic hydrazide 112 reaction with thioamides 
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Upon treatment of thioamide 111 with formic hydrazide, the N-H group of the thioamide was 
expected to attack the aldehyde carbonyl of formic hydrazide 112 to give the corresponding alcohol 
95. Subsequent intramolecular nucleophilic addition of the hydrazide group to the thioamide, 
followed by dehydration and loss of H2S would then give the triazole ring of the triazoleindolone 
structure (Scheme 4.4). Regioselective formation of thioamide in preference to a thioketone was 
expected as the amide carbonyl is generally the most easily thionated of the carbonyl groups, owing 
to the delocalisation of the nitrogen lone pair onto the C=S bond.149  
Full conversion of sulfonamide 109 in the presence of LR was observed within 2 hrs in DME 
or THF at room temperature. In both solvents, a TLC of the reaction mixture revealed several spots. 
Successful conversion of sulfonamide 109 to the corresponding thioamide 111 was confirmed by 
LCMS, which showed the thioamide product, as well as a number of by-products. The reaction was 
performed under dilute conditions in an attempt to avoid side product formation. Purification of the 
crude residue obtained proved challenging as it contained a range of closely eluting components. 
Instead, the mixture was separated into crude fractions by column chromatography, in an attempt 
to obtain thioamide 111 in a cleaner mixture. Unfortunately, thioamide 111 appeared to be unstable 
as the product peak observed by LCMS prior to crude purification was not present in any of the 
fractions following flash column chromatography. Formation of the thioamide and proceeding to the 
next step without purification, heating with formic hydrazide in cyclohexanol, failed to give the 
desired triazoleindolone heterocycle 104 (Scheme 4.2).  
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Scheme 4.5: Unsuccessful P2S5 thionation of amide 109.149, 150 
 
In an attempt to successfully isolate thioamide 111, P2S5 was employed as an alternative, 
milder thionating agent, but the reaction in THF and toluene failed to give any trace of the desired 
product (Scheme 4.5).  
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Scheme 4.6: Preparation of ketal protected isatin sulfonamide 118 
It is likely that possible intermolecular reactions of the thioamide group with the electrophilic 
ketone centre may have been responsible for the numerous by-products observed with LR. Hence, 
the reaction was repeated with protected ketone 118, prepared from the acid catalysed 
condensation of isatin sulfonamide 109 with 1,3-propanediol in toluene in 78 % yield (Scheme 4.6).  
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Scheme 4.7: Attempts to prepare the ketal protected thioamide 119 
Unfortunately, no reaction was observed using ketal 118 and LR in THF, at either room 
temperature or heating to reflux. The same outcome was observed with P2S5 (Scheme 4.7). Unlike 
the reaction of isatin 109 with LR, no trace of the thioamide product was observed with all attempts 
to prepare the ketal protected thioamide 119 (Scheme 4.7). The reason for lack of reaction of ketal 
118 with LR or P2S5 is not known, though possible steric effects due to the presence of the 6 
membered 1,3-dioxolane ring may have hindered reaction with the thionating agents. As a result, 
triazoleindolone synthesis from a thioamide intermediate was terminated and the imidoyl chloride 
strategy was explored.  
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Scheme 4.8: Triazoleindolone synthesis via the imidoyl chloride 120.151, 152 
The formation of imidoyl chlorides from isatin rings have been reported in literature by 
Katritzky et al. and Campagna et al.151, 153 Preparation of the imidoyl chloride intermediate 120 
involved heating isatin sulfonamide 109 in POCl3 for 2.5 hrs, followed by subsequent removal of 
excess POCl3 under reduced pressure. The resulting intermediate was used in the next step without 
workup or purification, in order to avoid the facile hydrolysis of the labile imidoyl chloride group 
(Scheme 4.8).153 
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Scheme 4.9: The mechanism of imidoyl chloride reaction with formic hydrazide 
It was hoped that imidoyl chloride 120 would react with formic hydrazide 112 to give the 
triazoleindolone heterocycle 104. The proposed mechanism of formic hydrazide reaction with imidoyl 
chloride 120 to give the corresponding triazoleindolone structure is shown in Scheme 4.9. 
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TLC of the sulfonamide-POCl3 reaction mixture showed complete consumption of isatin 
sulfonamide starting 109 after 2.5 hrs, while 1H NMR showed one major product with loss of the 
amide hydrogen, suggesting successful formation of imidoyl chloride 120. Following a reported 
procedure,152 the residue was heated to reflux with formic hydrazide 112 in nBuOH. Disappointingly, 
a complex mixture suggesting complete decomposition was obtained, which may have resulted from 
side reactions such as formic hydrazide condensation with the ketone group to give formic hydrazone 
species which could undergo further reactions. It was possible that ketone 109 protection as a ketal 
118 would block the formation of by-products and decomposition resulting from unwanted reactions 
of the isatin ketone group. However, given that the by-product of POCl3 reaction with an amide to 
form an imidoyl chloride is HCl, a ketal group was expected to undergo hydrolysis under the reaction 
conditions. 
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Scheme 4.10: Attempts to prepare triazoleindolone 104 from ketal 118 and hydrazinocarboxylate 124 
 Subsequently, hydrazinocarboxylate 124 was used as an electrophile with ketal sulfonamide 
118. This involved treating ketal 118 with a base (NaH or tBuOK), prior to the addition of 
hydrazinocarboxylate 124, in either THF or DMF at 135 ᴼC (Scheme 4.10). However, no reaction was 
observed with either of the two bases and solvents, possibly due to the limited electrophilicity of the 
carbonyl group of hydrazinocarboxylate 124. 
In successive reactions, preparation of the triazoleindolone heterocycle 104 from imidate 
based intermediates was explored. This route involved the formation of a reactive methyl or triflate 
imidate from isatin sulfonamide 109, using powerful alkylating agents such as triflic anhydride and 
the Meerwein’s salt.154-156 The resulting imidate intermediate would contain a methoxy or a triflate 
leaving group which could be treated with formic hydrazide 112 to give the triazoleindolone 
heterocycle 104. Trialkyloxonium salts such as [BF4][OMe3] (“Meerwein salts”),157, 158 are versatile 
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reagents for the O-alkylation of amides, lactams and related functional groups in preference to N-
alkylation.155, 159, 160 
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Scheme 4.11: Attempts to achieve triazoleindolone 104 from the methyl imidate intermediate 127.154-156 
In the initial reaction, the Meerwein’s salt, [BF4][OMe3] was employed to O-alkylate isatin 
sulfonamide 109 and give the methyl imidate 127, following reported procedures.154, 155 After heating 
for two days in acetonitrile, only the starting material 109 was isolated from the reaction mixture 
(Scheme 4.11). Repeating the reaction in DCM or adding the base, disodium hydrogen phosphate 
according to other reported conditions,156 did not change the outcome of the reaction and the methyl 
imidate intermediate 127 was not obtained (Scheme 4.11).  
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Scheme 4.12: Attempts to achieve triazoleindolone derivative 129 from the reaction of imidate 
intermediates 128a/b with formic hydrazide 112 
Methyl imidate formation was subsequently repeated with the ketal protected isatin 
sulfonamide 118, using [BF4][OMe3] as the alkylating agent (Scheme 4.12). It was hoped that 
replacement of the ketone group with a ketal would increase the electron density of the isatin ring, 
increasing the chances of nucleophilic attack on the alkylating agent. At all temperatures trialled, 
though the starting material was the major component of the reaction mixture, minor reactions was 
observed overnight to give a bright yellow compound. Crude 1H NMR of the reaction mixture showed 
that the product of the incomplete reaction was not the desired product, but a close derivative of 
the starting material 118 in which the ketal protecting group was displaced. Given that isatin rings 
are characterised by a bright yellow/orange colour, turning colourless upon protection/removal of 
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the ketone, it was possible that the strong alkylating agent resulted in hydrolysis of the ketal bond, 
to give a brightly coloured ketone species. The small amount of a side product could not be isolated 
for further characterisation. The reaction appeared to halt after a day as there was no significant 
increase in consumption of the starting material after prolonged stirring for up to 3 days. It is worth 
noting that the reaction was carried out in anhydrous solvents under argon, as the presence of water 
was expected to react with any resulting methyl imidate product 127/128 to regenerate the starting 
material.  
Triflate anhydride is another strong electrophile used for O-sulfonation.161-163 This reagent 
was also used in attempts to prepare the imidate intermediate of the ketal 118 (Scheme 4.12). 
Similarly to reactions with [BF4][OMe3], an LCMS showed that the major component of the reaction 
mixture after one day was unreacted starting material 118. It was thought that the limited solubility 
of triflate anhydride in DCM, as well as the inherent instability of the triflyl imidate 128a could 
account for the fact that no reaction was observed. As a result, another reaction was carried out in 
the more polar acetonitrile, where instead of attempting to isolate the triflate intermediate 128a, 
formic hydrazide 112 was added to the reaction mixture, and after one day, the mixture was heated 
overnight to force the reaction. It was hoped that the ketal-protected triazoleindolone 129 would be 
obtained in a one-pot synthesis (Scheme 4.12). Again, no reaction was observed and only the starting 
material 118 was isolated. The apparent lack of reactivity of ketal-protected and unprotected isatin 
sulfonamide 118 and 109 towards triflic anhydride and [BF4][OMe3] could be a result of the 
sulfonamide substituent significantly reducing the nucleophilicity of the amide group. It is also 
possible that the electron deficiency of the isatin sulfonamide gave rise to imidate intermediates 
which were highly unstable and easily hydrolysed. As a result of the lack of reaction with triflic 
anhydride and [BF4][OMe3], synthesis via imidate intermediates was abandoned.  
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Scheme 4.13: Attempted preparation of the triazoleindolone 104 from carbamate 131  
Subsequently, triazoleindolone synthesis via a carbamate intermediate was investigated. The 
strategy for this route was to prepare the carbamate derivative 131 of isatin sulfonamide 109, which 
would be treated with hydrazine to give the species 132, followed by dehydration to give the 
triazoleindolone heterocycle 104 (Scheme 4.13). Such reactions of isatin carbamate derivatives and 
other heterocycles with hydrazine to give the corresponding triazoloindole-dione 132 have been 
reported in literature.164, 165 The first attempt to obtain the carbamate derivative of isatin 
sulfonamide 109 involved treatment with ethyl chloroformate 130. Although isatin derivatives have 
reportedly been successfully N-acyalted,164, 166 a range of reactions using different bases and solvents 
failed to give the desired carbamate 131 (Scheme 4.14, Table 4.1). Instead, the open ring α-keto ester 
133 was obtained (Scheme 4.14), using a range of bases including, pyridine, triethylamine, potassium 
tert-butoxide and sodium hydride. As well as ethyl chloroformate 130, the bulkier isobutyl 
chloroformate 134 and Boc2O were also utilised as acylating agents, as it was hoped these reagents 
would sterically hinder isatin ring opening. 
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Scheme 4.14: Acylation of isatin sulfonamide 109 with chloroformate and Boc2O                          
Table 4.1: Acylation reaction conditions and obtained products 
Entry Acylating agent Base Solvent Temp (oC) Product 
1 Ethyl chloroformate Pyridine PhMe rt 133 
2 Ethyl chloroformate Et3N THF rt 133 
3 Ethyl chloroformate K2CO3 DMF rt 133 
4 Ethyl chloroformate tBuOK DMF rt 133 
5 Ethyl chloroformate NaH THF 0 133 
6 Isobutyl chloroformate NaOEt MeOH 0 136 and 137 
7 Isobutyl chloroformate LiHMDS THF 0 - 
8 Boc2O DMAP* DCM rt 139 and 140 
*Catalytic amount of DMAP used 
When isobutyl chloroformate 134 was used as the acylating agent with sodium ethoxide as 
the base in methanol, a mixture of two open ring α-keto esters were obtained, the ethoxy ester 136 
and the methoxy ester 137 (Table 4.1, Entry 6; Scheme 4.14). By contrast, the use of LiHMDS as the 
base with isobutyl chloroformate 134 led to complete decomposition, likely due to the much stronger 
base promoting multiple side reactions (Table 4.1, Entry 7). Likewise, the use of Boc2O led to open 
ring structures, giving a mixture of α-keto ester 139 and α-keto carboxylic acid 140 (Table 4.1, Entry 
8; Scheme 4.14). It is likely that the acylation reactions generated the alcohol derivatives of the 
corresponding chloroformate which then acted as a nucleophile, attacking the carbonyl of the initially 
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formed desired carbamate product, and opening the isatin ring. Ring opening by alcohol derivatives 
could account for the fact that, a mixture of the open ring methyl and ethyl esters (136 and 137) were 
obtained when the nucleophilic base, NaOEt was used with MeOH as the solvent (Table 4.1, Entry 6; 
and Scheme 4.14).  
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Scheme 4.15: Successful synthesis of carbamate 141 
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           Scheme 4.16: Preparation of the ethoxy carbamate 142 from ketal 118 in 96 % yield  
By contrast, acylation reactions with ketal 118 and Boc2O successfully gave the desired 
carbamate 141 in 34 % yield (Scheme 4.15). The ethoxy carbamate 142 was prepared in the higher 
yield of 96 % from ethyl chloroformate 130 and ketal 118 (Scheme 4.16). The ethyl carbamate 142 
was preferred for the next step instead of the tert-butyl carbamate 141 as the ethoxide is less 
sterically hindered and a better leaving group.  
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Scheme 4.17: Treatment of carbamate 142 with hydrazine in toluene and THF 
Unfortunately, the next step involving the reaction of carbamate 142 with hydrazine failed to 
give the desired spiro-triazoloindolone 143 (Scheme 4.17). The disappearance of carbamate 142 
within 2 hours in either toluene or THF was observed by TLC. In addition to a mixture of unknown 
species, the ketal-protected isatin sulfonamide 118 was regenerated and recovered from the 
reaction mixture. Hydrazine apparently reacted with carbamate 142 to displace the isatin ring rather 
than the ethoxide as the leaving group (Scheme 4.18).  
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Scheme 4.18: Possible reaction leading to the regeneration of ketal 118 upon treatment of carbamate 142 
with hydrazine 
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While hydrazide based reagents, including formic hydrazide 112, hydrazinocarboxylate 124 
and hydrazine were employed for reactions with isatin sulfonamide intermediates with the aim of 
achieving the triazoleindolone heterocycle 104, bromoacetonitrile was utilised for the preparation of 
the imidazoleindolone heterocycle 60 from ketal 118.  
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Scheme 4.19: Attempts to prepare the imidazoleindolone heterocycle 60 from ketal 118 and 
bromoacetonitrile 
In an attempt to form the imidazole ring of the imidazoleindolone scaffold, ketal 118 was first 
N-alkylated with bromoacetonitrile in the presence of potassium tert-butoxide to give the nitrile 
intermediate 144 in 71 % yield (Scheme 4.19). In an analogous reaction described for the 
pyrimidoindolone synthesis in Chapter III, the next step involved the Raney Ni catalysed nitrile 
reduction to give primary amine 145 in 65 % yield (Scheme 4.19). Intramolecular 
cyclisation/dehydration would then give the amidine ring 146 which would be oxidised to the 
aromatic imidazole ring, followed by ketal hydrolysis to give the imidazoleindolone heterocycle 60 
(Scheme 4.19). However, unlike the pyrimidoindolone synthesis (Chapter III), heating to effect 
dehydration/cyclisation in order to obtain amidine 146 led to the decomposition of primary amine 
145. For the pyrimidoindolone synthesis, Thorpe-Ingold effect of the bulky cyclopentyl ring could 
account for the facile dehydration of the amine intermediate 78 to give pyrimidoindolone 79 
(Chapter III, Scheme 3.6).167  
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Cyclisation of the primary amine 145 was subsequently attempted using POCl3 as a 
dehydrating agent but this was also unsuccessful, with no reaction and quantitative isolation of the 
starting material. Similar dehydration reactions have been achieved using acid catalysts such as TsOH, 
acetic acid or camphorsulfonic acid, though in the absence of acid sensitive ketal groups.168-170 
However, acid catalysed cyclisation was not attempted with amine 145 as it was believed that ketal 
hydrolysis would be faster than cyclisation and the resulting ketone could then react with the amine 
group to give dimeric species leading to decomposition.  
IV.3. Imidazoleindolone and Triazoleindolone Synthesis via SNAr Fluoride 
displacement   
The synthetic results thus far have shown that the preparation of the triazoleindolone 104 
and imidazoleindolone 60 heterocycles from isatin sulfonamide intermediates was hampered by 
problems associated with unexpected reactions or lack of reaction in some cases. As a result, the 
synthetic route for achieving the indolone heterocycles was re-evaluated and an alternative 
retrosynthetic approach was devised. Since attempts to incorporate the imidazole or triazole ring 
onto the intact indolinone ring of isatin sulfonamide intermediates proved problematic, we 
investigated a route where the entire indolone would be constructed in sequence. The retrosynthetic 
approach is shown below in Scheme 4.20.  
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Scheme 4.20: Retrosynthetic analysis of an alternative route to the triazoleindolone and imidazoleindolone 
heterocycles  
The key step in the revised route is the formation of the indolone ring system 147 from an 
intramolecular SNAr displacement of an aryl fluoride by the azole nitrogen atom. Fluoride is a stable 
leaving group with high yielding intermolecular and intramolecular displacement of aromatic 
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fluorides by amino groups reported in literature.171-173 Introduction of the sulfonamide substituent 
was initially reserved for the final steps in order to avoid any problems that may arise from the strong 
electron withdrawing effects of the sulfonyl group. Halogen substituents were instead employed, 
with the aim of converting the halogen groups into the sulfonyl chloride following the formation of 
indolone scaffold. The resulting sulfonyl chloride 150/151 would then be treated with the relevant 
amine to give the corresponding sulfonamide.  
IV.3.1. Imidazoleindolone Synthesis  
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Scheme 4.21: Synthesis of imidazoleindolone 157 from the commercially available benzoic acid 152a and 
imidazole 155 
Starting from the commercially available 5-chloro-2-fluorobenzoic acid 152a, two reaction 
intermediates were prepared, methyl ester 153 in 89 % yield and the acid chloride 154 in assumed 
quantitative yield (Scheme 4.21). At first, phenyl-imidazole ketone 156 was prepared following a 
reported procedure, which involved the one-pot synthesis of SEM-protected imidazole, and 
subsequent imidazole C-2 lithiation and nucleophilic substitution of an ester reagent.174 Following 
this procedure, imidazole 155 was treated with nBuLi at -78 ᴼC and warmed to room temperature 
prior to the addition of SEM-Cl to generate the SEM-protected imidazole in situ. The mixture was 
then re-cooled to -78 ᴼC and treated with another equivalent of nBuLi, followed by quenching with 
methyl ester 153 to generate the SEM-protected ketone derivative of 156 in 22 % yield (Scheme 2.1). 
This was treated with HCl to remove the SEM protecting group, giving the deprotected ketone 156 in 
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69 % yield (Scheme 4.21). While the one-pot N-protection-substitution procedure reduced the 
number of steps, the modest yield of 22 % was not ideal.   
Bastiaansen et al. reported that the preparation of phenyl-imidazole ketone derivatives can 
be achieved without the need for N-protection of imidazole.175 Following the literature procedure,175 
imidazole was treated with triethylamine and two equivalents and benzoyl chloride 154, which was 
prepared by heating the benzoic acid 152a in thionyl chloride. After stirring in pyridine for 3.5 hours 
at room temperature, the mixture was treated with 7.5N NaOH and heated to reflux for one hour. 
Upon cooling, the desired ketone 156 precipitated from the reaction mixture in 65 % yield (Scheme 
4.21).  
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Scheme 4.22: A single-pot synthesis of 2-benzoylimidazole 156.175 
This reaction was reported to proceed via a benzoyl-pyridine adduct 158, acting as a powerful 
benzoylating agent to give an N-benzoylimidazole intermediate 159 (Scheme 4.22).175 Bastiaansen et 
al. concluded that N-benzoylimidazole 159 reacts with a second equivalent of benzoyl chloride, and 
upon aqueous workup with NaOH, 2-benzoylimidazole 156 is obtained.175 We believe that N-
benzoylimidazole intermediate (159) reacts with a second equivalent of benzoyl chloride to give an 
N,N-dibenzoylimidazole species (160), followed by C-2 deprotonation and benzoyl transfer to the 
imidazole C-2 position to give a 1,2-dibenzoyl intermediate (161). This is then cleaved by NaOH on 
the N-benzoyl bond to give the phenyl-imidazole ketone (156) (Scheme 4.22).  
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Following the successful formation of phenyl-imidazole ketone 156, K2CO3 was utilised as a 
base in DMF, stirring at 145 ᴼC to achieve the intramolecular SNAr displacement of the fluoride 
substituent by the imidazole group. This successfully gave the anticipated imidazoleindolone 
heterocycle 157 in 64 % yield (Scheme 4.21).  
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R = Bn, 162
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OR
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Scheme 4.23: Conversion of aromatic halides to sulfonyl chlorides via nucleophilic substitution and oxidative 
chlorination.176-180 
In successive reactions, conditions for the preparation of 7-sulfonyl imidazoleindolone 151 
from 7-chloro imidazoleindolone 157 were explored. The functional group interconversion of 
aromatic chlorides into sulfonyl groups have been reported to occur in a two-step process, involving 
nucleophilic chloride displacement by a sulfur nucleophile followed by oxidative chlorination to give 
the corresponding sulfonyl chloride (Scheme 4.23).176-179 A range of sulfur nucleophiles can be 
employed, though benzylthiol is the most commonly used, and oxidative chlorination typically occurs 
in aqueous acidic media (Scheme 4.23). Langler proposed that oxidative chlorination occurs via an 
initial loss of benzyl cation and concomitant formation of a sulfenyl chloride 166,181 while Barnwell 
et al. observed that oxidative chlorination proceeded via an initial formation of a sulfoxide 172.182 
The proposed oxidative chlorination pathways by the two groups are shown in Scheme 4.24.  
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Scheme 4.24: Two proposed mechanisms for the oxidative chlorination of thioether intermediates181, 182 
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Scheme 4.25: An initial attempt to prepare the sulfonyl chloride substituted imidazoleindolone heterocycle 
151a  
Following a reported procedure,180 an initial attempt to introduce the sulfonyl group involved 
treatment of a mixture of 7-chloroimidazoleindolone 157 and benzyl thiol with K2CO3, aiming to 
obtain the benzyl thioether intermediate 162 (Scheme 4.25). Given that the imidazoleindolone 
heterocycle was designed to incorporate thiols as a caspase-binding inhibitor, an excess amount of 
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benzyl thiol was used in order to counteract any trapping of the thiol reagent by the ketone carbonyl. 
However, the formation of the thioether 162 was unsuccessful, with only unreacted 
imidazoleindolone 157 isolated from the reaction mixture.  
N
Cl
N
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EtOH/H2O
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Cl-SO3H
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157
175
151174
Not observed
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Scheme 4.26: An attempt to prepare sulfonyl chloride 151 via the sodium salt 174 using sodium sulfite  
Sodium sulfide (Na2S)179, 180 was also utilised for the SNAr displacement of the aryl chloride 
157 in DMSO at room temperature. A TLC and crude 1H NMR of the resulting reaction mixture 
suggested complete decomposition of the starting material. In an attempt to achieve the sodium 
sulfonate salt 174, sodium sulfite (Na2SO3) was utilised, following literature procedures (Scheme 
4.26).183, 184 In this case, ring opening to give the ethyl benzoate ester 175 was observed (Scheme 
4.26), which was attributed to the reaction of solvent ethanol with the ketone carbonyl of 
imidazoleindolone 157. The imidazoleindolone scaffold is known to be stable in ethanol or methanol. 
Hence, it is likely that sodium sulfite catalysed the nucleophilic addition of ethanol to 
imidazoleindolone 157 (Scheme 4.14). The reaction was repeated in DMF, but no reaction occurred, 
likely due to the limited solubility of sodium sulfite in DMF.  
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Scheme 4.27: Attempts to prepare the ketal protected derivatives of imidazoleindolone  
It was hoped that protection of the ketone carbonyl as a ketal would lead to successful 
reactions with sulfur nucleophiles. Hence, protection of imidazoleindolone 157 as ketal 177 using 
1,3-propanediol and catalytic TsOH was attempted (Scheme 4.27), but similarly to the reaction 
resulting in the formation of ethyl benzoate ester 175 (Scheme 4.26), the open ring ester 179 was 
obtained. Ring opening was also observed when ethylene glycol was used instead of 1,3-propanediol, 
so the size of the ketal had no effect on the reaction outcome (Scheme 4.27).  
F
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NBr
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Ethylene glycol
Dean Stark, Reflux
1. TsOH, PhMe
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180 181  
Scheme 4.28: Attempts to prepare ketal 181 from ketone 180 
The bromo-substituted imidazoleindolone 58 was also prepared using the same steps 
employed for the preparation of the chloro-substituted imidazoleindolone 157 (Scheme 4.21). 
Aromatic bromides are reportedly converted to sulfonyl chlorides in a process that involves 
treatment with nBuLi, with lithium-halogen exchange giving an anion which is treated with a sulfur 
electrophile such as sulfuryl chloride (SO2Cl2) to give the desired sulfonyl chloride.185 This procedure 
required the protection of the ketone carbonyl as a ketal in order to avoid undesired trapping of nBuLi 
by the carbonyl group. As treatment of the imidazoleindolone ring with ethylene glycol or 
propanediol in the presence of an acid catalyst led to ring opening, ketone protection was attempted 
prior to SNAr cyclisation with phenyl-imidazole ketone 180. This involved treatment of ketone 180 
with ethylene glycol and TsOH in toluene, heating to reflux (Scheme 4.28). After 12 hrs, no reaction 
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was observed. It was initially thought that the lack of reaction could be due to ethylene glycol 
azeotroping with toluene when heated to reflux, hindering reaction with ketone 180. However, using 
benzene as the solvent made no difference to the reaction outcome. It was likely that protonation of 
the basic imidazole ring prevented protonation of the ketone impeding ketal formation. 
We considered alternative ketone protecting groups such as 1,3-dithioacetals. However, the 
open ring reactions observed during ketal formation attempts (Scheme 4.27) stemmed from the 
nucleophilic displacement of the imidazole ring by the diol reagent. A thiol utilised for dithioacetal 
formation was expected to behave in a similar way. The alcohol derivative of imidazoleindolone 182 
was instead explored as an alternative to ketal-protection of the ketone group (Scheme 4.29).  
Br
N
N
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NaBH4
MeOH, 0oC
Br
N
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58 182 (92%)  
Scheme 4.29: Reduction of imidazoleindolone 58 
Treatment of ketone 58 with sodium borohydride in methanol gave the alcohol product 182 
according to a crude 1H NMR analysis. However, after aqueous work-up and concentration in vacuo, 
an insoluble solid, unable to dissolve in a range of solvents, including hot methanol, DMF, DMSO, 
water, and DCM/MeOH mixtures was obtained. Ketone reduction was repeated, and without work-
up, the polar but soluble alcohol product 182 was obtained in 92 % yield (Scheme 4.29).  
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Scheme 4.30: An attempt to protect alcohol 182 as a benzyl ether prior to the introduction of the sulfonyl 
chloride substituent 
Unfortunately, treatment of alcohol 182 with benzyl bromide and NaH in order to obtain the 
benzyl ether protected alcohol 183 was unsuccessful, giving a decomposed mixture with no signs of 
the desired product (Scheme 4.30).  
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Scheme 4.31: An attempt to introduce the sulfonyl chloride group to the unsubstituted imidazoleindolone 
heterocycle 52 
We subsequently investigated the direct sulfonation of the phenyl group of unsubstituted 
imidazoleindolone 52. It was hoped that the presence of the electron donating imidazole ring would 
direct sulfonation to the desired 7-position of the imidazoleindolone heterocycle. No reaction was 
observed when imidazoleindolone 52 was heated with chlorosulfonic acid in DCM for 12 hours, but 
stirring in neat chlorosulfonic acid at either room temperature or at 70 ᴼC resulted in full 
consumption of the starting material (Scheme 4.31). A mixture of products was observed by TLC, but 
the only product isolated was the 5-chlorosulfonyl gem-dichloride 184, in 11 % yield (Scheme 4.31). 
Since the sulfonyl chloride was introduced in the desired 7-position, hydrolysis of the gem-dichloride 
group to give a ketone using reported conditions,186 could give the sulfonyl substituted 
imidazoleindolone 151. However, the poor yield of the reaction discouraged further use of gem-
dichloride 184.  
As a result of the problems encountered with attempts to introduce the sulfonyl substituent 
following the successful formation of the halogen-substituted and unsubstituted imidazoleindolone 
heterocycles, the synthetic sequence was reversed to incorporate the sulfonamide substituent in the 
initial steps prior to the formation of the indolone heterocycle.  
 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
142 | P a g e  
 
Cl-SO3H
O
OMe
F
DCM
0oC - 70oC
S
Cl
OO O
OR
F
186 a/b, R = Me / H(1:4)
DCM, Et3N
0oC - rt
S
N
OO O
OR
F
O
F
F
185
Amine 108
(95%)
187 a/b
 
Scheme 4.32: Preparation of 5-sulfonamide-2-fluorobenzoate 187a/b 
The first step in the preparation of the sulfonamide substituted intermediate 187, involved 
treatment of methyl 2-fluorobenzoate 185 with chlorosulfonic acid at 70 ᴼC. This exclusively added 
the chlorosulfonyl group to the 5-phenyl position to give methyl ester 186a as the minor product and 
the ester hydrolysed carboxylic acid 186b as the major product in a 1:4 ratio (Scheme 4.32). The 
acid/ester mixture was used in the next step, treating with the previously described amine 108 
(Scheme 4.1) to give 5-sulfonamide methyl benzoate 187a and the benzoic acid derivative 187b in a 
total yield of 95 % (Scheme 4.32).  
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Scheme 4.33: Preparation of sulfonamide substituted phenyl-imidazole ketone 201 using the one-pot 
synthesis of 2-benzoylimidazoles with unprotected imidazole 
In the next step, 5-sulfonamide-benzoic acid 187b was treated with thionyl chloride, giving 
benzoyl chloride 188 (Scheme 4.33). This was used in the one-pot synthesis of 2-benzoylimidazoles 
with unprotected imidazole, which successfully gave the halogen substituted ketone 157 (Scheme 
4.22). Unfortunately the reaction was less efficient with sulfonamide substituted 188 with only 15 % 
of the desired ketone 201 isolated and in less than 80 % purity (Scheme 4.33).  
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Scheme 4.34: Preparation of N-trityl protected phenyl-imidazole ketone 191 from benzoyl chloride 188  
A more stepwise approach was adopted where imidazole was first protected with a trityl 
group, a protecting group chosen for its facile synthesis and easy handling of the solid 1-trityl-1H-
imidazole 190 (Scheme 4.34).187 Trityl protected imidazole 190 was prepared in 80 % yield by 
treatment of imidazole with Tr-Cl and NaH in DMF (Scheme 4.34). This was then lithiated on the C-2 
position using nBuLi in THF at -78 ᴼC, prior to quenching with benzoyl chloride 188. However, there 
was no improvement in the reaction efficiency, with ketone 191 isolated in only 10 % yield (Scheme 
4.34). As a result, 5-sulfonamide-carboxylate 187a was employed as an alternative, milder acylating 
agent.  
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Scheme 4.35: Preparation of N-trityl protected imidazole-ketone 191 from 5-sulfonamide methoxy benzoate 
187a  
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Treatment of lithiated trityl-imidazole anion 190 with methyl carboxylate 187a inconsistently 
gave the desired ketone 191 in 15 – 45 % yield (Scheme 4.35). The major product of the reaction was 
the fluoride displaced, methoxide-substituted ketone 192, presumably formed from further reaction 
of the desired product 191 with the methoxide leaving group of ester 187a. Despite the formation of 
the methoxide substituted species 192 as the major product, nucleophilic substitution using the ester 
187a gave the ketone in higher yield and purity, compared to the use of acid chloride 188. Efforts 
were made to increase the percentage yield of ketone 191 formation. Controlling the speed of ester 
187a addition to the lithiated imidazole solution whilst maintaining the temperature at or below -78 
ᴼC; quenching the reaction mixture below -50 ᴼC; or varying the reaction concentration made very 
little difference to the reproducibility and yield of ketone 191 formation.   
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Scheme 4.36: High yielding preparation of trityl protected ketone 194 – 196 from halogen-substituted and 
unsubstituted ester electrophile, 153, 185 and 193 
It is worth noting that nucleophilic substitution of 5-bromo-, 5-chloro- and unsubstituted 2-
fluoro-methylbenzoate (194, 195 and 196; Scheme 4.36) with lithiated trityl imidazole 190 proceeded 
efficiently to give the corresponding ketone products (52, 58 and 157; Scheme 4.36) in reproducible 
70 – 80 % yields, higher than the percentage yields obtained using the one-pot synthesis with 
unprotected imidazole (Scheme 4.22). Hence, the poor yield and irreproducibility observed with the 
nucleophilic substitution using methyl benzoate 187a was attributed to the strong electron 
withdrawing effect of the sulfonamide group activating the phenyl ring to side reactions.  
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Scheme 4.37: Preparation of Weinreb amide 197188 and its use in nucleophilic substitution with lithiated 
imidazole anion 190 
Aiming to optimise the production of ketone 191, alternative acylating agents were 
investigated, including Weinreb amide 197 and pentafluorophenoxide ester 200. Weinreb amide 197 
was prepared in 82 % yield from treatment of benzoyl chloride 188 with N,O-dimethylhydroxylamine, 
using pyridine as the base (Scheme 4.37). The reaction of Weinreb amides with organometallic 
reagents such as 2-lithum-tritylimidazole 190 is believed to proceed via a tetrahedral intermediate 
stabilised by chelation with the amide methoxy group as illustrated in Scheme 4.37.188 The resulting 
ketone is subsequently released following reaction workup. It was hoped that this chelation 
mechanism, which halts the release of a leaving group before work-up, would hinder undesired 
nucleophilic substitution of the 2-fluoride substituent. However, treatment of Weinreb amide 197 
with lithiated trityl-imidazole 190 only gave trace amounts of the desired ketone 191, observed by 
LCMS, with isolation of 25 % of unreacted trityl-imidazole 190 and no recovery of Weinreb amide 
197. 
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Scheme 4.38: Preparation of pentafluorophenoxy ester 200 and its reaction with 2-lithium-tritylimidazole 
190 
Following the disappointing results observed with Weinreb amide 197, the bulky 
pentafluorophenoxy ester 200 was prepared from acid chloride 188 and pentafluorophenol 199 in 
68 % yield (Scheme 4.38). We hoped that displacement of the pentafluorophenoxide group following 
nucleophilic substitution of ester 200 with deprotonated imidazole would give a stable, bulky anion 
that would be a poor nucleophile for further side reactions involving undesired SNAr displacement of 
the phenyl fluoride. Unfortunately, only a small percentage (< 20 %) of unreacted trityl-imidazole 190 
was isolated from the reaction mixture with no trace of the desired ketone 191 (Scheme 4.38).   
The fact that unreacted trityl-imidazole 190 was isolated from the nucleophilic substitution 
reactions, with no recovery of Weinreb amide 197 or pentafluorophenoxy ester 200, suggested 
possible deprotonation of the electron deficient sulfonamide substituted phenyl ring by the 
imidazole anion. Such deprotonation could account for the recovery of trityl-imidazole 190, despite 
confirmation of full deprotonation by nBuLi, observed by the incorporation of deuterium in samples 
of lithiated trityl-imidazole solutions quenched with deuterium oxide. The deprotonated acylating 
agents could then undergo further reactions leading to decomposition.  
To address the inefficient nucleophilic substitution reaction of lithiated trityl-imidazole 190 
with the sulfonamide substituted acylating agents, alternative synthetic routes were proposed which 
are described in the next section. However, a sufficient amount of trityl-protected imidazole-ketone 
191 was obtained from nucleophilic substitution reactions using ester 187a. This was successfully 
utilised in the preparation the sulfonamide substituted imidazoleindolone target 60 (Scheme 4.39).  
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Scheme 4.39: The final steps in the synthesis of target 5-sulfonamide-imidazoleindolone 60 
Trityl deprotection of 191 was achieved using 4M HCl in 1,4-dioxane to give ketone 201 in 70 
% yield. Facile intramolecular SNAr cyclisation was achieved by treatment of ketone 201 with K2CO3 
in DMF, stirring at 50 ᴼC to give the target 5-sulfonamide substituted imidazoleindolone 60 in 90 % 
yield (Scheme 4.39).  
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Scheme 4.40: Preparation of bromide substituted imidazoleindolone 59 
In addition to the target 7-sulfonamide substituted imidazoleindolone 60, the 2/3-bromo-
substituted derivative 59 was prepared for use in the UV-vis titrations detailed in Chapter II. This 
involved treating the core imidazoleindolone 52 with N-bromosuccinimide in chloroform at room 
temperature, which successfully gave the desired product in a moderate 26 % yield (Scheme 4.40). 
This was sufficient for use in the UV-vis experiment (Chapter II). The bromide substituent on the 
imidazole ring could also act as handle for future introduction of functional groups. The product 59 
was assumed to be a mixture of 2- and 3-bromo-imidazoleindolone regioisomers.  
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IV.3.2. Triazoleindolone Synthesis  
The retrosynthetic approach shown in Scheme 4.20 was devised for the synthesis of both the 
imidazoleindolone and triazoleindolone heterocycles. In the first step of the forward synthesis, unlike 
the preparation of phenyl-imidazole ketone 156 (Scheme 4.22), formation of phenyl-triazole ketone 
203 could not be achieved in one-pot using unprotected 1,2,4-triazole and benzoyl chloride 154 
(Scheme 4.41). As a result, the trityl-protected triazole 204 was prepared for use in nucleophilic 
substitution reactions with acylating agents (Scheme 4.42).   
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Scheme 4.41: An attempt to prepare phenyl-triazole ketone 203 from unprotected triazole 202 
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Scheme 4.42: Preparation of trityl protected triazole 204 
Preparation of N-trityl triazole 204 from Tr-Cl regioselectively gave the isomer 204 in 
preference to the alternative symmetric 204’ (Scheme 4.42). Trityl-triazole 204 was initially prepared 
in ACN using a mixture of K2CO3 and NaOH, with TBAI used as a catalyst (Scheme 4.42).189 Though 
giving the product 204 in moderate yield of 67 %, the reaction was relatively slow, taking 2 days to 
complete. An improved yield of 91 % and faster reaction time of 5 hours was achieved using the 
weakly nucleophilic base DBU as a proton sponge (Scheme 4.42). 
Towards The Development of Caspase-3/7 Inhibitor(s) for In Vivo PET Imaging of Cancer Apoptosis. 
 
149 | P a g e  
 
Cl
OMe
O
F
N N
N
Tr
nBuLi, THF
-78oC
Cl
O
F
205 (62%)
N
N
N
Cl
O
F
203 (73%)
N
N
H
N
3M HCl
1,4-dioxane
70oC
Tr
Cl
Cl
O
F
N N
N
Tr
nBuLi, THF
-78oC
Cl
O
F
205 (0 - 20%)
N
N
N
Tr
154
204
153
204
 
Scheme 4.43: Preparation of phenyl-triazole ketone 203 
In the next step, trityl-triazole 204 was deprotonated with nBuLi in THF at -78 ᴼC. Trapping of 
triazole anion with acyl chloride 154 at -78 ᴼC, inconsistently gave ketone 205 in  0 – 20 % yield 
(Scheme 4.43). By contrast, trapping the trityltriazole anion with methyl benzoate 153 was more 
consistent, successfully giving the desired product 205 with an average yield of 62 % (Scheme 4.43). 
The trityl protecting group was subsequently removed by acid catalysed hydrolysis to give ketone 
203 in 73 % yield.  
Unlike the facile SNAr cyclisation of phenyl-imidazole ketone 156, initial attempts to achieve 
triazoleindolone 206 from ketone 203 via the intramolecular SNAr substitution of the aryl fluoride, 
resulted in the unexpected formation of 1-pheny-1,2,4-triazole 207 (Scheme 4.44). The different 
reaction conditions used in attempts to prepare the triazoleindolone heterocycle 206 are shown in 
Table 4.3.  
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Scheme 4.44: Attempts to prepare the triazoleindolone heterocycle 206, resulted in the formation of 1-
phenyl-1,2,4-triazole 207 
Table 4.2: Reaction conditions and results observed for attempts to prepare the triazoleindolone 206  
Entry Base Solvent Temp (ᴼC) Time Result 
1 K2CO3 DMF 145 18 hrs 207  
2 Cs2CO3 DMF 145 18 hrs 207  
3 K2CO3 DMF 80 18 hrs No reaction 
4 Cs2CO3 DMF 50-100 18 hrs No reaction 
5 K2CO3 DMF 180* 20 mins 207 
6 Cs2CO3 DMF 180* 20 mins 207 
7 Cs2CO3 DMSO 180* 20 mins 207 
8 NaOH DMF 180* 20 mins Decomposition 
*Microwave irradiation 
Identical conditions used for the SNAr cyclisation of phenyl-imidazole ketone 156 (Scheme 
4.21) was initially employed for the equivalent reaction with phenyl-triazole ketone 203 (Scheme 
4.44; Table 4.2, Entries 1 and 2). After overnight heating at 145 ᴼC using either K2CO3 or Cs2CO3, the 
starting material had fully reacted, but the only component isolated from the mixture was 1-phenyl-
triazole 207 in 68 % yield. The reaction was repeated at lower temperatures in order to limit side 
reactions. However, no reaction was observed at 80 ᴼC using K2CO3, or at 50 – 100 ᴼC using Cs2CO3, 
despite overnight heating (Table 4.2, Entries 3 and 4). At low temperatures (50 – 100 ᴼC), no reaction 
was observed but at a higher temperature (145 ᴼC), prolonged heating was required to drive the 
reaction to completion. With the aim of quickly forcing the reaction to limit the formation of side 
products, microwave irradiation was employed, stirring at 180 ᴼC for 20 mins with either K2CO3 or 
Cs2CO3 (Table 4.2, Entries 5 and 6). These conditions also gave 1-phenyl-triazole 207.  DMSO was used 
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as the solvent instead of DMF in order to eliminate the possibility that reactions with DMF was 
responsible for the apparent decarbonylation to give the 1-phenyl-triazole 207, but the same result 
was observed (Table 4.2, Entry 7). The mechanism of phenyl-triazole ketone 203 reaction to give the 
1-phenyl-triazole species 207 is not known, though it is possible the reaction proceeded via the 
desired triazoleindolone 206 which quickly decomposes by a decarbonylation mechanism to give the 
species 207.  
N N
N
O
F
N
N
N
HO
K2CO3, DMF
180oC, MW
208 53  
Scheme 4.45: Intramolecular SNAr cyclisation attempt with unsubstituted phenyl-triazole ketone 208 
To assess the possibility that the observed decarbonylation could have been driven by the 
presence of the electron withdrawing chloride substituent, the unsubstituted phenyl-triazole ketone 
208 was prepared, using the same conditions described for the formation of chloro-substituted 
ketone 203 (Scheme 4.43, 4.45) and used in in the SNAr cyclisation reaction. Unfortunately, irradiating 
ketone 208 in DMF with K2CO3 at 180 ᴼC (Scheme 4.45), resulted in complete decomposition, 
attributed to the lack of an electron withdrawing substituent activating the phenyl ring to 
nucleophilic attack which was supported by the fact that no reaction was observed with conventional 
heating of a mixture of ketone 208 and K2CO3 in DMF at 145 ᴼC. 
Cl
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Scheme 4.46: Attempts to prepare the ketal protected derivative of ketone 203  
Since a form of decarbonylation was responsible for the formation of 1-phenyl-triazole 207, 
it was hoped that using the ketal protected derivative of ketone 203 would lead to successful SNAr 
cyclisation to give the ketal protected derivative of triazoleindolone 206. Treatment of ketone 203 
with 1,3-propanediol and TsOH in toluene, in an attempt to obtain ketal 210, led to triazole ring 
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displacement to give the species 211, while the use of ethylene glycol successfully gave ketal 209 in 
56 % yield (Scheme 4.46). Unlike the unsuccessful reaction of imidazoleindolone derivatives with 
diols (Schemes 4.27 and 4.28), the size of the ketal appears to be an important factor for the effective 
formation of phenyl-triazole ketal 209. Imidazole (pKa, 1H-imidazlole = 14.5) is a much stronger base 
than 1,2,4-triazole (pKa, 1H-1,2,4-triazole = 10.3).  It was therefore likely that, unlike 1,2,4-triazole, 
imidazole acted as a strong proton sponge, hindering ketal formation.  
N NH
N
F
Cl
OO
Cs2CO3, DMA
MW, 180oC, 35mins N
N
N
O
O
Cl
N
N
N
Cl
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209
212
207
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N
N
N
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Scheme 4.47: Synthesis of triazole-1,3-dioxolane 212 from ketal 209 
The obtained ketal 209, was treated with Cs2CO3 and irradiated in a microwave in an attempt 
to achieve SNAr cyclisation. DMA was found to be give a cleaner reaction than DMF with less by-
products, successfully giving the cyclised ketal 212, albeit with a low yield of 35 % (Scheme 4.47). 1-
Phenyl-triazole 207 obtained from ketone 203 was not observed, suggesting that ketal protection 
indeed hinders the unwanted decarbonylation reaction. It is worth noting that X-ray crystallography 
was used to confirm the regiochemistry of the cyclised ketal as exclusively 212 instead of the 
alternative 212’ (Scheme 4.47, Figure 4.4 below). This was supported by the obtained regioisomer of 
1-phenyl-triazole 207 (Scheme 4.44), with two singlet chemical shifts observed for the triazole ring 
by 1H NMR, instead of the one singlet peak expected from the symmetric regioisomer 207’. Full 
crystallography data for the ketal 212 can be found in the appendix. 
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Figure 4.4: The crystal structure of ketal-protected triazoleindolone 212 
Following the successful formation of the ketal protected triazoleindolone 212, ketal 
deprotection would then complete the synthesis of the triazoleindolone heterocycle 206. 
Unfortunately, problems with ring opening reactions were encountered when ketal deprotection was 
attempted (Scheme 4.48). Table 4.3 summarises the ketal deprotection reaction conditions utilised 
with the resulting observations.  
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Scheme 4.48: Attempted deprotection of ketal 212 
Table 4.3: The employed ketal deprotection reaction conditions 
Entry Solvent Catalyst/reagent Temp ᴼC Time (hrs) Result 
1 H2O/Acetone TsOH rt 15 No reaction 
2 H2O/Acetone TsOH 70 - 90 20 No reaction 
3 THF 3M HCl rt 18 No reaction 
4 THF 3M HCl 90 5 213 
5 MsOH MsOH rt 5 214 
6 H2O/Acetone PPTS reflux 18 No reaction 
7 DCM Ph3BF4 rt 24 No reaction 
 
In the first ketal deprotection attempt, TsOH was employed with acetone/water mixture used 
as the solvent. No reaction was observed at room temperature, or at 70 – 90 ᴼC (Table 4.3, Entries 1 
and 2). When aqueous 3M HCl was used as the acid catalyst, no reaction was observed at room 
temperature (Table 4.3, Entry 3), but at 90 ᴼC, full reaction occurred to give C-N ring hydrolysis, 
resulting in the open ring phenolic species 213 with the ketal group still intact (Table 4.3, Entry 4).  
Likewise, the use of MsOH led to ring hydrolysis, this time giving mesylate 214 at room temperature 
(Table 4.3, Entry 5).  
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Scheme 4.49: Ring hydrolysis of heterocycle 212 under acidic conditions  
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It was highly likely that the ring opening reactions were a direct result of triazole ring 
protonation, catalysing indolone ring hydrolysis in preference to ketal hydrolysis when heated with 
HCl or at room temperature with the strong acid, MsOH (Scheme 4.49). Given the acid sensitivity of 
the heterocycle, mild, non-protic deprotection conditions were employed, involving the use of 
PPTS190, 191 and Ph3BF4192 (Table 4.3, Entries 6 and 7) which unfortunately proved unsuccessful. 
Though we came close to obtaining the triazoleindolone heterocycle 206, deprotection of ketal 212 
was ultimately not achieved.  
Proceeding via the alcohol derivative of phenyl-triazole ketone 203 was considered, but the 
problems encountered with the protection of the imidazoleindolone alcohol derivative 182 (Scheme 
4.29) discouraged this approach. We investigated an alternative route involving the fully reduced 
ketone derivative, 215a (Scheme 4.50) and the chloride substituted equivalent, 215b (Scheme 4.51), 
which would then be re-oxidised back to the ketone, following SNAr ring cyclisation. Initial 
preparation of benzyl-triazole 215a from lithiated trityltriazole 204 and benzyl bromide resulted in 
complete decomposition (Scheme 4.50). Since ketone 203 could be prepared in facile steps, we 
focused on obtaining the fluorobenzyl-triazole 215b by the reduction of ketone 203, using Wolf 
Kishner reduction conditions (Scheme 4.51).193, 194  
1a. nBuLi,
THF, -78oC
N
N
N Tr
F
N
N
N
H
1b. BnBr
204 2. HCl, dioxane 215a  
Scheme 4.50: An attempt to prepare fluorobenzyl-triazole 215a from BnBr 
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Scheme 4.51: Wolf-Kishner reduction attempt of ketone 203  
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Wolf Kishner reduction is known to proceed via the formation of a hydrazone intermediate 
and subsequent hydrazone deprotonation to displace nitrogen gas and give the corresponding alkyl 
group.193, 194 To obtain the fully reduced compound 215b, a mixture of ketone 203 and excess KOH in 
hydrazine was irradiated in a microwave at 180 ᴼC for 30 minutes. Surprisingly, the precipitate 
isolated from the reaction mixture was shown to be the cyclised hydrazone 216 in 48 % yield, with 
only minor traces of the expected fluorobenzyl-triazole 215b observed from an LCMS of the reaction 
mixture (Scheme 4.51). Prolonged heating for up to one hour only served to decompose the 
hydrazone product, reducing its yield to 10 %, while conventional heating resulted in the slower 
formation of hydrazone 216 with more side products. Hydrolysis of hydrazone 216 would give the 
corresponding ketone and therefore the triazoleindolone heterocycle 206. However, given the 
problems encountered with hydrolysis attempts of the more labile ketal 212, hydrolysis of hydrazone 
216 was not expected to occur with ease. 
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N
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Scheme 4.52: Hydrazone hydrolysis attempt to give ketone 206195 
The commonly used acid hydrolysis of hydrazones196 was not considered an option for 
hydrazone 216, given the demonstrated acid sensitivity of the heterocycle. The use of non-acidic 
conditions was considered essential. The oxidation of hydrazones to diazomethanes is well 
documented.197, 198 Ozonation of diazomethanes is then reported to result in ketone equivalents, 
with the overall reaction being the hydrolysis of a hydrazone in two steps (Scheme 4.52).164, 199 
Following the reported conditions,195 a solution of hydrazone 216 and N-methylmorpholine in DMF 
was treated with Pb(OAc)4 at -60 ᴼC and stirred for 30 minutes. Following aqueous work up at 0 ᴼC 
and concentration in vacuo, the resulting pale yellow solid was dissolved in a DCM/methanol mixture 
and bubbled with ozone for 30 minutes to give a colourless precipitate. As indolone heterocycles are 
characterised with bright colours, the colourless precipitate immediately indicated that the desired 
ketone 206 was not obtained. This precipitate was found to be highly insoluble, failing to dissolve in 
solvents ranging from DMF, DMSO, water, DCM, methanol and acetone, and hence could not be 
characterised. The high insolubility suggested a possible by-product or complex of the lead catalyst 
used. 
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Scheme 4.53: Wolf-Kishner reduction of trityl-protected ketone 205  
Hydrolysis of hydrazone 216 was ultimately not achieved. To block the formation of the 
cyclised hydrazone 216, Wolf Kishner reduction was attempted with the N-trityl protected ketone 
205 (Scheme 4.53). Though the presence of the desired product 218 was confirmed by LCMS and 
crude 1H NMR, the reaction contained a mixture of closely eluting components, making purification 
difficult and product 218 was not isolated (Scheme 4.53).  
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Scheme 4.54: Preparation of unsubstituted fluorobenzyl-triazole 215a 
Wolf Kishner reduction was subsequently attempted with the unsubstituted ketone 208 
(Scheme 4.54). In the absence of the electron withdrawing chloride substituent to drive SNAr 
cyclisation of a hydrazone intermediate, the fully reduced, unprotected fluorobenzyl-triazole 215a 
was isolated as the only product in 55 % yield, with minor traces of the cyclised hydrazone 219 
observed from an LCMS of the reaction mixture (Scheme 4.54). The absence of an electron 
withdrawing group led to successful Wolf Kishner reduction, but it also hindered SNAr cyclisation in 
the next step and the reduced derivative of the triazoleindolone heterocycle 220 was not achieved 
(Scheme 4.54). As a result of the apparent importance of an electron withdrawing substituent to 
activate the phenyl ring to nucleophilic attack and SNAr cyclisation, we progressed to introduce the 
sulfonamide substituent of the target triazoleindolone heterocycle, using the 5-sulfonamide methyl 
benzoate ester 187a in a nucleophilic substitution reaction with deprotonated trityl-triazole 204.   
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Scheme 4.55: An attempt to prepare the sulfonamide substituted phenyl-triazole ketone 221 
The initial attempt to prepare the sulfonamide substituted phenyl-triazole ketone 221 
involved treatment of trityl-triazole 204 with nBuLi in THF at -78 ᴼC, prior to the addition of 5-
sulfonamide-methylbenzoate 187a. Using trityl-imidazole 190, this reaction gave a mixture 
containing the desired ketone 191 and a side product resulting from further reaction of product 191 
with the methoxide leaving group of the ester reagent to give the methoxide substituted species 192 
(Scheme 4.35). In the analogous reaction with trityl-triazole 204, only the fluoride-displaced by-
product 222 was isolated from the reaction mixture in 60 % yield (Scheme 4.55). Given the problems 
encountered with this SNAr route to the triazoleindolone heterocycle, alternative robust reaction 
pathways were investigated.  
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IV.4. Alternative Routes to the Imidazoleindolone and Triazoleindolone Targets 
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Scheme 4.56: The explored isatin sulfonamide and SNAr cyclisation routes, and two alternative routes to the 
triazoleindolone and imidazoleindolone heterocycles 
Scheme 4.56 summarises the retrosynthetic analysis for preparation of the triazoleindolone 
and imidazoleindolone scaffolds, via the explored isatin sulfonamide (section IV.2) and the SNAr 
cyclisation routes (section IV.3), in addition to two proposed alternative reaction pathways. The isatin 
sulfonamide route 1 was hampered by difficulties with forming the required reactive intermediates 
(section IV.2). For the imidazoleindolone synthesis, the SNAr cyclisation route 2 was limited by the 
problematic nucleophilic substitution of trityl-imidazole 190 with sulfonamide substituted acylating 
agents, though the target imidazoleindolone 60 was successfully synthesised using this route. For the 
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triazoleindolone synthesis, the SNAr cyclisation route 2 was fraught with the formation of undesired 
products, with only the precursors, ketal 212 and hydrazone 216, successfully prepared. 
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Scheme 4.57: Friedel-Crafts acylation reaction mechanism200 
An alternative route to the indolone ring formation involves disconnection of the phenyl-
carbonyl bond of the indolone heterocycle, where the synthetic equivalent is a 1-phenyl-2/5-acyl-
azole 223, and the forward reaction would involve an intramolecular Friedel-Crafts acylation reaction 
(Scheme 4.56, Route 3).200 This route came with the worry that the oxonium ion species 228 (Scheme 
4.57) may undergo decarbonylation to displace CO faster than Friedel –Crafts acylation. There were 
also concerns that the Lewis acid catalyst required for Friedel-Crafts acylation may coordinate to the 
azole nitrogen atoms, hindering reaction. The acidic conditions, with HCl as a by-product of the 
reaction, may also lead to the indolone product ring hydrolysis. Nevertheless, this route was briefly 
explored as described below, in order to assess its viability for use in imidazoleindolone and 
triazoleindolone synthesis.  
Fewer problems were anticipated with a second alternative route which involves 
disconnection of the carbonyl-azole bond of the indolone ring (Scheme 4.56, Route 4). The deduced 
forward reaction for this disconnection is an intramolecular nucleophilic addition of an azole ring to 
a benzonitrile 226. This would give an iminium ion which would hydrolyse upon aqueous workup to 
give the corresponding ketone 147. 
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IV.4.1. Investigating the Friedel-Crafts Route 
IV.4.1.1. Imidazoleindolone Synthesis 
In the first step in the sequence, 1-phenylimidazole 229 was initially prepared from the 
coupling of iodobenzene and imidazole in the presence of a Cu(II) catalyst and Cs2CO3 (Scheme 4.58). 
This condition gave 1-phenylimidazole 229 with a maximum yield of 30 %.201 Huang et al. reported 
the superiority of Cu(I) to Cu(II) in catalysing N-arylation reactions, with KOH giving much higher yields 
than carbonate bases.202 Repeating the reaction using these conditions, copper(I) oxide and KOH in 
DMSO, gave product 229 in a much higher yield of 80 % (Scheme 4.58).                                               
I
N NH
N
N
a. Cu(OAc)2.H2O, DMF
Cs2CO3, 110
oC, 30% yield
b. Cu2O, DMSO, KOH,
110oC, 80% yield225
229
155  
Scheme 4.58: Preparation of 1-Phenyl-1H-imidazole 229201, 202 
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Scheme 4.59: Acylation of 1-phenyl-imidazole 229 
Subsequently, 1-phenylimidazole 229 was lithiated and treated with methyl chloroformate in 
order to achieve the ester 230 (Scheme 4.59). As well as the desired ester 230, which was obtained 
in only 13 % yield, a dimeric ketone species 231, resulting from further reaction of the ester product 
was obtained as the major product in 25 % yield. However, adding a solution of deprotonated 229 to 
the chloroformate solution (instead of the other way round) gave the desired ester 230 in a 
significantly improved yield of 60 % (Scheme 4.59). 
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Scheme 4.60: Sulfonation of 1-phenyl-imidazole 230  
To introduce the sulfonyl chloride group, ester 230 was initially treated with chlorosulfonic 
acid and stirred overnight at room temperate, but no reaction was observed. When stirred at 70 ᴼC 
for 3 hrs, the starting material fully reacted to give a crude mixture of two isomers that could not be 
separated. 1H NMR analysis of the crude product indicated a mixture of the meta and para sulfonyl 
substituted regioisomers 232 and 232’, with the unwanted meta-isomer being the major product 
(Scheme 4.60). Formation of the meta isomer 232’ was attributed to protonation of the imidazole 
ring under the strongly acidic conditions, directing addition of the chlorosulfonyl group to the meta 
position.  As well as giving a mixture of isomers, the reaction underwent decomposition and only 15 
% of a crude product mixture was obtained. Further reactions to optimise the efficiency of the 
sulfonation reaction were not carried out as we aimed to first investigate the feasibility of the key 
Friedel-Crafts cyclisation step before future reaction optimisations. We therefore proceeded with the 
unsubstituted 1-phenyl-imidazole ester 230. However, it is worth noting that, a solution to the poor 
yield and preferential formation of the meta regioisomer would be to introduce the sulfonyl group 
earlier in the reaction sequence, as illustrated Scheme 4.61 below. It has been reported that N-
arylation of imidazole is successful using bromobenzenesulfonamide or bromobenzenesulfonic acid 
based reagents.203-205  
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Scheme 4.61: Proposed introduction of the sulfonyl group in the early stages of the Friedel-Crafts synthetic 
route  
N
N
OMe
O
Dioxane, rt
1. 2N NaOH
2. LiOH
N
N
ONa/Li
O
230 239  
Scheme 4.62: Base catalysed hydrolysis of ester 230 
Proceeding with ester 230, it was treated with 2N NaOH in 1,4-dioxane (Scheme 4.62) to give 
the carboxylate 239 which was confirmed by crude 1H NMR and mass spectrometry analysis. 
However, after aqueous work-up, less than 10 % of the mass before work up was recovered, with the 
rest presumed to remain in the aqueous solution. Subsequently, ester hydrolysis was repeated using 
LiOH which is monobasic and therefore could be used in one equivalent, without the need to remove 
excess LiOH with an aqueous work-up. The resulting lithium carboxylate salt was used in the next 
step without work-up or purification, aiming to convert lithium carboxylate 239 into acid chloride 
240, the intermediate required for the Friedel-Crafts cyclisation step (Scheme 4.63).  
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Scheme 4.63: An attempt to prepare acid chloride 240 from carboxylate salt 239 
Heating carboxylate 239 in SOCl2 or with excess oxalyly chloride in THF led to complete 
decomposition (Scheme 4.63). As facile formation of the acid chloride 240 was not be achieved, 
investigation of imidazoleindolone synthesis via the Friedel-Crafts route was halted.  
IV.4.1.2. Triazoleindolone Synthesis 
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Scheme 4.64: Preparation of 1-phenyl-triazole 241 by transamination206 
Unlike the formation of 1-phenylimidazole 230, copper-catalysed N-arylation of 1,2,4-triazole 
was unsuccessful. Naik et al. reported the preparation of N-aryl 1,2,4-triazoles from transamination 
of primary amines with dimethylformamide azine dichloride 243 (Scheme 4.64).206 Following the 
reported conditions,206  azine dichloride 243 was successfully prepared in 80 % yield by stirring a 
mixture of excess DMF with thionyl chloride to give the reactive intermediate, 
(chloromethylene)dimethylammoniun chloride 242. This was treated with hydrazine to give the azine 
salt 243 (Scheme 4.64).206 A suspension of the azine 243 and aniline was then heated to reflux, giving 
1-phenyltriazole 241 in 75 % yield (Scheme 4.64).   
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Scheme 4.65: Acylation of 1-phenyl-triazole 241 with methyl chloroformate, leading to a mixture of 2 
products 
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Scheme 4.66: Proposed mechanism for the formation of methyl cyano(phenyl)carbamate 246 
Subsequently, 1-phenyltriazole 241 was treated with nBuLi at -78 ᴼC, followed by the addition 
of methyl chloroformate. Surprisingly this gave the desired ester 245 as the minor product in 25 % 
yield and the cyano phenylcarbamate species 246 as the major product 54 % yield, a ratio of 
approximately 1:2 (Scheme 4.65). We attributed this formation of cyano phenyl carbamate 246 to 
cleavage of the triazole N-N bond following deprotonation by nBuLi, leading to the displacement of 
hydrogen to give a highly stabilised anion 248, which then reacted with methyl chloroformate to give 
cyano phenyl carbamate 246 (Scheme 4.66). In the initial reaction, a solution of 1-phenyltriazole 241 
in THF at -78 ᴼC was stirred for 15 minutes after the addition of nBuLi and prior to quenching with 
methyl chloroformate. In a separate reaction, in an attempt to limit the displacement of hydrogen 
cyanide and trap the triazole anion, methyl chloroformate was added within 2.5 minutes of adding 
nBuLi to a solution of 1-phenyltriazole 241. This made no difference to the proportion of products 
obtained. Presumably, the displacement of hydrogen cyanide to give the stabilised N-
phenylcyanamide anion 248 occurs almost instantly. A sufficient amount of the desired ester 245 was 
obtained and used in the next step, towards assessment of the Friedel-Crafts route.   
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Scheme 4.67: Treatment of ester 245 with chlorosulfonic acid 
In an attempt to introduce the para-sulfonyl substituent, ester 245 was treated with 
chlorosulfonic acid (Scheme 4.67). 1-Phenyltriazole 245 reacted more slowly with chlorosulfonic acid, 
requiring overnight heating at 70 ᴼC for complete consumption of the starting material 245, 
compared to the full reaction of 1-phenyl-imidazole 230 within 3 hrs at 70 ᴼC. A TLC and crude 1H 
NMR suggested complete decomposition of the ester 245 and no product was isolated or clearly 
identified from the reaction mixture.  
At this stage in the triazoleindolone synthetic sequence towards Friedel-Crafts cyclisation, 
difficulties encountered with the formation of the imidazole acyl chloride species 240, combined with 
the poor yield of 1-phenyltriazole-2-carboxylate 245 formation, discouraged further work on this 
route. However, there is scope for future work on this route, optimising/employing different reaction 
conditions to potentially achieve efficient reactions.  
IV.4.2. Investigating the ‘Addition to Benzonitrile’ Route  
CN
F
N NH
Cs2CO3, DMF
100oC
CN
N N
LDA
THF, -78oC N
N
O
227 226 52
(74%)
155
 
Scheme 4.68: Imidazoleindolone 52 formation via intramolecular imidazole addition to benzonitrile 226 
As discussed above, azole addition to benzonitrile was proposed as an alternative ring closure 
method to give the indolone ring system. Preliminary experiments to give an overview of the viability 
of this route was conducted with imidazole only. In the first step, 2-imidazolebenzonitrile 226 was 
prepared from the base catalysed SNAr reaction of imidazole with 2-fluorobenzonitrile 227 in 74 % 
yield (Scheme 4.68). 2-Imidazolebenzonitrile 226 was subsequently treated with LDA, with the aim 
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of achieving an intramolecular nucleophilic addition of the imidazole C-2 carbon to the nitrile group. 
Following work-up and column chromatography, the isolated material appeared to be a crude 
residue containing the desired imidazoleindolone 52. LCMS further confirmed the presence of 
imidazoleindolone 52, though separation from the unknown co-eluting side product was not 
achieved by flash column chromatography. Nevertheless, the observed result was encouraging, 
showing that intramolecular imidazole addition to benzonitrile 226 can be achieved. Future 
optimisation reactions would explore conditions that would reduce the formation of the co-eluting 
side-product, in addition to exploring alternative purification methods such as re-crystallisation. The 
use of 5-sulfonamide substituted benzonitrile as the starting material may also result in a more 
efficient reaction. The promising results from the initial reactions makes this route top priority for 
future work on the imidazoleindolone and triazoleindolone synthesis. 
IV.5. Conclusion  
N
N
O
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N
N
O
58, 157
X
N
N
O
Br
N
N
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N
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O
F
F
N
N
N
N
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O
O
Cl Cl
212
Successfully prepared imidazleindolone heterocycles
Successfully prepared precursors of the triazoledinolone heterocycle  
Figure 4.5: Products successfully prepared from the explored triazoleindolone and imidazoleindolone 
synthetic strategies 
Four different routes were explored for the synthesis of the imidazoleindolone and 
triazoleindolone heterocycles, including the use of isatin sulfonamide intermediates, an 
intramolecular SNAr cyclisation route, Friedel-Crafts cyclisation method and cyclisation by 
nucleophilic addition to benzonitrile. The use of isatin sulfonamide intermediates was impeded by 
problems associated with unpredictable reactions of the isatin carbonyl centre. Using the SNAr 
cyclisation route, where the phenyl-azole bond is formed from the intramolecular nucleophilic 
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displacement of an aryl fluoride, the substituted and unsubstituted imidazoleindolone heterocycles 
were successfully achieved (Figure 4.5). Preparation of the target sulfonamide substituted 
imidazoleindolone 60 was tempered by a problematic step, involving the nucleophilic substitution of 
sulfonamide substituted acylating agents with C-2 deprotonated trityl-imidazole. Using the SNAr 
route, only the triazoleindolone precursors, hydrazone 216 and ketal 212 were achieved. The Friedel-
Crafts cyclisation route was briefly explored and halted when problems were encountered with the 
preparation the acid chloride intermediate required for the key cyclisation step. Indolone ring 
formation by the intramolecular addition of the azole ring to benzonitrile was also briefly 
investigated, and initial results were encouraging, showing the successful formation of the core 
imidazoleindolone heterocycle 52, albeit in low purity. 
In general, 1,2,4-triazole species appeared to be less reactive than their imidazole 
equivalents, requiring harsher conditions to force reactions or failing altogether. This was attributed 
to the higher nucleophilicity of imidazole compared with 1,2,4-triazole. The difference in 
nucleophilicity was manifested in conditions used for SNAr cyclisation reactions by nucleophilic attack 
of the azole nitrogen on the phenyl-fluoride bond. Microwave irradiation or prolonged heating was 
required for triazole derivatives, compared to the conventional heating of imidazole derivatives for 
significantly less time and at lower temperatures. Both heterocycles showed sensitivity to acidic 
conditions, which was attributed to their basic properties, leading to the azole ring protonation which 
either hindered reactions or catalysed the opening of the indolone scaffolds.  
Based on the positive computational modelling results (Chapter II), it would be worth 
dedicating future efforts to further studies aimed at optimising reaction conditions to successfully 
achieve the triazoleindolone heterocycle. Studies aimed at understanding the mechanism of 
decarbonylation leading to the formation of the 1-phenyltriazole species 207 may shed some light on 
the triazoleindolone ring stability. The two alternative synthetic routes briefly explored (Routes 3 and 
4, Scheme 4.56) could be expanded to evaluate their robustness and efficacy in the synthesis of the 
triazoleindolone and imidazoleindolone heterocycles. Optimisation of the imidazoleindolone 
heterocycle synthesis would be necessary for future work, involving the preparation of a library of 
derivatives for SAR studies. 
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GENERAL SUMMARY & PERSPECTIVE 
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Figure 5.1: Reported isatin sulfonamide and the prepared pyrimidoindolone radiotracer 
Imaging attempts using 18F-labelled isatin sulfonamide 22 (Figure 5.1) have shown elevated 
background uptake of the radiotracer, attributed to non-specific in vivo binding interactions.57 The 
research described is part of an ongoing effort to develop caspase-3 binding radioligands with 
optimal properties for the PET imaging of apoptosis. Three series of heterocycles were proposed as 
possible alternatives to the isatin sulfonamides, for the selective inhibition of caspase-3, the 
biomarker of apoptosis for PET imaging. The series based on the pyrimidoindolone 42, 
triazoleindolone 53 and imidazoleindolone 52 (Figure 5.1) heterocycles are structurally similar to the 
isatin heterocycle, with all containing the crucial ketone responsible for caspase inhibition via the 
formation of a thiohemiketal in the enzyme active site. The presence of an azole ring in the 
imidazoleindolone and triazoleindolone heterocycles, and the amidine group of the 
pyrimidoindolone system, instead of the dicarbonyl function of the isatin ring was expected to modify 
the reactivity the ketone. It was hoped that this would lead to specific binding interactions with 
caspase-3, reducing non-specific interactions with cytosolic nucleophilic moieties liable for the low 
target-to-background ratio of isatin PET images.  
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Figure 5.2: Imidazoleindolone and triazoleindolone heterocycles – target and successfully prepared 
structures 
While the imidazoleindolone and triazoleindolone heterocycles were structurally novel, 
unexplored systems, pyrimidoindolones were previously reported by Havran et al. as potent caspase-
3 inhibitors.58 Aiming to investigate radiotracer properties of the pyrimidoindolone heterocycle, an 
initial target structure [18F]62 (Figure 5.1) was designed, synthesised and radiolabelled. The designed 
target [18F]62 was modelled on the structure of the lead isatin sulfonamide [18F]22 to allow direct 
comparison. Initial biological results, including IC50 measurement, cell uptake studies, in vivo 
biodistribution and metabolic profiles, showed that the pyrimidoindolone has a similar biological 
profile as the isatin sulfonamide though further characterisation and whole body imaging in mice is 
still required.  
We employed computational studies to model the favourability of thiohemiketal formation 
of the unexplored imidazoleindolone and triazoleindolone structures, in comparison to the 
pyrimidoindolone and isatin sulfonamide systems. Values obtained included free energies of 
reactions, equilibrium constants and intramolecular hydrogen bonding distances.  Computational 
results suggested that, like the isatin ring, the pyrimidoindolone, imidazoleindolone and 
triazoleindolone heterocycles would favourably incorporate a thiol group to give the corresponding 
thiohemiketal products. The order of thiohemiketal favourability according to the obtained Gibbs 
free energy was shown to be isatin > triazoleindolone > pyrimidoindolone > imidazoleindolone. As 
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the research was aimed at developing potent caspase inhibitors with increased specific binding 
interactions, possibly through the modulation of ketone reactivity, the computational results were 
considered encouraging, despite the alternative heterocycles showing lower favourabilities than the 
isatin system.  
Following the encouraging computational modelling results, initial imidazoleindolone and 
triazoleindolone heterocycles were designed for synthesis and experimental characterisation. The 
target structures 60 and 104 (Figure 5.2) incorporated the same sulfonamide substituent as the lead 
isatin 22, shown to be highly favourable by reported isatin SAR studies. Four different synthetic 
strategies were investigated for the syntheses of the imidazoleindolone and triazoleindolone 
heterocycles including, the use of isatin sulfonamide intermediates, an intramolecular SNAr 
cyclisation route, Friedel-Crafts cyclisation method and cyclisation by nucleophilic addition to a 
benzonitrile. The preparation of the unsubstituted, halogen-substituted and sulfonamide-substituted 
imidazoleindolone heterocycles (Figure 5.2) were achieved using SNAr cyclisation route.  
Although the imidazoleindolone and triazoleindolone differ by only one nitrogen atom, their 
different properties and reactivities were highlighted during the synthetic studies. Preparation of the 
triazoleindolone heterocycle proved challenging with only the core heterocyclic precursors, 
hydrazone 216 and ketal 212 (Figure 5.2) currently achieved, using the SNAr cyclisation route. 
Hydrolysis of the hydrazone and ketal groups would give the core triazoleindolone heterocycle. 
However, sensitivity of the ring system led to side reactions that destroyed the heterocycle.  
Both the imidazoleindolone and triazoleindolone heterocycles demonstrated sensitivity to 
acidic conditions, attributed to protonation of the basic azole rings, which led to indolone ring 
hydrolysis or the inhibition of reactions at the ketone or ketal-protected centre. The apparent acid 
sensitivity raised concerns for the in vivo aqueous stability of the heterocycles, as well as their 
potential selectivity in interactions with nucleophilic moieties in the cytosol, a problem believed to 
be responsible for the sub-optimal imaging properties of isatin sulfonamides. However, the acid 
sensitivity of the heterocycle was only manifested when heated under acidic conditions or when a 
very strong acid such as MsOH was used. Tumour cells are typically more acidic than normal cells, 
but with a median pH value of approximately 7.0 compared to 7.5 in normal tissues, excluding the 
more acidic stomach pH.207 Given the pH range of body tissues, the acid sensitivity of the heterocycles 
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is not expected to impede potential in vivo applications of radiotracers based on the 
imidazoleindolone and triazoleindolone structures.  
Future work would involve continued optimisation reactions designed to successfully give the 
triazoleindolone ring system, as well as improving the efficiency of the imidazoleindolone formation, 
prior to biological characterisation in cell based models. Further biological characterisation, including 
whole body PET imaging in mice would be carried out with the pyrimidoindolone radiotracer [18F]62 
with encouraging results leading to the preparation of a library for SAR studies and radiotracer 
optimisation.  
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EXPERIMENTAL 
General Methods 
Reagents were used as commercially supplied without further purification. All reactions and 
manipulations of air or moisture sensitive materials were conducted in oven dried glassware under 
an atmosphere of dry nitrogen or argon. Reaction solvents were distilled from CaH2 
(dichloromethane, triethylamine, pyridine), Na (toluene), Na-Ph2CO (tetrahydrofuran) and Mg 
turnings-I2 (methanol). Petroleum ether refers to the fraction distilled at 40-60 oC. Manual flash 
column chromatography were carried out using neutral silica gel. Thin Layer Chromatography (TLC) 
were developed on pre-coated aluminium backed plates and visualised under UV light (254 nm lamp) 
or by staining with potassium permanganate, vanillin or phosphomolybdic acid stains as appropriate. 
1H NMR spectra were recorded using a 400 MHz Bruker DRX-400 spectrometer. 13C NMR 
spectra were recorded using a 101 MHz or 126 MHz Bruker DRX-400 spectrometer. All spectra were 
recorded under the supervision of the Imperial College London Department of Chemistry NMR 
Service. Chemical shifts () are quoted in parts per million (ppm) and are referenced to the residual 
solvent peaks, CDCl3 (H: 7.26, C: 77.0) and DMSO-d6 (H: 2.50, C: 39.4). Coupling constants (J) are 
quoted to the nearest 0.5 Hz. Low and high resolution mass spectrometry were recorded by the 
Imperial College London Department of Chemistry Mass Spectrometry Service, using a Micromass 
Platform II or a Micromass AutoSpec-Q spectrometer.  
UV-vis spectra were recorded with a Perkin Elmer Lambda 25 spectrometer, using 3.5 mL 
stoppered ES Quartz cuvettes and, IR spectra were measured on a Perkin Elmer Spectrum Express, 
version 1.01.00. Microwave reactions were conducted in a CEM Discover S Class microwave in 
Dynamic mode setting with a fixed hold time and IR temperature probe. All microwave reactions 
were conducted in DMF or DMA at 180 oC with a default pressure of 1 – 5 bar.  
For computational calculations, geometry optimisations were performed using the wB97xD 
and M062X functionals, and the 6-31G (2d,2p) basis set. Frequency calculations were performed to 
identify energy minima (no imaginary frequencies) and transition states (one imaginary frequency). 
Thermal corrections for Gibbs free energy were calculated at 298K. For conversions of Gaussian 
computational data output in Hartree to kJ/mol, a factor of 2625.5 was used.  
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Purity analysis for compounds used in radiochemistry was evaluated by analytical and 
preparatory HPLC. [18F]Fluoride was produced by a cyclotron (GE PETrace), utilising the [18O(p,n)18F] 
nuclear reaction with 16.4 MeV proton irradiation of an enriched [(18O)H2O] target.  
HPLC Methods 
Analytical and preparatory HPLC methods of non-radioactive compounds were developed on 
an Agilent 1100 series system with Laura 3 software and linear UV detector recording absorption at 
254 nm. Preparatory and analytical radio-HPLC were carried out on a Beckman System Gold machine 
fitted with a Bioscan Flowcount FC-3400 PIN diode detector (Lablogic) and a linear UV-200 detector 
recording at 254 nm. 
For analytical HPLC, a Phenomenex 4.6 x 50 mm C18 (2) column was used in 15 min running 
time and 1ml/min flow rate. For preparatory HPLC, a Phenomenex 10 x 250 mm C18 (2) column was 
used in 30 min running time and 3ml/min flow rate. Isocratic elution methods were used which 
composed of a mobile phase of ethanol and 0.1 M ammonium formate. 60 % and 35 % or 45 % of 
ethanol was used for analytical and preparatory isocratic elution respectively.  
9H-Imidazo[1,2-a]indol-9-one 52 
N
N
O
 
A mixture of the trityl-deprotected 2-fluorophenyl-imidazomethanone 196 (0.54 g, 2.85 mmol) and 
K2CO3 (1.18 g, 8.55 mmol) in DMF (60 mL) was stirred at 145 ᴼC for 10 hours. The reaction mixture 
was allowed to cool to room temperature before diluting with ethyl acetate (50 mL), and washing 
with water (50 mL) and brine (3 x 150 mL). The organic layer was dried over MgSO4 and concentrated 
in vacuo. Purification by flash column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ 
petroleum ether gave the imidazoleindolone heterocycle 52 as an orange solid (0.34 g, 69 % yield): 
1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.8 Hz, 1H), 7.30 (m, 2 H), 7.44 (br m, 1H), 7.56 (td, J = 1.0 Hz, 
7.8 Hz, 1H), 7.68 (d, J = 6.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 111.5, 115.0, 125.4, 127.3, 128.4, 
135.5, 137.5, 141.5, 146.1, 177.7; max/cm-1 1719 (C=O), 1618, 1504, 1469, 1346; HRMS (ES) m/z = 
171.0550 [M+H]+ found, C10H7N2O needs 171.0553. 
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Reverse phase prep HPLC chromatogram of the imidazoleindolone 52, eluting with a mobile phase of 35 % 
ethanol  
2'H-Spiro[cyclopentane-1,3'-pyrimido[1,2-a]indol]-10'(4'H)-one 57 
N
N
O
 
The ketal-protected pyrimidoindolone 94 (0.025 g, 0.08 mmol) was treated with methanesulfonic 
acid (0.3 mL) and the resulting yellow solution was stirred at room temperature for 2 hours. The 
mixture was then treated with saturated aqueous Na2CO3 solution until a pH of ~9 was reached. The 
aqueous solution was extracted with DCM (4 x 10 mL) with the combined organic extracts dried over 
MgSO4 and concentrated in vacuo. The crude material was purified by flash column chromatography, 
eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to give the pyrimidoindolone heterocycle 57 as 
a yellow foam (0.017 g, 89 % yield); 1H NMR (400 MHz, CDCl3) δ 1.55 (m, 2H), 1.77 (m, 6H), 3.38 (s, 
2H), 3.67 (s, 2H), 6.78 (d, J = 8.3 Hz, 1H), 7.00 (br td, J = 8.0 Hz, 1H), 7.55 (m, 1H), 7.67 (m, 1H); 13C 
NMR (101 MHz, CDCl3) δ 25.1, 36.2, 39.9, 49.8, 57.4, 107.8, 119.4, 121.1, 125.2, 137.7, 148.5, 152.3, 
184.4; max/cm-1 1714 (C=O), 1653, 1606 (C=N), 1473, 1370, 1122; HRMS (ES) m/z = 241.1341 [M+H]+ 
found, C15H17N2O needs 241.1341; Rf = 0.29 (1:1 ethyl acetate/petroleum ether).  
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Reverse phase prep HPLC chromatogram of the pyrimidoindolone 57, eluting with a mobile phase of 35 % 
ethanol  
7-Bromo-9H-imidazo[1,2-a]indol-9-one 58 
N
N
O
Br
 
A solution of 5-bromo-2-fluorophenyl-imidazomethanone 180 (0.50 g, 1.86 mmol) and Cs2CO3 (1.81 
g, 5.57 mmol) in DMF (30 mL) was stirred at 140 ᴼC for 1.5 hours. After cooling to room temperature, 
the mixture was diluted with ethyl acetate (50 mL) and washed with water (2 x 20 mL) and brine (3 x 
100 mL). The organic layer was dried over MgSO4 and concentrated in vacuo, prior to purification by 
flash column chromatography, eluting with 1:1 ethyl acetate/ petroleum ether to give the 
imidazoleindolone 58 as a yellow solid (0.29 g, 63 % yield): 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 
7.8 Hz, 1H), 7.26 (m, 1H), 7.45 (m, 1H), 7.68 (dd, J = 2.0 Hz, 7.8 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 113.0, 115.3, 120.3, 128.6, 129.8, 137.8, 137.9, 140.1, 145.8, 176.1; max/cm-
1 1699 (C=O), 1612 (C=N), 1476, 1390, 1262; HRMS (ES) m/z = 248.9651 [M+H]+ found, C10H6BrN2O 
needs 248.9658.  
 
Reverse phase prep HPLC chromatogram of the bromo-substituted imidazoleindolone 58, eluting with a 
mobile phase of 35 % ethanol 
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2/3-Bromo-9H-imidazo[1,2-a]indol-9-one 59 
N
N
O
Br  
To a solution of imidazoleindolone 52 (0.05 g, 0.39 mmol) in chloroform (1.5 mL), was added NBS 
(0.10 g, 0.58 mmol) and the mixture was stirred at room temperature for 15 hours. DCM (10 mL) was 
subsequently added, prior to washing with water (5 mL) and brine (5 mL). The organic layer was dried 
over MgSO4 and concentrated in vacuo, followed by purification by flash column chromatography, 
eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to give the bromo-substituted 
imidazoleindolone 59 as an orange solid (0.019 g, 26 % yield): 1H NMR (400 MHz, CDCl3) δ 7.17 (d, J 
= 7.8 Hz, 1H), 7.34 (m 2H), 7.60 (td, J = 1.5 Hz, 7.8 Hz, 1H), 7.70 (br d, J = 8.0 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 111.7, 114.9, 123.2, 125.7, 126.9, 127.9, 135.7, 141.1, 144.2, 176.4; max/cm-1 3120, 
1715 (C=O), 1617 (C=N), 1471, 1427, 1349; HRMS (ES) m/z = 248.9657 [M+H]+ found, C10H6BrN2O 
needs 248.9658; Rf = 0.12 (1:4 ethyl acetate/ petroleum ether). 
 
Reverse phase prep HPLC chromatogram of the bromo-substituted imidazoleindolone 59, eluting with a 
mobile phase of 35 % ethanol  
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(S)-7-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-9H-imidazo[1,2-a]indol-9-one 60 
S
N
OO
O
F
F
N
N
O
 
A mixture of 5-sulfonamide-2-fluorophenyl-imidazomethanone 201 (0.04 g, 0.09 mmol) and K2CO3 
(0.04 g, 0.27 mmol) in DMF (3 mL) was stirred at 120 ᴼC for 1 hour. Then, the reaction mixture was 
allowed to cool to room temperature, before diluting with ethyl acetate (5 mL), and washing with 
water (5 mL) and brine (3 x 10 mL). The organic layer was dried over MgSO4 and concentrated in 
vacuo. Purification by flash column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ petroleum 
ether gave the imidazoleindolone target 60 as an orange solid (0.037 g, 92 % yield): 1H NMR (400 
MHz, CDCl3) δ 1.79 (m, 2H), 2.05 (m, 2H), 3.20 (m, 1H), 3.52 (m, 1H), 4.00 (m, 2H), 4.18 (m, 1H), 6.77 
(m, 2H), 6.91 (m, 1H), 7.26 (m, 2H), 7.46 (s, 1H), 8.03 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 24.2, 29.0, 
49.5, 58.7, 71.5, 104.8 (dd, J = 21.8 Hz, 27.2 Hz), 110.4 (dd, J = 4.4 Hz, 22.9 Hz), 111.9, 115.4, 115.4 
(m), 124.2, 128.9, 135.1, 137.3, 138.6, 142.9 (dd, J = 3.3 Hz, 10.9 Hz), 143.9, 146.3, 152.3 (dd, J = 12.0 
Hz, 248.5 Hz), 156.5 (dd, J = 9.8 Hz, 242.0 Hz), 175.6; max/cm-1 1719 (C=O), 1614, 1508 (C=N), 1476, 
1337, 1146; HRMS (ES) m/z = 446.0986 [M+H]+ found, C21H18F2N3O4S needs 446.0986; Rf = 0.34 (ethyl 
acetate). 
 
Reverse phase prep HPLC chromatogram of the imidazoleindolone target 60, eluting with a mobile 
phase of 35 % ethanol 
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(S)-8'-(2-(((1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)pyrrolidin-1-ylsulfonyl)-2'H-
spiro[cyclopentane-1,3'-pyrimido[1,2-a]indol]-10'(4'H)-one, 62     
N
O
S
N
O O
O
N
N N
N
F  
Part 1: To a solution of 1-fluoroethyltosylate 75 (0.10 g, 0.46 mmol) in DMF (2 mL) was added NaN3 
(0.09 g, 1.40 mmol) and the mixture was stirred at room temperature for 15 hours. A TLC showed the 
full disappearance of the 1-fluoroethyltosylate 75 and a new polar product, indicating conversion to 
1-fluoroethylazide 37.  
Part 2: CuSO4 (0.006 g, 0.025 mmol) and L-ascorbic acid (0.009 g, 0.05 mmol) were added to a 
separate reaction flask, followed by the addition of the alkyne precursor 81 (0.022 g, 0.05 mmol) in 
DMF (1.5 mL). The mixture was stirred to give a dark brown solution. Then, fluoroethylazide 37 (0.26 
mL, 0.06 mmol of the filtered solution from part 1) was added and stirring was continued at room 
temperature for 1 hour. This was followed by quenching with 10 % aqueous NH4Cl solution (10 mL) 
and extraction with ethyl acetate (2 x 10 mL). The combined organic extracts was washed with brine 
(2 x 15 mL) and water (2 x 5 mL), dried over MgSO4 and concentrated in vacuo. Purification by flash 
column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ petroleum ether gave the 
pyrimidoindolone target 62 as a yellow foam (0.013 g, 50 % yield); 1H NMR (400 MHz, CDCl3) δ 1.55 
(m, 12H), 3.15 (m, 1H), 3.42 (m, 3H), 3.54 (m, 1H), 3.76 (m, 4H), 4.67 (m, 3H), 4.75 (m, 2H), 4.89 (m, 
1H), 6.88 (d, J = 8.5 Hz, 1H), 7.73 (s, 1H), 8.02 (dd, J = 8.5 Hz, 1.8 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 24.1, 25.1, 28.9, 36.1, 39.9, 49.3, 50.0, 50.5 (d, J = 20.7 Hz), 57.5, 59.1, 64.6, 
72.7, 81.0 (d, J = 173.3 Hz), 108.1, 119.1, 123.6, 124.7, 130.8, 137.0, 145.2, 147.9, 154.2, 183.3; 
max/cm-1 1728 (C=O), 1660, 1603 (C=N), 1484, 1461, 1334 (-SO2-N), 1276, 1151, 1127 (C-F), 1075 (C-
O-C); HRMS (ES) m/z = 531.2183 [M+H]+ found, C25H32FN6O4S needs 531.2184; [αD]20 = -50.4 (c 0.004, 
CHCl3); Rf = 0.11 (ethyl acetate).  
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Reverse phase prep HPLC chromatogram of the pyrimidoindolone target 62, eluting with a 
mobile phase of 45 % ethanol 
5-Chlorosulfonylisatin 6469 
N
H
O
O
S
Cl
OO
 
To a suspension of sodium-5-isatinsulfonate 63 (10.00 g, 35.10 mmol) in sulfolane (50 mL) was added 
POCl3 (16 mL, 176.50 mmol) and the mixture was stirred at 60 ᴼ C for 3 hours. The dark-brown solution 
was cooled to 0 ᴼC and ice-cold water (150 mL) was cautiously added. The resulting precipitate was 
filtered and washed with water (100 mL). The solid was then dissolved in ethyl acetate (100 mL) and 
further washed with water (50 mL). This was followed by drying over MgSO4 and concentration in 
vacuo to give a solid residue which was recrystallised from an ethyl acetate/hexane mixture to give 
the sulfonyl chloride 64 as an orange solid (3.72 g, 43 % yield): 1H NMR (400 MHz, DMSO) δ 6.86 (d, 
J = 7.8 Hz, 1H), 7.58 (d, J = 1.5 Hz, 1H), 7.80 (dd, J = 1.5 Hz, 7.8 Hz, 1H), 11.11 (s, 1H); 13C NMR (126 
MHz, DMSO) δ 111.5, 117.0, 121.4, 135.5, 143.2, 150.7, 159.7, 184.3; MS – a molecular ion was not 
observed. 
(S)-tert-Butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate 66208 
N
OHBoc  
To a solution of 2-pyrrolidinemethanol 65 (5 mL, 51.00 mmol) in anhydrous DCM (100 mL) was added 
Et3N (21.2 mL, 152.00 mmol), followed by the addition of Boc2O (13.30 g, 60.84 mmol). The mixture 
was stirred under argon at room temperature for 1 hour. Then, the pale yellow reaction mixture was 
washed with water (100 mL) and the organic extract was dried over MgSO4 and concentrated in 
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vacuo. The crude product was purified by flash column chromatography, eluting with 1:1 - 1:0 ethyl 
acetate/ petroleum ether to give the Boc-protected prolinol 66 as a colourless solid (9.08 g, 89 % 
yield): 1H NMR (400 MHz, CDCl3) δ 1.48 (s, 9H), 1.81 (m, 2H), 2.01 (m, 1H), 3.31 (m, 1H), 3.46 (m 1H), 
3.61 (m, 3H), 3.98 (br m, 1H), 4.77 ( br m, 1H); 13C NMR (101 MHz, CDCl3) δ 24.1, 28.5, 28.7, 47.6, 
60.2, 67.8, 80.2, 157.2; HRMS (ES) m/z = 224.1256 [M+Na]+ found, C10H19NNaO3 needs 224.1257; Rf 
= 0.31 (1:1 ethyl acetate/ petroleum ether).  
(S)-tert-Butyl 2-(benzyloxymethyl)pyrrolidine-1-carboxylate, 6758 
BnO
N
Boc  
To a solution of N-Boc-prolinol 66 (6.00 g, 30.00 mmol) and NaH (60 % in mineral oil, 2.40 g, 60.00 
mmol) in anhydrous THF (70 mL) at 0 ᴼC, was added BnBr (4.3 mL, 36.00 mmol) and the mixture was 
stirred at 0 ᴼC for 30 minutes and then at room temperature for 16 hours. This was followed by 
washing with water (100 mL), drying over MgSO4 and concentration in vacuo. The crude residue was 
purified by flash column chromatography, eluting with 1:9 ethyl acetate/ petroleum ether to give the 
benzyl ether 67 as a colourless oil (8.03 g, 92 % yield): 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 1.88 
(m, 4H), 3.40 (m, 3H), 3.63 (br m, 1H), 3.95 (br m, 1H), 4.54 (m, 2H), 7.30 (m, 5H); 13C NMR (101 MHz, 
CDCl3) δ 23.35 (d, J = 91.6 Hz), 28.5, 46.4 (br d), 56.5, 60.3, 70.9 (br d), 73.2, 79.2, 127.5, 127.5, 128.4, 
138.4, 154.6; HRMS (ES) m/z = 314.1732 [M+Na]+, C17H25NNaO3 needs 314.1732; Rf = 0.20 (1:9 ethyl 
acetate/ petroleum ether).  
(S)-2-(Benzyloxymethyl)pyrrolidine 6858 
BnO
N
H .HCl  
A solution of the Boc-protected amine 67 (7.70 g, 26.50 mmol) in 4M HCl in dioxane (65 mL) and DCM 
(50 mL) was stirred at room temperature for 12 hours. Then, the reaction mixture was concentrated 
in vacuo to give the HCl salt of the amine 68 as a colourless solid (5.85 g, 97 % yield): 1H NMR (400 
MHz, CDCl3) δ 1.96 (m, 4H), 3.30 (s, 2H), 3.77 (m, 3H), 4.63 (q, J = 35.2 Hz, 11.7 Hz, 2H), 7.35 (m, 5H), 
9.27 (s, 1H), 10.14 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 24.2, 27.2, 45.7, 58.5, 68.8, 73.4, 127.9, 128.1, 
128.4, 137.5; max/cm-1 2873 - 2657 (br -NH2+), 1575, 1497, 1390, 1088; HRMS (ES) m/z = 192.1387 
[M+H]+ found, C12H18NO needs 192.1388. 
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 (S)-5-(2-(Benzyloxymethyl)pyrrolidin-1-ylsulfonyl)indoline-2,3-dione 6958 
N
H
O
O
S
N
OO
BnO  
To a solution of 2-benzyloxymethyl pyrrolidine 68 (HCl salt, 3.79 g, 16.70 mmol) and Et3N (7.40 mL, 
53.13 mmol) in 1:1 mixture of THF and DCM (300 mL) at 0 ᴼC, was added a solution of isatin-5-sulfonyl 
chloride 64 (3.72 g, 15.18 mmol) in THF (50 mL) over 30 minutes, maintaining the temperature at 0 
ᴼC. The mixture was stirred at room temperature for 1 hour and concentrated in vacuo. Purification 
of the resulting residue by flash column chromatography, eluting with 1:1 ethyl acetate/ petroleum 
ether gave the sulfonamide 69 as an orange solid (5.05 g, 83 % yield): 1H NMR (400 MHz, DMSO) δ 
1.53 (m, 2H), 1.79 (m, 3H), 3.09 (m, 1H), 3.43 (m, 1H), 3.58 (m, 1H), 3.72 (m, 1H), 4.51 (s, 2H), 7.07 
(d, J = 8.3 Hz, 1H), 7.33 (m, 5H), 7.76 (d, J = 2.0 Hz, 1H), 8.01 (dd, J = 2.0 Hz,  8.3 Hz, 1H), 11.44 (s, 1H); 
13C NMR (101 MHz, DMSO) δ 24.1, 28.8, 49.5, 59.3, 72.7, 72.8, 113.2, 118.6, 123.6, 127.9, 127.9, 
128.7, 131.4, 137.3, 138.8, 154.1, 160.0, 183.5; max/cm-1 3240 (N-H),  1730 (C=O ketone), 1615 (C=O 
amide), 1344, 1467; HRMS (ES) m/z = 401.1165 [M+H]+ found, C20H21N2O5S needs 401.1166; Rf = 0.15 
(1:1 ethyl acetate/ petroleum ether). 
(S)-5'-(2-(Benzyloxymethyl)pyrrolidin-1-ylsulfonyl)spiro[[1,3]dioxane-2,3'-indolin]-2'-one 7058 
N
H
O
S
N
OO
BnO
O
O
 
To a solution of isatin sulfonamide 69 (2.42 g, 6.00 mmol) and 1,3-propanediol (4.3 mL, 60.00 mmol) 
in toluene (100 mL), was added toluenesulfonic acid (0.29 g, 1.50 mmol) and the mixture was refluxed 
for 12 hours, collecting water with a Dean Stark trap. The mixture was subsequently allowed to cool 
to room temperature, washed with saturated aqueous Na2CO3 solution (70 mL), water (100 mL) and 
brine (100 mL), before drying over MgSO4. After concentration in vacuo, the crude product was 
purified by flash column chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to 
give the ketal protected sulfonamide 70  as a colourless foam (2.39 g, 87 % yield): 1H NMR (400 MHz, 
CDCl3) δ 1.64 (m, 3H), 1.92 (m, 2H), 2.39 (m, 1H), 3.08 (m, 1H), 3.48 (m, 2H), 3.82 (m, 2H), 4.00 (m, 
2H), 4.57 (m, 2H), 4.94 (m, 2H), 6.88 (d, J = 8.3 Hz, 1H), 7.35 (m, 5H), 7.80 (m, 2H), 7.91 (d, J = 2.0 Hz, 
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1H); 13C NMR (126 MHz, CDCl3) δ 24.0, 25.1, 28.8, 49.3, 59.2, 61.2, 72.8, 73.5, 93.0, 110.0, 124.4, 
127.7, 127.7, 128.4, 128.6, 131.1, 132.3, 138.2, 143.9, 173.0; max/cm-1 3280 (N-H), 1620 (C=O), 1473, 
1335 (-SO2-N), 1201 (O-C-O); HRMS (ES) m/z = 459.1583 [M+H]+ found, C23H27N2O6S needs 459.1584; 
Rf = 0.32 (1:1 ethyl acetate/ petroleum ether).   
1-(Chloromethyl)cyclopentanecarbonitrile 72117 
CN
Cl
 
A mixture of cyclopentanecarbonitrile 71 (6.6 mL, 63.00 mmol) and bromochloromethane (14.4 mL, 
221.00 mmol) in THF (100 mL) was cooled to -78 ᴼC. A solution of LDA, prepared by the addition of 
nBuLi (1.6 M in hexane, 59 mL, 94.50 mmol) to diisopropylamine (13.26 mL, 94.50 mmol) in THF (50 
mL) at 0 ᴼC, was cooled to -78 ᴼC in a separate flask. The two solutions were quickly mixed and stirred 
at -78 ᴼC for 3 hours, before allowing to stand at room temperature overnight. This was followed by 
quenching with water (150 mL) and washing with brine (50 mL). The organic extract was dried over 
MgSO4 and concentrated in vacuo. Purification by flash column chromatography, eluting with 1:19 
ethyl acetate/ petroleum ether gave the 1-chloromethyl cyclopentanecarbonitrile 72 as a pale yellow 
oil (2.16 g, 24 % yield): 1H NMR (400 MHz, CDCl3) δ 1.85 (m, 6H), 2.24 (m, 2H), 3.61 (s, 2H) ); 13C NMR 
(101 MHz, CDCl3) δ 24.7, 36.7, 45.4, 48.5, 123.1; HRMS (CI) m/z = 161.0846 [M+NH4]+ found, C7H14ClN2 
needs 161.0846; Rf = 0.30 (1:5 ethyl acetate/ petroleum ether).   
(S)-1-((5'-(2-(Benzyloxymethyl)pyrrolidin-1-ylsulfonyl)-2'-oxospiro[[1,3]dioxane-2,3'-indoline]-1'-
yl)methyl)cyclopentanecarbonitrile 7758 
N
O
S
N
OO
BnO
CN
O
O
 
A mixture of ketal-protected isatin sulfonamide 70 (1.60 g, 3.50 mmol) and tBuOK (0.98 g, 8.75 mmol) 
in DMF (10 mL) was stirred at room temperature for 1 hour. The alkylating agent, 1-chloromethyl 
cyclopentanecarbonitrile 72 (1.50 g, 10.50 mmol) was added and stirring was continued at 140 ᴼC for 
2 days. The reaction mixture was subsequently concentrated in vacuo and purified by flash column 
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chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to give the nitrile 77 as a 
colourless foam (1.40 g, 71 % yield): 1H NMR (400 MHz, CDCl3) δ 1.91 (m, 8H), 2.17 (m, 3H), 2.42 (m, 
1H), 3.09 (m, 1H), 3.49 (m, 3H), 3.66 (m, 1H), 3.77 (m, 1H), 3.86 (m, 3H), 4.01 (m, 2H), 4.57 (m, 2H), 
4.92 (m, 2H), 7.20 (d, J = 8.3 Hz, 1H), 7.36 (m, 5H), 7.86 (dd, J = 2.0 Hz, 8.3 Hz, 1H), 7.93 (d, J = 2.0 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 23.8, 24.0, 25.1, 28.8, 36.5, 43.9, 45.5, 49.2, 59.2, 61.3, 72.8, 73.4, 
92.7, 109.7, 124.0, 127.7, 127.7, 128.0, 128.4, 131.1, 132.8, 132.8, 138.2, 145.9, 172.7; max/cm-1 2235 
(C≡N), 1721 (C=O), 1661 (C=N), 1342 (-SO2-N), 1055 (O-C-O); HRMS (ES) m/z = 566.2325 [M+H]+ 
found, C30H36N3O6S needs 566.2325; Rf = 0.52 (1:1 ethyl acetate/ petroleum ether).   
(S)-8'-(2-(Benzyloxymethyl)pyrrolidin-1-ylsulfonyl)-2'H-spiro[cyclopentane-1,3'-pyrimido[1,2-
a]indole]-10',10'-(1,3-dioxolane) 7958 
N
S
N
OO
BnO
N
O
O
 
A mixture of the nitrile 77 (0.113 g, 0.20 mmol) and a spatula of wet Raney Ni in 2M methalonic 
ammonia (5 mL) was hydrogenated in an autoclave at a hydrogen pressure of ~70 psi for 7 hours. The 
suspension was filtered through Celite® and the filtrate was refluxed for a further 5 hours. After 
cooling to room temperature and concentration in vacuo, the crude product was purified by flash 
column chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to give the amidine 
79 as a colourless foam (0.091 g, 83 % yield): 1H NMR (400 MHz, CDCl3) δ 1.48 (m, 2H), 1.59 (m, 4H), 
1.75 (m, 5H), 1.90 (m, 2H), 2.27 (m, 1H), 3.07 (m, 1H), 3.30 (s, 2H), 3.45 (m, 4H), 3.79 (m, 2H), 3.97 
(m, 2H), 4.57 (m, 2H), 5.07 (m, 2H), 6.62 (d, J = 8.4 Hz, 1H), 7.36 (m, 5H), 7.80 (dd, J = 1.8 Hz, 8.4 Hz, 
1H), 7.92 (d, J = 1.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 24.0, 25.0, 25.5, 28.8, 35.9, 38.5, 49.2, 50.2, 
55.9, 59.0, 60.2, 73.0, 73.4, 96.0, 105.5, 124.0, 127.6, 127.7, 128.4, 128.5, 129.1, 131.4, 138.3, 147.6, 
156.2; max/cm-1 2954, 1611 (C=N), 1494, 1466, 1335, 1264, 1153; HRMS (ES) m/z = 552.2532 [M+H]+ 
found, C30H38N3O5S needs 552.2532; Rf = 0.34 (1:1 ethyl acetate/ petroleum ether).  
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(S)-8'-(2-(Hydroxymethyl)pyrrolidin-1-ylsulfonyl)-2'H-spiro[cyclopentane-1,3'-pyrimido[1,2-a]indol]-
10'(4'H)-one 8058  
N
S
N
OO
HO
N
O
 
The ketal/benzyl protected pyrimidoindolone 79 (0.22 g, 0.40 mmol) was dissolved in 
methanesulfonic acid (3 mL) and the resulting yellow solution was stirred at room temperature for 5 
hours. The mixture was then cooled to 0 ᴼC and treated with saturated aqueous Na2CO3 solution until 
a pH of ~8 was reached. This was followed by extraction with DCM (4 x 10 mL). The combined organic 
extracts was dried over MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography, eluting with ethyl acetate gave the fully deprotected pyrimidoindolone 80 as a 
yellow foam (0.13 g, 81 % yield); 1H NMR (400 MHz, CDCl3) δ 1.57 (m, 5H), 1.78 (m, 7H), 2.64 (s, 1H), 
3.26 (m, 1H), 3.49 (m, 3H), 3.72 (m, 5H), 6.90 (d, J = 8.5 Hz, 1H), 8.05 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 8.12 
(d, J = 1.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 24.3, 25.1, 29.0, 29.7, 36.1, 39.9, 50.1, 57.5, 61.9, 65.8, 
108.2, 119.3, 124.9, 130.0, 137.1, 147.9, 154.4, 183.2; HRMS (ES) m/z = 404.1644 [M+H]+ found, 
C20H26N3O4S needs 404.1644; Rf = 0.12 (ethyl acetate).  
(S)-8'-(2-((Prop-2-ynyloxy)methyl)pyrrolidin-1-ylsulfonyl)-2'H-spiro[cyclopentane-1,3'-pyrimido[1,2-
a]indol]-10'(4'H)-one, 81      
N
S
N
OO
O
N
O
 
A solution of the ketal-protected alkyne 83 (0.18 g, 0.36 mmol) in methanesulfonic acid (2 mL) was 
stirred at room temperature for 12 hours. The mixture was slowly quenched with saturated aqueous 
Na2CO3 solution until a pH of ~8 was reached, before extracting with DCM (3 x 15 mL). This was 
followed by drying over MgSO4 and concentration in vacuo. Purification by flash column 
chromatography, eluting with 1:1 – 1:0 ethyl acetate/ petroleum ether, gave deprotected alkyne 81 
as a yellow foam (0.091 g, 58 % yield); 1H NMR (400 MHz, CDCl3) δ 1.65 (m, 10H), 1.93 (m, 2H), 2.49 
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(t, J = 2.4 Hz, 1H), 3.13 (m, 1H), 3.44 (m, 3H), 3.54 (m, 1H), 3.71 (s, 2H), 3.77 (m, 2H), 4.19 (d, J = 2.4 
Hz, 2H), 6.89 (d, J = 8.4 Hz, 1H), 8.04 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 8.11 (d, J = 1.8 Hz, 1H); 13C NMR (101 
MHz, CDCl3) δ 24.0, 25.1, 28.9, 36.1, 39.9, 49.4, 50.0, 57.5, 58.6, 59.0, 72.4, 74.7, 79.6, 108.2, 119.2, 
124.9, 130.5, 137.0, 147.9, 154.3, 183.3; max/cm-1 2924 (C≡C), 1727 (C=O), 1605 (C=N), 1464, 1334, 
1151, 1093; HRMS (ES) m/z = 442.1801 [M+H]+ found, C23H28N3O4S needs 442.1801; [αD]20 = -60.3(c 
0.003, CDCl3); Rf = 0.37 (ethyl acetate).  
(S)-8'-(2-(Hydroxymethyl)pyrrolidin-1-ylsulfonyl)-2'H-spiro[cyclopentane-1,3'-pyrimido[1,2-
a]indole]-10',10'(1,3)-dioxolane 8258 
N
S
N
OO
HO
N
O
O
 
A mixture of ketal/benzyl protected pyrimidoindolone 79 (0.50 g, 0.91 mmol) and 10 % Pd/C (0.05 g) 
in EtOH (2 mL) was degassed for 20 minutes. 1,4-Cyclohexadiene (15 mL) was added and the mixture 
was refluxed for 2 days. After cooling to room temperature, the suspension was filtered through 
Celite® and the resulting filtrate was concentrated in vacuo. Purification by flash column 
chromatography, eluting with 3:7 acetone/ petroleum ether gave the benzyl deprotected ketal 82 as 
a colourless foam (0.27 g, 64 % yield); 1H NMR (400 MHz, CDCl3) δ 1.56 (m, 5H), 1.75 (m, 8H), 2.31 
(m, 1H), 2.84 (m, 1H), 3.28 (m, 3H), 3.46 (m, 3H), 3.69 (m, 3H), 3.97 (m, 2H), 5.09 (br td, J = 11.2 Hz, 
2.7 Hz, 2H), 6.65 (d, J = 8.3 Hz, 1H), 7.81 (dd, J = 8.3 Hz, 1.8 Hz, 1H), 7.92 (d, J = 1.8 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 24.3, 25.0, 25.4, 28.9, 29.2, 35.9, 38.6, 50.2, 55.9, 60.2, 61.8, 66.0, 97.0, 105.6, 
124.1, 128.4, 128.7, 131.5, 147.9, 155.9; max/cm-1 3427 (O-H), 1671, 1611 (C=N), 1266, 1152 (O-C-
O); HRMS (ES) m/z = 462.2063 [M+H]+ found, C23H32N3O5S needs 462.2063; Rf = 0.26 (ethyl acetate). 
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(S)-10',10'-(1,3)Dioxolane-8'-(2-((prop-2-ynyloxy)methyl)pyrrolidin-1-ylsulfonyl)-4',10'-dihydro-2'H-
spiro[cyclopentane-1,3'-pyrimido[1,2-a]indole] 83 
N
S
N
OO
O
N
O
O
 
To a solution of alcohol 82 (0.016 g, 0.03 mmol) in THF (0.5 mL) was added NaH (60 % in mineral oil, 
1.00 mg, 0.07 mmol) and the mixture was stirred at room temperature for 10 minutes. Propargyl 
bromide (80 % in toluene, 0.01 mL, 0.14 mmol) was added and stirring was continued at room 
temperature for 12 hours. Then, the reaction mixture was poured into 1M NaOH solution (3 mL) and 
partitioned between water (5 mL) and DCM (5 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. Purification of the crude material by flash column chromatography, eluting 
with 1:4 – 1:0 ethyl acetate/ petroleum ether gave the alkyne 83 as a colourless foam (0.009 g, 60 % 
yield): 1H NMR (400 MHz, CDCl3) δ 1.50 (m, 2H), 1.61 (m, 4H), 1.74 (m, 5H), 1.90 (m, 2H), 2.31 (m, 
1H), 2.48 (t, J = 2.3 Hz, 1H), 3.09 (m, 1H), 3.30 (s, 2H), 3.47 (m, 4H), 3.81 (m, 2H), 3.98 (m, 2H), 4.21 
(d, J = 2.3 Hz, 2H), 5.07 (m, 2H), 6.64 (d, J = 8.3 Hz, 1H), 7.81 (dd, J = 8.3 Hz, 1.8 Hz, 1H), 7.93 (d, J = 
1.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 25.1, 25.5, 28.8, 35.9, 38.6, 49.3, 50.3, 56.0, 58.6, 58.8, 
60.2, 72.7, 74.6, 79.7, 96.0, 105.6, 124.0, 128.6, 129.0, 131.5, 147.7, 156.2; max/cm-1 3279 (C≡C), 
1670, 1612 (C=N), 1464, 1335 (-SO2-N), 1263 (C-O-C), 1155, 1018; HRMS (ES) m/z = 500.2219 [M+H]+ 
found, C26H34N3O5S needs 500.2219; [αD]20 = -65.6 (c 0.0025, CDCl3); Rf = 0.40 (ethyl acetate). 
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(S)-2-(4-(((1-(10',10'-(1,3)Dioxolane-4',10'-dihydro-2'H-spiro[cyclopentane-1,3'-pyrimido[1,2-
a]indole]-8'-ylsulfonyl)pyrrolidin-2-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)ethyl 4-
methylbenzenesulfonate  84 
N
S
N
OO
O
O
O
N
N N
OTs
N
 
A mixture of CuSO4 (0.011 g, 0.045 mmol), L-ascorbic acid (0.016 g, 0.09 mmol) and the alkyne 83 
(0.045 g, 0.09 mmol) in DMF (1.0 mL) was stirred at room temperature for 10 minutes to give a pale 
yellow solution. Tosylethylazide 36 (0.027 g, 0.11 mmol) in DMF (0.5 mL) was added and stirring was 
continued at room temperature for 1 hour. This was followed by quenching with 10 % NH4Cl aqueous 
solution (10 mL) and extraction with ethyl acetate (2 x 10 mL). The combined organic extracts was 
washed with brine (2 x 15 mL) and water (2 x 15 mL), dried over MgSO4 and concentrated in vacuo. 
The crude mixture was purified by flash column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ 
petroleum ether to give the tosylate 84 as a colourless foam (0.036 g, 54 % yield); 1H NMR (400 MHz, 
CDCl3) δ 1.50 (m, 2H), 1.61 (m, 4H), 1.75 (m, 5H), 1.89 (m, 2H), 2.31 (m, 1H), 2.47 (s, 3H), 3.09 (m, 
1H), 3.31 (s, 2H), 3.44 (br s, 3H), 3.54 (m, 1H), 3.79 (m, 2H), 3.96 (m, 2H), 4.44 (t, J = 5.1 Hz, 2H), 4.68 
(m, 4H), 5.08 (m, 2H), 6.65 (d, J = 8.3 Hz, 1H), 7.36 (d, J = 8.3 Hz, 2H), 7.66 (s, 1H), 7.72 (d, J = 8.3 Hz, 
2H), 7.80 (dd, J = 8.3 Hz, 1.7 Hz, 1H), 7.91 (d, J = 1.7 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 21.7, 24.0, 
25.1, 25.5, 28.8, 35.9, 38.6, 49.0, 49.3, 50.3, 56.0, 59.0, 60.2, 64.6, 67.6, 73.1, 96.0, 105.6, 123.7, 
124.0, 127.9, 128.6, 129.0, 130.1, 131.4, 132.1, 145.3, 145.5, 147.7, 156.2; max/cm-1 1674, 1612 
(C=N), 1465, 1335 (-SO2-N), 1152 (C-O-C), 1117, 1032 (O-C-O); HRMS (ES) m/z = 741.2740 [M+H]+ 
found, C35H45N6O8S2 needs 741.2740; [αD]20 = -50.4 (c 0.004, CDCl3); Rf = 0.16 (ethyl acetate). 
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(S)-tert-Butyl 2-((prop-2-ynyloxy)methyl)pyrrolidine-1-carboxylate 8557 
O
N
Boc 
To a mixture of N-Boc-prolinol 66 (4.20 g, 20.90 mmol) and NaH (60 % in mineral oil, 4.18 g, 104.50 
mmol) in anhydrous THF (100 mL) at 0 ᴼC, was added propargyl bromide 74 (80 % in toluene, 23.29 
mL, 326.60 mmol) and the mixture was stirred at room temperature for 18 hours. The mixture was 
then poured into 1M NaOH solution (50 mL) and extracted with DCM (100 mL). The organic layer was 
washed with water (100 mL) and brine (50 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash column chromatography, eluting with 1:19 – 1:4 ethyl acetate/ 
petroleum ether to give the alkyne 85 as a pale yellow oil (3.42 g, 65 % yield): 1H NMR (400 MHz, 
CDCl3) δ 1.47 (s, 9H), 1.86 (m, 4H), 2.43 (s, 1H), 3.35 (m, 3H), 3.66 (dd, J = 9.0 Hz, 3.4 Hz, 1H), 3.94  (m, 
1H), 4.16 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 22.9, 23.8, 28.5, 46.4, 56.3, 58.4, 70.8, 74.3, 79.4, 79.9, 
154.7; HRMS (ES) m/z = 262.1419 [M+Na]+ found, C13H21NNaO3 needs 262.1419; Rf = 0.29 (1:4 ethyl 
acetate/ petroleum ether). 
(S)-2-((Prop-2-ynyloxy)methyl)pyrrolidine hydrochloride 86  
O
N
H
.HCl  
A solution of the Boc-protected alkyne 85 (3.42 g, 13.56 mmol) in 4M HCl in dioxane (34 mL, 135.60 
mmol) and DCM (30 mL) was stirred at room temperature for 12 hours. The mixture was 
subsequently concentrated in vacuo to give the HCl salt of the deprotected amine 86 as a colourless 
solid (2.26 g, 97 % yield): 1H NMR (400 MHz, CDCl3) δ 1.89 (m, 1H), 2.13 (m, 3H), 2.49 (s, 1H), 3.42 (br 
s, 2H), 3.92 (m, 3H), 4.35 (br s, 2H), 9.24 (s, 1H), 10.13 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 24.2, 27.2, 
45.8, 58.5, 58.7, 68.3, 75.3, 79.0; max/cm-1 3230 (C≡C), 3162, 2907 - 2737 (-NH2+), 2503, 2441, 2106 
(C≡C), 1605, 1397, 1355, 1096; HRMS (ES) m/z = 140.1075 [M+H]+ found, C8H14NO needs 140.1075. 
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(S)-5-(2-((Prop-2-ynyloxy)methyl)pyrrolidin-1-ylsulfonyl)indoline-2,3-dione 8757  
N
H
O
O
S
N
OO
O
 
To a solution of the amine 86 (HCl salt, 3.28 g, 18.72 mmol) and Et3N (8.29 mL, 59.57 mmol) in a 1:1 
mixture of THF and DCM (300 mL) at 0 ᴼC was added dropwise, a solution of 5-chlorosulfonylisatin 
64 (4.17 g, 17.02 mmol) in THF (50 mL), maintaining the temperature at 0 ᴼ C. The mixture was allowed 
to warm to room temperature with further stirring for an hour. After concentration in vacuo, the 
crude product was purified by flash column chromatography, eluting with 1:1 ethyl acetate/ 
petroleum ether to give the sulfonamide 87 as an orange solid (5.07 g, 85.6 % yield); 1H NMR (400 
MHz, DMSO) δ 1.52 (m, 2H), 1.76 (m, 2H), 3.07 (m, 1H), 3.48 (m, 3H), 3.65 (m, 2H), 4.18 (m, 2H), 7.10 
(d, J = 8.3 Hz, 1H), 7.79 (s, 1H), 8.04 (br d, J = 8.1 Hz, 1H), 11.47 (s, 1H); 13C NMR (126 MHz, DMSO) δ 
23.5, 28.3, 49.0, 57.8, 58.5, 71.7, 77.2, 80.2, 112.8, 118.1, 123.1, 130.8, 136.8, 153.6, 159.4, 183.0; 
HRMS (ES) m/z = 349.0843 [M+H]+ found, C16H17N2O5S needs 349.0843. 
(S)-5'-(2-((Prop-2-ynyloxy)methyl)pyrrolidin-1-ylsulfonyl)spiro[[1,3]dioxane-2,3'-indolin]-2'-one 88  
N
H
O
S
N
OO
O
O
O
 
A mixture of isatin sulfonamide 87 (4.87 g, 13.99 mmol), 1,3-propanediol (10.1 mL, 139.90 mmol) and 
p-toluenesulfonic acid (0.67 g, 3.50 mmol) in toluene (150 mL) was refluxed for 15 hours, collecting 
water with a Dean Stark trap. The mixture was subsequently allowed to cool to room temperature, 
washed with saturated aqueous Na2CO3 solution (70 mL), water (100 mL), and brine (100 mL), before 
drying over MgSO4. Concentration in vacuo gave a crude product which was purified by flash column 
chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether to give the ketal-protected 
isatin sulfonamide 88 as a colourless foam (3.60 g, 64 % yield): 1H NMR (400 MHz, CDCl3) δ 1.67 (m, 
1H), 1.92 (m, 3H), 2.48 (m, 2H), 3.09 (m, 1H), 3.50 (m, 2H), 3.77 (m, 3H), 4.01 (m, 2H), 4.20 (m, 2H), 
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4.94 (m, 2H), 6.95 (d, J = 8.2 Hz, 1H), 7.82 (dd, J = 8.2 Hz, 1.9 Hz, 1H), 7.90 (d, J = 1.9 Hz, 1H), 8.31 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 25.2, 28.8, 49.3, 58.6, 58.9, 61.2, 72.5, 74.7, 79.6, 93.0, 110.1, 
124.4, 128.7, 131.2, 132.1, 144.0, 173.0; HRMS (ES) m/z = 407.1272 [M+H]+ found, C19H23N2O6S needs 
407.1271; Rf = 0.36 (1:1 ethyl acetate/ petroleum ether).  
(S)-1-((2'-Oxo-5'-(2-((prop-2-ynyloxy)methyl)pyrrolidin-1-ylsulfonyl)spiro[[1,3]dioxane-2,3'-
indoline]-1'-yl)methyl)cyclopentanecarbonitrile 89  
N
O
S
N
OO
O
O
O
CN
 
A mixture of isatin sulfonamide 88 (0.10 g, 0.25 mmol) and tBuOK (0.08 g, 0.75 mmol) in DMF (0.5 
mL) was stirred under argon at room temperature for 30 minutes. 1-Chloromethylcarbonitrile 72 
(0.11 g, 0.75 mmol) in DMF (0.5 mL) was added and stirring was continued at 140 ᴼC for 2 days. After 
cooling to room temperature, the reaction mixture was concentrated in vacuo and purified by flash 
chromatography, eluting with 1:5 – 1:1 ethyl acetate/ petroleum ether to give the nitrile 89 as a 
colourless foam (0.076 g, 59 % yield); 1H  NMR (400 MHz, CDCl3) δ 1.67 (m, 3H), 1.91 (m, 7H), 2.18 
(m, 2H), 2.43 (m, 2H), 2.97 (m, 2H), 3.50 (m, 2H), 3.81 (m, 2H), 3.90 (s, 2H), 4.00 (m, 2H), 4.19 (d, J = 
2.3 Hz, 2H), 4.91 (m, 2H), 7.24 (d, J = 8.3 Hz, 1H), 7.89 (m, 2H), 7.94; 13C NMR (101 MHz, CDCl3) δ 23.8, 
24.0, 25.1, 28.8, 36.5, 43.9, 45.6, 49.3, 58.6, 58.9, 61.4, 66.8, 72.5, 74.7, 79.6, 92.7, 109.8, 124.1, 
128.0, 131.1, 132.7, 146.0, 172.7; max/cm-1 3276 (C≡C), 2235 (C≡N), 1729 (C=O), 1615, 1441, 1340 (-
SO2-N), 1151, 1036; HRMS (ES) m/z = 514.2005 [M+H]+ found, C26H32N3O6S needs 514.2006; Rf = 0.55 
(1:1 ethyl acetate/ petroleum ether). 
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(S)-2-(4-(((1-(1'-((1-Cyanocyclopentyl)methyl)-2'-oxospiro[[1,3]dioxane-2,3'-indoline]-5'-
ylsulfonyl)pyrrolidin-2-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)ethyl-4-methylbenzenesulfonate 91  
N
O
S
N
OO
O
O
O
CN
N
N N
OTs  
A mixture of CuSO4 (0.036 g, 0.145 mmol), L-ascorbic acid (0.051 g, 0.29 mmol) and alkyne 89 (0.150 
g, 0.29 mmol) in DMF (3 mL) was stirred at room temperature for 10 minutes, prior to the addition 
of  a solution of tosylethylazide 36 (0.084 g, 0.35 mmol) in DMF (1.5 ml) with stirring for 1 hour. The 
reaction mixture was poured into 10 % aqueous NH4Cl solution (15 mL) and extracted with DCM (3 x 
15 mL). The combined organic extract was dried over MgSO4 and concentrated in vacuo, followed by 
purification by flash column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ petroleum ether 
to give the triazole 91 as a colourless foam (0.132 g, 50 % yield); 1H NMR (400 MHz, CDCl3) δ 1.66 (m, 
3H), 1.90 (m, 8H), 2.16 (m, 2H), 2.45 (m, 4H), 3.08 (m, 1H), 3.43 (m, 1H), 3.53 (m, 1H), 3.78 (m, 2H), 
3.90 (s, 2H), 4.00 (m, 2H), 4.42 (t, J = 5.2 Hz, 2H), 4.65 (m, 4H), 4.91 (m, 2H), 7.22 (d, J = 8.3 Hz, 1H), 
7.34 (d, J = 8.3 Hz, 2H), 7.64 (s, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.86 (dd, J = 8.3 Hz, 1.9 Hz, 1H), 7.90 (d, J 
= 1.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 21.7, 23.8, 24.0, 25.1, 28.8, 36.5, 43.9, 45.5, 49.0, 49.3, 
59.1, 61.3, 64.6, 67.6, 73.0, 92.7, 109.8, 123.8, 124.0, 124.0, 127.9, 128.0, 130.1, 131.1, 132.0, 132.7, 
145.1, 145.5, 146.0, 172.7; HRMS (ES) m/z = 755.2533 [M+H]+ found, C35H43N6O9S2 needs 755.2533; 
Rf = 0.34 (ethyl acetate). 
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Spiro[[1,3]dioxane-2,3'-indolin]-2'-one 92209 
N
H
O
O
O
 
To a solution of isatin 61 (1.00 g, 6.80 mmol) and 1,3-propanediol (4.9 mL, 68 mmol) in toluene (40 
mL) was added p-toluenesulfonic acid (0.32 g, 1.70 mmol) and the mixture was refluxed for 12 hours, 
collecting water with a Dean Stark trap. This was followed by cooling to room temperature, prior to 
washing with water (100 mL) and brine (100 mL). Subsequent drying over MgSO4 and concentration 
in vacuo gave a crude residue which was purified by flash column chromatography, eluting with 1:9 
– 1:1 ethyl acetate/ petroleum ether to give the corresponding ketal 92 as a colourless solid (0.70 g, 
50 % yield): 1H NMR (400 MHz, CDCl3) δ 1.68 (m, 1H), 2.42 (m, 1H), 4.01 (m, 2H), 5.02 (m, 2H), 6.81 
(d, J = 7.8 Hz, 1H), 7.10 (m, 1H), 7.31 (m, 1H), 7.45 (br m, 2H); 13C NMR (101 MHz, CDCl3) δ 25.3, 61.2, 
93.6, 109.9, 123.3, 124.4, 127.8, 130.9, 139.9, 173.2; max/cm-1 3139 (N-H), 1705 (C=O), 1622, 1470, 
1212 (O-C-O), 1024; HRMS (CI) m/z = 206.0817 [M+H]+ found, C11H12NO3 needs 206.0817.  
1-((2'-Oxospiro[[1,3]dioxane-2,3'-indoline]-1'-yl)methyl)cyclopentanecarbonitrile 93 
N
O
O
O
CN
 
A mixture of ketal-protected isatin 92 (0.50 g, 2.44 mmol) and tBuOK (0.68 g, 6.10 mmol) in DMSO (7 
mL) was stirred at room temperature for 1 hour. Then, carbonitrile 72 (0.70 g, 4.88 mmol) was added 
and stirring was continued at 130 ᴼC for 12 hours. Additional carbonitrile reagent 72 was added to 
the mixture with further stirring at 140 ᴼC for 24 hours. This was followed by cooling to room 
temperature, diluting with ethyl acetate (30 mL) and washing with water (50 mL) and brine (100 mL). 
The organic layer was dried over MgSO4 and concentrated in vacuo. The crude residue was purified 
by flash column chromatography, eluting with 1:4 – 3:7 ethyl acetate/ petroleum ether to give the 
nitrile 93 as pale yellow foam (0.11 g, ~ 80% purity). The crude product was used in the next reaction 
step, to prepare the amidine 94 without further purification: HRMS (ES) m/z = 313.1545 [M+H]+ 
found, C18H21N2O3 needs 313.1547.  
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Pyrimidoindole-1,3-dioxolane 94 
N
N
O
O
 
A solution of the crude nitrile 93 (0.10 g, 0.32 mmol) and a spatula of wet Raney Ni in 2M methalonic 
ammonia (5 mL) was hydrogenated in an autoclave at a pressure of ~130 psi for 12 hours. The mixture 
was filtered through Celite® with the resulting filtrate refluxed for 12 hours. This was followed by 
cooling to room temperature and concentration in vacuo. The residue was purified by flash column 
chromatography, eluting with 1:4 ethyl acetate/ petroleum ether to give the amidine 94 as colourless 
foam (0.025 g): 1H NMR (400 MHz, CDCl3) δ 1.65 (m, 4H), 1.76 (m, 5H), 2.25 (m, 1H), 3.38 (s, 2H), 3.42 
(s, 2H), 4.02 (m, 2H), 5.08 (m, 2H), 6.60 (d, J = 7.8 Hz, 1H), 6.96 (t, J = 7.6 Hz, 1H), 7.29 (m, 1H), 7.51 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 25.1, 25.6, 36.0, 38.6, 50.1, 56.0, 60.2, 96.9, 105.9, 120.8, 124.0, 
127.8, 130.7, 144.2, 157.1; HRMS (ES) m/z = 299.1755 [M+H]+ found, C18H23N2O2 needs 299.1754.  
(S)-tert-Butyl 2-(tosyloxymethyl)pyrrolidine-1-carboxylate 10573 
N
OTs
Boc
 
To a solution of N-Boc-prolinol 66 (6.20 g, 31.00 mmol) and pyridine (20 mL) in DCM (40 mL) at 0 ᴼC, 
was added p-toluenesulfonyl chloride (7.44 g, 39.00 mmol) and the mixture was stirred at 0 ᴼC for 15 
minutes, and then at room temperature for 12 hours. This was followed by quenching with water 
(100 mL) and extracting with DCM (50 mL). The organic extract was washed with 10 % aqueous citric 
acid solution (100 mL), brine (50 mL), saturated aqueous NaHCO3 solution (50 mL). Subsequent drying 
over MgSO4 and concentration in vacuo gave a crude product which was purified by flash column 
chromatography, eluting with 1:9 – 1:4 ethyl acetate/ petroleum ether to give the tosylate 105 as a 
pale yellow oil (9.28 g, 84 % yield); 1H NMR (400 MHz, CDCl3) δ 1.40 (br d, J = 14 Hz, 9H), 1.90 (br m, 
4H), 2.46 (s, 3H), 3.29 (m, 2H), 4.09 (br m, 3H), 7.35 (br m, 2H), 7.79 (d, J = 7.8 Hz, 2H); 13C NMR (101 
MHz, CDCl3) δ 21.6, 22.8, 23.8, 28.4, 46.5, 55.6, 70.0, 79.9, 127.9, 129.9, 132.9, 144.8, 154.3; HRMS 
(ES) m/z = 378.1351 [M+Na]+ found, C17H25NNaO5S needs 378.1351; Rf = 0.22 (1:4 ethyl acetate/ 
petroleum ether).  
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(S)-tert-Butyl 2-((2,4-difluorophenoxy)methyl)pyrrolidine-1-carboxylate 10757 
N
O
Boc
F
F
 
To a solution of 2,4-difluorophenol (3.22 g, 24.80 mmol) in anhydrous DMF (60 mL) was added NaH 
(60 % dispersion in mineral oil, 1.24 g, 31.00 mmol) and the mixture was stirred at room temperature 
for 30 minutes. This was followed by the addition of tosylate 105 (7.00 g, 20.60 mmol) and stirring 
was continued at 80 ᴼC for 8 hours. After cooling to room temperature, the mixture was poured into 
1M aqueous NaOH (100 mL) and extracted with DCM (2 x 60 mL). The combined organic extract was 
dried over MgSO4 and concentrated in vacuo. Purification by flash column chromatography, eluting 
with 1:9 ethyl acetate/ petroleum ether gave the phenyl ether 107 as a colourless oil (4.00 g, 62 % 
yield); 1H NMR (400 MHz, CDCl3) δ 1.49 (s, 9H), 2.00 (br m, 4H), 3.41 (br s, 2H), 4.15 (br m, 3H), 6.79 
(m, 1H), 6.89 (m, 1H), 7.01 (br s, 1H); 13C NMR (126 MHz, CDCl3) δ 22.8, 23.8, 28.5, 46.6 (d, J = 53.4 
Hz), 55.9, 70.3 (d, J = 122.1 Hz), 79.6 (d, J = 44.7 Hz), 104.7 (m), 110.3 (dd, J = 3.3 Hz, 22.9 Hz), 115.8 
(m), 143.5 (m), 154.5 (m), 155.7, 157.5 (m); HRMS (ES) m/z = 336.1387 [M+Na]+ found, 
C16H21F2NNaO3 needs 336.1387; Rf = 0.17 (1:9 ethyl acetate/ petroleum ether).  
(S)-2-((2,4-Difluorophenoxy)methyl)pyrrolidine hydrochloride 10857 
N
O
H
F
F
.HCl
 
To a solution of Boc-protected amine 107 (3.70 g, 11.80 mmol) in DCM (50 mL), was added 4M HCl 
in dioxane (29.5 mL) and the mixture was stirred at room temperature for 18 hours. Subsequent 
concentration in vacuo gave the HCl salt of the amine 108 as a colourless solid (2.80 g, 95 % yield); 
1H NMR (400 MHz, CDCl3) δ 2.05 (m, 2H), 2.21 (m, 2H), 3.45 (m, 2H), 4.06 (m, 1H), 4.35 (m, 2H), 6.81 
(m, 2H), 7.24 (m, 1H), 9.73 (s, 1H), 10.30 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 27.2, 45.8, 58.1, 
69.8, 104.9 (dd, J = 22.5 Hz, 27.7 Hz), 110.8 (dd, J = 3.5 Hz, 22.5 Hz), 118.6 (m), 142.2 (dd, J = 3.5 Hz, 
10.4 Hz), 153.0 (dd, J = 12.1 Hz, 248.7 Hz), 157.7 (dd, J = 10.4 Hz, 244.5 Hz); max/cm-1 3026 – 2722 
(N-H), 1509, 1453 (C-F), 1400, 1260 (C-O-C), 1209; HRMS (ES) m/z  = 214.1043 [M+H]+ found, 
C11H14F2NO needs 214.1043. 
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(S)-5-(2-((2,4-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)indoline-2,3-dione 10957 
N
H
S
N
OO
O
O
F
F
O
 
A solution of amine 108 (HCl salt, 0.10 g, 0.41 mmol) in DCM (2 mL) was slowly added to a solution 
of 5-chlorosulfonylisatin 64 (0.10 g, 0.41 mmol) and Et3N (0.17 mL, 1.23 mmol) in THF (2 mL) at 0 ᴼC. 
The mixture was stirred at 0 ᴼC for 30 minutes and then at room temperature for 1 hour. Subsequent 
concentration in vacuo and purification by flash column chromatography, eluting with 1:1 ethyl 
acetate/ petroleum ether gave the sulfonamide 109 as an orange solid (0.12 g, 70 % yield); 1H NMR 
(400 MHz, DMSO) δ 1.66 (m, 2H), 1.90 (m, 2H), 3.14 (m, 1H), 3.37 (m, 1H), 3.93 (m, 1H), 4.10 (m, 2H), 
7.05 (m, 2H), 7.27 (m, 2H), 7.79 (d, J = 2.0 Hz, 1H), 8.05 (dd, J = 2.0 Hz, 8.3 Hz, 1H), 11.46 (s, 1H); 13C 
NMR (126 MHz, DMSO) δ 23.6, 28.4, 49.2, 58.2, 71.4, 104.8 (dd, J = 22.9 Hz, 27.8 Hz), 110.8 (dd, J = 
3.3 Hz, 22.3 Hz), 112.8, 115.6 (dd, J = 2.2 Hz, 9.3 Hz), 118.1, 123.1, 130.7, 136.8, 142.9 (dd, J = 2.7 Hz, 
10.4 Hz), 151.0 (dd, J = 12.0 Hz, 246.9 Hz), 153.8, 155.6 (dd, J = 10.4 Hz, 239.8 Hz), 159.4, 182.9; 
max/cm-1 3263 (N-H), 1747 (C=O ketone), 1618 (C=O amide), 1510, 1470 (C-F), 1347 (-SO2-N); HRMS 
(ES) m/z = 423.0821 [M+H]+ found, C19H17F2N2O5S needs 423.0821; Rf = 0.45 (ethyl acetate).  
(S)-5'-(2-((2,4-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)spiro[[1,3]dioxane-2,3'-indolin]-2'-
one 118123 
N
H
O
S
N
OO
O
O
O
F
F  
To a solution of isatin sulfonamide 109 (1.12 g, 2.65 mmol) and 1,3-propanediol (3.05 mL, 42.3 mmol) 
in toluene (60 mL) was added p-toluenesulfonic acid (0.20 g, 1.05 mmol) and the mixture was refluxed 
for 18 hours, collecting water with a Dean Stark trap. After cooling to room temperature, saturated 
aqueous Na2CO3 solution (40 mL) was added, followed by washing with water (60 mL) and brine (60 
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mL). The organic extract was dried over MgSO4 and concentrated in vacuo. Purification by flash 
column chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether gave the ketal 
protected isatin sulfonamide 118 as a colourless foam (1.00 g, 78 % yield); 1H NMR (400 MHz, CDCl3) 
δ 1.74 (m, 3H), 2.04 (m, 2H), 2.42 (m, 1H), 3.13 (m, 1H), 3.55 (m, 1H), 3.99 (m, 4H), 4.32 (m, 1H), 4.96 
(m, 2H), 6.92 (m, 3H), 7.03 (td, J = 9.1 Hz, 5.3 Hz, 1H), 7.65 (s, 1H), 7.83 (dd, J = 8.2 Hz, 1.8 Hz, 1H), 
7.92 (d, J = 1.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 24.0, 25.1, 28.9, 49.4, 58.3, 61.2, 71.9, 92.9, 104.9 
(dd, J = 22.0 Hz, 26.9 Hz), 110.4, 110.6 (dd, J = 3.7 Hz, 22.4 Hz), 115.5 (m), 124.4, 128.7, 131.1, 131.9, 
143.1 (dd, J = 3.2 Hz, 10.8 Hz), 144.0, 152.3 (dd, J = 12.0 Hz, 248.0 Hz), 156.5 (dd, J = 10.4 Hz, 241.0 
Hz), 173.0; max/cm-1 3329 (N-H), 1771 (C=O), 1611, 1512, 1328, 1144, 1034; HRMS (ES) m/z = 
481.1245 [M+H]+ found, C22H23F2N2O6S needs 481.1245; Rf = 0.34 (1:1 ethyl acetate/ petroleum 
ether).   
(S)-tert-Butyl-5'-(2-((2,4-difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2'-oxospiro[[1,3]dioxane-
2,3'-indoline]-1'-carboxylate 141  
N
O
S
N
OO
O
O
O
F
F
O
O
 
Boc2O (0.026 g, 0.12 mmol) was added to a solution of ketal-protected isatin sulfonamide 118 (0.050 
g, 0.10 mmol) in DCM (1 mL) with stirring at room temperature. A TLC showed that no reaction had 
occurred after 6 hours. DMAP (0.002 g, 0.02 mmol) was added and stirring was continued at room 
temperature for 16 hours. The reaction mixture was then partitioned between DCM (5 mL) and water 
(5 mL) and the organic layer was dried over MgSO4 and concentrated in vacuo. Subsequent 
purification by flash column chromatography, eluting with 1:9 – 1:1 ethyl acetate in petroleum ether, 
gave the carbamate 141 as a colourless foam (0.021 g, 34 % yield); 1H NMR (400 MHz, CDCl3) δ 1.68 
(m, 12H), 2.03 (m, 2H), 2.43 (m, 1H), 3.15 (m, 1H), 3.56 (m, 1H), 4.00 (m, 4H), 4.32 (m, 1H), 4.92 (m, 
2H), 6.86 (m, 2H), 7.02 (td, J = 9.1 Hz, 5.2 Hz, 1H), 7.90 (dd, J = 8.6 Hz, 2.0 Hz, 1H), 7.97 (d, J = 2.0 Hz, 
1H), 8.00 (d, J = 8.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 25.0, 28.1, 28.9, 49.5, 58.4, 61.5, 71.8, 
85.5, 91.8, 104.9 (m), 110.4 (m), 115.5 (m), 115.6, 123.9, 127.7, 130.8, 133.6, 142.9, 143.2 (m), 148.7, 
154.6 (m), 156.8 (m), 168.7; max/cm-1 3090 (O-tBu), 1775, (C=O amide), 1732 (C=O carbamate), 1615, 
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1514, 1476, 1337 (-SO2-N), 1300, 1254, 1124; HRMS (ES) m/z = 581.1764 [M+H]+ found, 
C27H31F2N2O8S needs 581.1764; Rf = 0.26 (1:4 ethyl acetate/ petroleum ether). 
(S)-Ethyl-5'-(2-((2,4-difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2'-oxospiro[[1,3]dioxane-2,3'-
indoline]-1'-carboxylate, 142 
N
O
S
N
OO
O
O
O
F
F
O
O
 
To a solution of ketal-protected isatin sulfonamide 118 (0.20 g, 0.42 mmol) in anhydrous THF (1.5 
mL) was added NaH (60 % in mineral oil, 0.034 g, 0.84 mmol) and the mixture was stirred at room 
temperature for 10 minutes. Ethyl chloroformate (0.05 mL, 0.50 mmol) was added and stirring was 
continued at room temperature for 30 minutes. The reaction mixture was diluted with DCM (10 mL) 
and washed with water (5 mL) and brine (5 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo to give the carbamate 142 as a colourless foam (0.22 g, 96 % yield); 1H NMR 
(400 MHz, CDCl3) δ 1.49 (t, J = 7.1 Hz, 3H), 1.74 (m, 3H), 2.04 (m, 2H), 2.43 (m, 1H), 3.15 (m, 1H), 3.55 
(m, 1H), 3.99 (m, 4H), 4.31 (m, 1H), 4.51 (q, J = 7.1 Hz, 2H), 4.90 (m, 2H), 6.85 (m, 2H), 7.02 (td, J = 9.1 
Hz, 5.2 Hz, 1H), 7.91 (dd, J = 8.6 Hz, 1.9 Hz, 1H), 7.97 (d, J = 1.9 Hz, 1H), 8.04 (d, J = 8.6 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 14.2, 24.0, 25.0, 28.9, 49.4, 58.4, 61.5, 64.1, 71.8, 91.9, 104.9 (dd, J = 21.8 
Hz, 24.0 Hz), 110.5 (dd, J = 3.3 Hz, 21.8 Hz), 115.5 (dd, J = 2.2 Hz, 9.8 Hz), 115.7, 124.0, 127.8, 130.9, 
134.1, 142.5, 143.1 (dd, J = 3.3 Hz, 10.9 Hz), 150.4, 152.3 (dd, J = 13.1 Hz, 249.6 Hz), 156.6 (dd, J = 
10.9 Hz, 242.0 Hz), 168.5; max/cm-1 1776 (C=O amide), 1743 (C=O carbamate), 1618, 1516, 1468, 
1355 (-SO2-N), 1292; HRMS (ES) m/z = 553.1451 [M+H]+ found, C25H27F2N2O8S needs 553.1451; Rf = 
0.42 (1:1 ethyl acetate/ petroleum ether). 
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(S)-2-(5'-(2-((2,4-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2'-oxospiro[[1,3]dioxane-2,3'-
indoline]-1'-yl)acetonitrile  144  
N
O
S
N
OO
O
O
O
F
F
CN
 
A mixture of ketal-protected isatin sulfonamide 118 (0.78 g, 1.63 mmol) and tBuOK (0.91 g, 8.15 
mmol) in anhydrous THF (25 mL) was stirred at room temperature for 10 minutes. Bromoacetonitrile 
(0.34 mL, 4.90 mmol) was added and stirring was continued at room temperature for 4 hours. The 
reaction mixture was then partitioned between DCM (15 mL) and water (30 mL). The organic layer 
was washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. Purification by flash 
column chromatography, eluting with 1:4 – 1:1 ethyl acetate/ petroleum ether gave the nitrile 144 
as a colourless foam (0.60 g, 71 % yield); 1H NMR (400 MHz, CDCl3) δ 1.76 (m, 3H), 2.05 (m, 2H), 2.44 
(m, 1H), 3.13 (m, 1H), 3.56 (m, 1H), 4.01 (m, 4H), 4.31 (m, 1H), 4.63 (m, 2H), 4.90 (m, 2H), 6.87 (m, 
2H), 7.04 (m, 2H), 7.96 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 24.0, 25.0, 27.2, 28.9, 49.5, 58.5, 61.6, 
71.8, 93.0, 104.9 (m), 108.8, 110.4 (dd, J = 3.5 Hz, 22.5 Hz), 113.0, 115.6 (m), 124.4, 128.1, 131.4, 
133.4, 143.1 (m), 143.5, 152.4 (dd, J = 12.1 Hz, 249.7 Hz), 156.7 (dd, J = 10.4 Hz, 241.0 Hz), 170.0; 
max/cm-1 1738 (C=O), 1617, 1512, 1334 (-SO2-N), 1266, 1138; HRMS (ES) m/z = 520.1347 [M+H]+ 
found, C24H24F2N3O6S needs 520.1348; Rf = 0.40 (1:1 ethyl acetate/ petroleum ether). 
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(S)-1'-(2-Aminoethyl)-5'-(2-((2,4-difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)spiro[[1,3]dioxane-
2,3'-indolin]-2'-one, 145 
N
O
S
N
OO
O
O
O
F
F
NH2
 
A mixture of nitrile 144 (0.10 g, 0.19 mmol) and a spatula of wet Raney Ni in 0.25M methalonic 
ammonia (5 mL) was hydrogenated in an autoclave at a pressure of ~70 psi for 12 hours. The reaction 
was filtered through Celite® and the resulting filtrate was concentrated in vacuo. The crude product 
was purified by flash column chromatography, eluting with 0:1 – 1:4 MeOH/ ethyl acetate to give the 
primary amine 145 as a colourless foam (0.065 g, 65 % yield): 1H NMR (400 MHz, CDCl3) δ 1.74 (m, 
4H), 2.60 (m, 2H), 2.42 (m, 1H), 3.05 (m, 3H), 3.53 (m, 1H), 3.75 (t, J = 6.4 Hz, 2H), 3.98 (m, 5H), 4.32 
(m, 1H), 4.97 (m, 2H), 6.86 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 7.04 (m, 1H), 7.86, (dd, J = 2.0 Hz, 8.3 Hz, 
1H), 7.90 (br s, 1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 25.2, 28.9, 39.7, 43.0, 49.4, 58.3, 61.3, 71.9, 
92.9, 104.8 (dd, J = 22.5 Hz, 26.0 Hz), 108.7, 110.4 (dd, J = 3.5 Hz, 22.5 Hz), 115.6 (m), 124.0, 128.3, 
131.3, 131.7, 143.1 (m), 146.6, 152.3 (dd, J = 12.1 Hz, 248.0 Hz), 156.5 (dd, J = 10.4 Hz, 241.0 Hz), 
172.1; max/cm-1 3370 (N-H), 1725 (C=O), 1615, 1512 (C-N, amine), 1338 (-SO2-N), 1297, 1146, 1027; 
HRMS (ES) m/z = 524.1660 [M+H]+ found, C24H28F2N3O6S needs 524.1661; Rf = 0.10 (1:4 MeOH/ ethyl 
acetate).  
Methyl 5-chloro-2-fluorobenzoate 153210 
Cl
OMe
O
F  
A solution of 2-fluoro-5-chlorobenzoic acid 152a (1.52 g, 8.71 mmol) in MeOH (20 mL) and 
concentrated HCl (1 mL) was refluxed for 3.5 hours. The mixture was concentrated in vacuo and the 
resulting residue was dissolved in DCM (20 mL) and washed with water (2 x 15 mL). The organic 
extract was dried over MgSO4 and concentrated in vacuo to give methyl 5-chloro-2-fluorobenzoate 
153 as a colourless oil (1.46 g, 89 % yield): 1H NMR (400 MHz, CDCl3) δ 3.94 (s, 3H), 7.10 (dd, J = 8.8 
Hz, 9.8 Hz, 1H), 7.47 (m, 1H), 7.91 (dd, J = 2.5 Hz, 5.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 52.6, 118.5 
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(d, J = 24.3 Hz), 119.9 (d, J = 10.4 Hz), 129.2 (m), 131.8, 134.3 (d, J = 8.7 Hz), 160.4 (d, J = 260.1 Hz), 
163.7; HRMS (EI) m/z = 188.0040 [M]+ found, C8H6ClFO2 needs 188.0040; Rf = 0.60 (1:1 ethyl acetate/ 
petroleum ether). 
(5-Chloro-2-fluorophenyl)(1H-imidazol-2-yl)methanone 156 
Cl
O
F
HN
N
 
A solution of benzoic acid 152a (2.30 g, 13.18 mmol) in thionyl chloride (10 mL) was refluxed for 2 
hours. Excess thionyl chloride was azeotroped with toluene and removed in vacuo to give the 
corresponding acid chloride 154, which was then dissolved in pyridine (0.50 mL). The resulting 
solution was added dropwise to a solution of imidazole 155 (0.45 g, 6.59 mmol) and Et3N (1.83 mL, 
13.18 mmol) in pyridine (1.5 mL) at 0 ᴼC, before warming to room temperature and stirring for 3.5 
hours. This was followed by the addition of aqueous NaOH (7.5N, 1.3 mL) and heating to reflux for 1 
hour. The mixture was then diluted with water (6 mL) and allowed to cool to room temperature. The 
resulting precipitate was filtered and washed with water (20 mL) and diethyl ether (20 mL). The 
precipitate was further purified by flash column chromatography, eluting with 1:3 -  1:1 ethyl acetate/ 
petroleum ether to give 2-acylimidazole 156 as a colourless solid (0.96 g, 65 % yield): 1H NMR (400 
MHz, CDCl3) δ 7.15 (m, 1H), 7.34 (br s, 1H), 7.40 (br s, 1H), 7.50 (m, 1H), 8.04 (dd, J = 2.9 Hz, 5.9 Hz, 
1H), 10.46 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 118.0 (d, J = 24.1 Hz), 120.9, 126.1 (d, J = 13.8 Hz), 
129.2 (d, J = 4.3 Hz), 131.6 (br m), 132.5 (br m), 133.5 (d, J = 8.6 Hz), 144.6, 159.5 (d, J = 256.0 Hz), 
179.7; max/cm-1 1659 (C=O), 1606, 1482, 1392, 1198, 792; HRMS (ES) m/z = 225.0224 [M+H]+ found, 
C10H7ClFN2O needs 225.0225; Rf = 0.45 (1:1 ethyl acetate/ petroleum ether). 
7-Chloro-9H-imidazo[1,2-a]indol-9-one 157 
N
Cl
N
O
 
A mixture of 2-acylimidazole 156 (0.56 g, 2.50 mmol) and K2CO3 (1.03 g, 7.46 mmol) in DMF (5 mL) 
was stirred at 140 ᴼC for 2.5 hours. After cooling to room temperature, the mixture was diluted with 
ethyl acetate (10 mL) and washed with water (2 x 10 mL) and brine (3 x 20 mL). The organic extract 
was dried over MgSO4 and concentrated in vacuo. Then, the crude residue was purified by flash 
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column chromatography, eluting with 1:3 – 1:1 ethyl acetate/ petroleum ether to give 
imidazoleindolone 157 as a yellow solid (0.33 g, 65 % yield): 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 
8.3 Hz, 1H), 7.24 (br m, 1H), 7.43 (br m, 1H), 7.50 (dd, J = 2.0 Hz, 8.3 Hz, 1H), 7.61 (d, J = 2.0 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 112.6, 112.6, 115.3, 125.8, 129.7, 133.1, 134.8, 137.9, 139.6, 176.2; 
max/cm-1 3135, 1702 (C=O), 1613, 1476 (C=N), 1428, 1390, 1262, 1180, 828; HRMS (ES) m/z = 
205.0169 [M+H]+ found, C10H6ClN2O needs 205.0169; Rf = 0.20 (1:1 ethyl acetate/ petroleum ether). 
Ethyl 5-chloro-2-(1H-imidazol-1-yl)benzoate 175 
Cl
O
O
N
N
 
To a solution of imidazoleindolone 157 (0.05 g, 0.245 mmol) in EtOH (1.00 mL) was added a solution 
of Na2SO3 (0.04 g, 0.32 mmol) in water (0.2 mL) and the mixture was refluxed for 2.5 hours. Ethanol 
was removed by concentration in vacuo, followed by partitioning between water (3 mL) and DCM (5 
mL). The organic extract was dried over MgSO4 and concentrated in vacuo to give a colourless 
product, 175 (0.045 g, 73 % yield): 1H NMR (400 MHz, CDCl3) δ 1.16 (t, J = 7.1 Hz, 3H), 4.18 (q, J = 7.1 
Hz, 2H), 7.06 (s, 1H), 7.18 (s, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.60 (m, 2H), 7.94 (d, J = 2.4 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 13.8, 62.2, 120.9, 128.9, 129.4, 129.8, 131.2, 132.6, 134.9, 135.0, 137.6, 
164.5; HRMS (ES) m/z = 251.0585 [M+H]+ found C12H12ClN2O2 needs 251.0582. 
2-Hydroxyethyl 5-bromo-2-(1H-imidazol-1-yl)benzoate 178 
O
O
OH
N
N
Br
 
A mixture of imidazoleindolone 58 (0.05 g, 0.20 mmol), ethylene glycol (0.11 mL, 2.00 mmol) and p-
toluenesulfonic acid (0.01 g, 0.05 mmol) in toluene (1.00 mL) was refluxed for 12 hours. After cooling 
to room temperature, the reaction mixture was diluted with ethyl acetate (3 mL) and washed with 
water (5 mL). The organic extract was dried over MgSO4 and concentrated in vacuo. Purification by 
flash column chromatography, eluting with 1:1 – 1:0 ethyl acetate/ petroleum ether gave the 
hydroxyl benzoate 178 as a colourless solid (0.028 g, 45 % yield): 1H NMR (400 MHz, CDCl3) δ 3.65 (m 
2H), 3.76 (s, 1H), 4.24 (m, 2H), 7.12 (s, 1H), 7.22 (s, 1H), 7.29 (m, 1H), 7.66 (s, 1H), 7.79 (dd, J = 8.4 Hz, 
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2.2 Hz, 1H), 8.21 (d, J = 2.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 60.2, 67.9, 121.2, 123.1, 129.3, 129.5, 
129.6, 134.8, 135.4, 136.1, 138.4, 164.4; max/cm-1 3500 (O-H), 1721 (C=O), 1499 (C=N), 1246 (C-O 
ester); HRMS (ES) m/z = 311.0031 [M+H]+ found, C12H12BrN2O3 needs 311.0031.  
(5-Bromo-2-fluorophenyl)(1H-imidazol-2-yl)methanone 180 
O
Br
F
N
N
H
 
To a solution of 1-trityl imidazole 190 (2.66 g, 8.58 mmol) in THF (75 mL) at -78 ᴼC was added nBuLi 
(1.6 M in hexane, 5.90 mL, 9.44 mmol) and the mixture was stirred for 15 minutes. A precooled 
solution of the ester 193 (2.00 g, 8.58 mmol) in THF (5 mL) at -78 ᴼC was added and stirring was 
continued for 30 minutes before warming to room temperature. The reaction mixture was then 
washed with water (30 mL) and brine (20 mL), dried over MgSO4 and concentrated in vacuo. The 
crude mixture was recrystallised from ethyl acetate/petroleum ether mixture to give the trityl-
protected ketone 195 as a colourless solid (3.12 g, 71 % yield). 
The resulting N-trityl ketone 195 (3.12 g, 6.10 mmol) was dissolved in a mixture of 1,4-dioxane (35 
mL) and 10 % aqueous HCl (15 mL) and allowed to stir at 70 ᴼC for 18 hours. After cooling to room 
temperature, the reaction mixture was made basic with saturated aqueous NaHCO3 solution (pH ~ 
8), re-acidified with solid citric acid (pH ~5) and extracted with ethyl acetate (3 x 60 mL). The 
combined organic extract was dried over MgSO4 and concentrated in vacuo. Recrystallisation from 
ethyl acetate/petroleum ether mixture gave the deprotected ketone 180 as a colourless solid (1.40 
g, 85 % yield): 1H NMR (400 MHz, CDCl3) δ 7.12 (t, J = 9.8 Hz, 1H), 7.36 (s, 1H), 7.43 (s, 1H), 7.67 (m, 
1H), 8.20 (dd, J = 2.4 Hz, 5.9 Hz, 1H), 10.70 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 116.4 (d, J = 3.4 Hz), 
118.4 (d, J = 23.3 Hz), 121.1 (br s), 126.5 (d, J = 12.9 Hz), 132.5 (br s), 134.5, 136.4 (d, J = 7.8 Hz), 
144.6, 160.0 (d, J = 256.9 Hz), 179.6; max/cm-1 3015 (N-H), 1649 (C=O), 1601 (C=N), 1476, 1395, 1196, 
1129; HRMS (ES) m/z = 268.9726 [M+H]+ found, C10H7BrFN2O needs 268.9726. 
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7-Bromo-9H-imidazo[1,2-a]indol-9-ol 182 
Br
N
N
OH
 
To a solution of imidazoleindolone 58 (0.030 g, 0.12 mmol) in MeOH (0.5 mL) and 3 drops of water, 
was added NaBH4 (0.002 g, 0.06 mmol), with stirring at room temperature for 1 hour. The mixture 
was subsequently concentrated in vacuo to give the alcohol 182 as a colourless solid (0.028 g, 92 % 
yield): 1H NMR (400 MHz, DMSO) δ 5.57 (s, 1H), 6.34 (s, 1H), 7.14 (s, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.67 
(m, 2H), 7.75 (m, 1H); 13C NMR (126 MHz, DMSO) δ 65.0, 112.3, 113.2, 117.0, 129.1, 132.1, 133.1, 
136.8, 140.8, 154.7; HRMS (ES) m/z = 250.9820 [M+H]+ found, C10H8BrN2O needs 250.9820. 
(S)-Methyl 5-(2-((2,5-difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluorobenzoate 187a and 
(S)-5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluorobenzoic acid 187b 
S
N
OO O
OR
F
O
F
F
 
Part 1: To a solution of methyl 2-fluorobenzoate 185 (0.38 mL, 3.00 mmol) in DCM (5 mL) was added 
chlorosulfonic acid (1.20 mL, 18.00 mmol), followed by stirring at 70 ᴼC for 12 hours. The reaction 
mixture was cooled to 0 ᴼC, slowly diluted with ice cold water (20 mL) and extracted with DCM (2 x 
10 mL). The organic extract was dried over MgSO4 and concentrated in vacuo to give a mixture of the 
ester and carboxylic acid sulfonyl chloride derivatives 186a/b as a colourless solid. The mixture of 
acid and ester products 186a/b was used in the next step without further purification.  
Part 2: To a solution of amine 108 (HCl salt, 1.14 g, 4.58 mmol) and Et3N (2.02 mL, 14.53 mmol) in 
DCM (40 mL) at 0 ᴼC, was slowly added, a solution of the sulfonyl chloride mixture 186a/b (1.00 g, 
4.10 mmol) in DCM (5 mL). The resulting solution was stirred at room temperature for 1 hour, before 
washing with water (50 mL), drying over MgSO4 and concentrating in vacuo. The residue was purified 
by flash column chromatography, eluting with 1:3 – 1:0 ethyl acetate/ petroleum ether and then with 
0:1 – 1:49 acetic acid/ ethyl acetate to give the ester 187a as a colourless solid (0.41 g, 95% yield) and 
the carboxylic acid 187b as a colourless solid (1.23 g, 95% yield). 
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Ester 187a: 1H NMR (400 MHz, CDCl3) δ 1.75 (m, 2H), 2.06 (m, 2H), 3.17 (m, 1H), 3.54 (m, 1H), 3.96 
(s, 3H), 4.00 (m, 2H), 4.24 (m, 1H), 6.83 (m, 2H), 6.97 (m, 1H), 7.29 (m, 1H), 8.00 (m, 1H), 8.42 (dd, J 
= 2.45 Hz, 6.36 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 24.1, 28.9, 49.5, 52.8, 58.6, 71.6, 104.9 (dd, J = 
21.8 Hz, 26.2 Hz), 110.5 (dd, J = 3.3 Hz, 21.8 Hz), 115.5 (m), 118.3 (d, J = 22.9 Hz), 119.7 (d, J = 10.9 
Hz), 131.9 (br s), 133.5 (d, J = 9.8 Hz), 133.8 (d, J = 3.3 Hz), 143.0 (dd, J = 3.3 Hz, 10.9 Hz), 152.3 (dd, J 
= 12.0 Hz, 249.6 Hz), 156.6 (dd, J = 10.9 Hz, 243.1 Hz), 163.1 (d, J = 4.4 Hz), 164.2 (d, J = 268.1 Hz); 
max/cm-1 2959, 1728 (C=O), 1608, 1514, 1343 (SO2-N), 1258 (C-O), 1105, 839; HRMS (ES) m/z = 
430.0936 [M+H]+ found, C19H19F3NO5S needs 430.0936; Rf = 0.23 (1:4 ethyl acetate/ petroleum 
ether). 
Acid 187b: 1H NMR (400 MHz, DMSO) δ 1.59 (m, 1H), 1.70 (m, 1H), 1.90 (m, 2H), 3.15 (m, 1H), 3.40 
(m, 1H), 3.94 (m, 1H), 4.07 (m, 1H), 4.13 (m, 1H), 7.01 (m, 1H), 7.26 (m, 2H), 7.55 (dd, J = 8.8 Hz, 10.3 
Hz, 1H), 8.12 (m, 1H), 8.23 (br m, 1H), 13.76 (br s, 1H); 13C NMR (126 MHz, DMSO) δ 23.5, 28.3, 49.1, 
58.3, 71.3, 104.7 (dd, J = 22.9 Hz, 27.2 Hz), 110.8 (dd, J = 3.3 Hz, 22.9Hz), 115.6 (br m), 118.7 (d, J = 
24.0 Hz), 120.5 (br m), 131.2 (br s), 133.0 (d, J = 3.3 Hz), 133.3 (d, J = 10.9 Hz), 142.8 (dd, J = 3.3 Hz, 
10.9 Hz), 151.2 (dd, J = 12.0 Hz, 246.3 Hz), 155.6 (dd, J = 10.9 Hz, 239.8 Hz), 163.2 (d, J = 263.8 Hz), 
163.7 (br m); max/cm-1 3000 (O-H), 1706 (C=O), 1604, 1512, 1343, 1167, 837; HRMS (ES) m/z = 
414.0623 [M-H]- found, C18H15F3NO5S needs 414.0623; Rf = 0.56 (1:49 acetic acid/ ethyl acetate) 
1-Trityl-1H-imidazole 190187 
N N
Tr
 
To a solution of imidazole (1.00 g, 14.71 mmol) in DMF (30 mL) at 0 ᴼC was added NaH (60 % in 
mineral oil, 0.71 g, 17.65 mmol), with stirring at 0 ᴼC for 15 minutes. Trityl chloride (5.33 g, 19.12 
mmol) was subsequently added, followed by warming to room temperature and continued stirring 
for 15 hours. The reaction mixture was diluted with ethyl acetate (100 mL), and washed with water 
(100 mL) and brine (3x 100 mL). The organic extract was dried over MgSO4, concentrated in vacuo 
and purified by flash column chromatography, eluting with 1:4 – 1:0 ethyl acetate/ petroleum ether 
to give 1-trityl imidazole 190 as a colourless solid (3.65 g, 80 % yield): 1H NMR (400 MHz, CDCl3) δ 
6.83 (s, 1H), 7.07 (s, 1H), 7.14 (m, 6H), 7.33 (m, 9H), 7.46 (s, 1H); 13C NMR (126 MHz, DMSO) δ 75.2, 
121.7, 128.0, 128.0, 128.3, 129.8, 139.0, 142.5; HRMS (ES) m/z = 311.1548 [M+H]+ found, C22H19N2 
needs 311.1548; Rf = 0.22 (1:1 ethyl acetate/ petroleum ether). 
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(S)-(5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluorophenyl)(1-trityl-1H-imidazol-
2-yl)methanone 191 and (S)-(5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-
methoxyphenyl)(1-trityl-1H-imidazol-2-yl)methanone 192 
S
N
OO O
F
O
F
F
N
N
Tr
           
S
N
OO O
O
O
F
F
N
N
Tr
Me
 
To a solution of N-trityl-imidazole 190 (1.00 g, 3.23 mmol) in THF (30 mL) at -78 ᴼC was added nBuLi 
(2.06 M in hexane, 1.88 mL, 3.88 mmol). After stirring for 10 minutes, a solution of the ester 187a 
(1.38 g, 3.22 mmol) in THF (5 mL) was added and stirring was continued at -78 ᴼC for 15 minutes, 
before allowing to warm to room temperature. The mixture was then diluted with ethyl acetate (20 
mL) and washed with water (30 mL) and brine (10 mL). This was followed by drying over MgSO4 and 
concentration in vacuo. The crude material was purified by flash column chromatography, eluting 
with 1:4 – 2:3 ethyl acetate/ petroleum ether to give the ketone 191 as a colourless foam (0.46 g, 20 
% yield) and the ketone 192 also as a colourless foam (1.25 g, 54 % yield, ~90% pure). 
Ketone 191: 1H NMR (400 MHz, CDCl3) δ 1.72 (m, 2H), 1.97 (m, 2H), 3.08 (m, 1H), 3.52 (m, 1H), 3.95 
(m, 2H), 4.27 (m, 1H), 6.84 (m, 2H), 6.98 (m, 1H), 7.19 (m, 9H), 7.34 (m, 9H), 7.82 (m, 1H), 7.88 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ 24.0, 28.9, 49.5, 58.6, 71.7, 82.0, 104.8 (dd, J = 22.1 Hz, 26.6 Hz), 
110.5 (dd, J = 3.8 Hz, 22.5 Hz), 115.5 (d, J = 9.6 Hz), 117.6 (d, J = 23.0 Hz), 121.3, 125.6 (d, J = 12.9 Hz), 
127.3, 127.9, 128.6, 132.4 (m), 132.6, 132.8 (d, J = 10.0 Hz), 133.2 (m), 143.1 (m), 144.5, 146.8, 152.3 
(dd, J = 11.9 Hz, 249 Hz), 156.5 (dd, J = 10.3 H, 231.7 Hz), 163.3 (d, J = 265.3 Hz), 179.0; HRMS (ES) 
m/z = 730.1979 [M+Na]+ found, C40H32F3N3NaO4S needs 730.1963; Rf = 0.28 (2:3 ethyl acetate/ 
petroleum ether). 
Ketone 192: HRMS (ES) m/z = 742.2156 [M+Na]+ found, C41H35F2N3O5S needs 742.2158. For further 
characterisation, the trityl group was removed, following the procedure outlined below for the 
deprotection of ketone 191 to give 201. For the deprotected derivative of ketone 192: 1H NMR (400 
MHz, CDCl3) δ 1.81 (m, 3H), 2.05 (m, 2H), 3.22 (m, 1H), 3.56 (m, 1H), 3.94 (s, 3H), 4.05 (m, 2H), 6.83 
(m, 2H), 7.03 (m, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.31 (br s, 2H), 8.00 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 8.31 (d, 
J = 2.4 Hz, 1H), 10.72 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 24.0, 28.8, 49.5, 56.3, 58.4, 71.8, 104.7 (m), 
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108.9, 110.4 (dd, J = 22.4 Hz, 3.7 Hz), 111.9, 115.3 (m), 126.6, 128.3, 131.3, 132.3, 143.0 (dd, J = 236.7 
Hz, 10.6 Hz), 144.9, 152.2 (dd, J = 236.7 Hz, 12.0 Hz), 156.4 (dd, J = 231.4 Hz), 161.4, 162.6, 182.1; 
max/cm-1 1655 (C=O), 1596, 1511 (C=N), 1411, 1260 (C-O-C), 1140; HRMS (ES) m/z = 478.1243 [M+H]+ 
found, C22H22F2N3O5S needs 478.1243. 
 (2-Fluorophenyl)(1-trityl-1H-imidazol-2-yl)methanone 196 
O
F
N
N
Tr
 
To a solution of 1-trityl imidazole 190 (2.03 g, 6.55 mmol) in THF (150 mL) at -78 ᴼC was added nBuLi 
(2.06 M in hexane, 3.50 mL, 7.21 mmol) with stirring for 15 minutes. A solution of the ester 185 (1.00 
mL, 7.86 mmol) in THF (10 mL) was added dropwise, maintaining the temperature at -78 ᴼC. Stirring 
was continued at -78 ᴼC for 30 minutes before warming to room temperature. The mixture was 
washed with water (100 mL) and brine (50 mL), dried over MgSO4 and concentrated in vacuo. 
Purification by flash column chromatography, eluting with 1:4 ethyl acetate/ petroleum ether gave 
the corresponding N-trityl protected ketone product 196 as a colourless foam (1.89 g, 67 % yield); 1H 
NMR (400 MHz, CDCl3) δ 7.01 (m, 1H), 7.11 (m, 1H), 7.18 (m, 1H), 7.28 (m, 16H), 7.40 (m, 2H); 13C 
NMR (101 MHz, CDCl3) δ 77.7, 116.0, 123.6 (m), 127.4, 127.6, 127.8, 127.8, 128.1, 130.0, 130.6 (m), 
132.7 (d, J = 8.6 Hz), 142.5, 145.3, 160.0 (d, J = 252.6 Hz), 180.3. 
The resulting N-trityl ketone 196 (1.50 g, 3.47 mmol) was dissolved in 1,4-dioxane (10 mL), treated 
with 10 % aqueous HCl solution (1 mL) and stirred at 70 ᴼC for 4 hours. The mixture was then made 
basic with saturated aqueous NaHCO3 solution (pH ~8), re-acidified with solid citric acid (pH ~5) and 
extracted with DCM (2 x 200 mL). The combined organic extract was dried over MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography, eluting with 1:4 – 1:1 ethyl 
acetate/ petroleum ether gave the deprotected ketone as a colourless solid (0.64 g, 97 % yield): 1H 
NMR (400 MHz, CDCl3) δ 7.22 (m, 1H), 7.33 (m, 2H), 7.42 (br s, 1H), 7.57 (m, 1H), 8.10 (td, J = 1.5 Hz, 
7.3 Hz, 1H), 10.93 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 116.5 (d, J = 21.4 Hz), 120.7, 123.9 (m), 125.0 
(d, J = 11.8 Hz), 132.0 (br s), 132.3 (br s), 133.9 (d, J = 8.8 Hz), 145.0, 161.0 (d, J = 256.5 Hz), 181.3; 
max/cm-1 1653 (C=O), 1608 (C=N), 1452, 1394, 899; HRMS (ES) m/z = 191.0621 [M+H]+ found, 
C10H8FN2O needs 191.0621. 
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(S)-5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluoro-N-methoxy-N-
methylbenzamide 197 
N
O
F
S
O O
N
O
F
F
O
 
The acid chloride 188 was initially prepared by the treatment of 2-fluorobenzoic acid 187a (0.15 g, 
0.36 mmol) with thionyl chloride (2 mL) and refluxing for 3 hours. Subsequent concentration in vacuo, 
azeotroping with toluene gave the acid chloride 188.  
To a solution of the resulting acid chloride 188 in DCM (2 mL), was added N,O-dimethylhydroxylamine 
hydrochloride (0.033 g, 0.34 mmol) and the mixture was cooled to 0 ᴼC. This was followed by the 
dropwise addition of pyridine (0.06 mL, 0.72 mmol), before warming to room temperature and 
stirring for a further 30 minutes. The reaction mixture was then diluted with DCM (10 mL) and washed 
with water (10 mL) and 10 % aqueous citric acid solution (3 x 20 mL). After drying over MgSO4 and 
concentrating in vacuo, the resulting residue was purified by flash column chromatography, eluting 
with 1:9 – 1:1 ethyl acetate/ petroleum ether to give the Weinreb amide 197 as colourless oil (0.135 
g, 82 % yield): 1H NMR (400 MHz, CDCl3) δ 1.76 (m, 2H), 2.06 (m, 2H), 2.39 (br s, 1H), 3.17 (m, 1H), 
3.40 (br s, 3H), 3.54 (br m, 3H), 4.01 (m, 2H), 4.29 (m, 1H), 6.86 (m, 2H), 7.01 (m, 1H), 7.22 (m, 1H), 
7.94 (m, 1H), 7.98 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 21.5, 24.0, 28.9, 49.5, 58.6, 61.5, 71.8, 105.1 
(dd, J = 22.4, 26.7 Hz), 110.6 (m), 115.6 (m), 116.8 (d, J = 22.4 Hz), 124.6 (d, J = 19.0 Hz), 125.3, 128.2, 
129.0 (m), 130.9 (br m), 143.1 (m), 152.3 (dd, J = 11.2, 250.0 Hz), 156.5 (dd, J = 10.3, 241.4 Hz), 161.3 
(d, J = 257.8 Hz); HRMS (ES) m/z = 459.1195 [M+H]+ found, C20H22F3N2O5S needs 459.1196. 
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(S)-Perfluorophenyl 5-(2-((2,5-difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluorobenzoate 
200 
O
O
F
S
O O
N
O
F
F
F
F
F
F
F
 
The acid chloride 188 was initially prepared by the treatment of 2-fluorobenzoic acid 187a (0.12 g, 
0.29 mmol) with thionyl chloride (2 mL) and refluxing for 3 hours. Subsequent concentration in vacuo, 
azeotroping with toluene gave the acid chloride 188.  
To a solution of the acid chloride 188 in DCM (2 mL) was added pentafluorophenol (0.053 g, 0.29 
mmol) and pyridine (0.03 mL, 0.38 mmol), with stirring at room temperature for 1 hour. The reaction 
mixture was then diluted with DCM (10 mL), washed with water (10 mL) and dried over MgSO4. After 
concentration in vacuo,  the crude material was purified by flash column chromatography, eluting 
with 1:4 ethyl acetate/ petroleum ether to give the pentafluorophenyl ester 200 as pale yellow oil 
(0.115 g, 68 % yield): 1H NMR (400 MHz, CDCl3) δ 1.85 (m, 2H), 2.12 (m, 2H), 3.25 (m, 1H), 3.56 (m, 
1H), 4.06 (m, 2H), 4.24 (m, 1H), 6.81 (m, 2H), 6.96 (m, 1H), 7.41 (t, J = 9.8 Hz, 1H), 8.17 (m, 1H), 8.61 
(dd, J = 2.4 Hz, 6.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 24.2, 29.0, 49.5, 58.7, 71.4, 104.9 (dd, J = 21.7 
Hz, 26.3 Hz), 110.5 (dd, J = 4.0 Hz, 22.5 Hz), 115.4 (m), 116.5 (d, J = 10.5 Hz), 118.8 (d, J = 23.1 Hz), 
124.6 (m), 132.4, 135.0 (d, J = 3.7 Hz), 135.3 (d, J = 10.1 Hz), 138.0 (m), 139.9 (m), 141.2 (m), 142.9 
(dd, J = 3.0 Hz, 11.1 Hz), 152.3 (dd, J = 10.1 Hz, 249.5 Hz), 156.7 (dd, J = 11.1 Hz, 243.4 Hz), 158.5 (m), 
164.6 (d, J = 272. 7 Hz); 19F NMR (471 MHZ, CDCl3) δ -161.9, -157.0, -152.3, -130.1, -119.7, -99.1; 
max/cm-1 1756 (C=O), 1611, 1516 (C-F), 1351 (C-O ester); HRMS (ES) m/z = 582.0621 [M+H]+ found, 
C24H16F8NO5S needs 582.0621.   
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(S)-(5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-fluorophenyl)(1H-imidazol-2-
yl)methanone 201 
S
N
OO O
F
O
F
F
N
N
H
 
To a solution of N-trityl protected ketone 191 (0.22 g, 0.31 mmol) in 1,4-dioxane (1.0 mL) was added 
10 % aqueous HCl (1 mL) and the solution was stirred at 70 ᴼC for 2 hours. After cooling to room 
temperature, the reaction mixture was made basic with saturated aqueous NaHCO3 solution (~pH 8), 
re-acidified with solid citric acid (pH ~5) and extracted with DCM (2 x 10 mL). The combined organic 
extract was dried over MgSO4 and concentrated in vacuo. The crude mixture was recrystallised from 
ethyl acetate/ petroleum ether mixture to give the deprotected ketone 201 as a colourless solid (0.10 
g, 70 % yield): 1H NMR (400 MHz, CDCl3) δ 1.92 (m, 2H), 2.10 (m, 2H), 3.25 (m, 1H), 3.60 (m, 1H), 4.03 
(m, 1H), 4.11 (m, 1H), 4.33 (dd, J = 2.9 Hz, 9.3 Hz, 1H), 6.79 (m, 1H), 6.87 (m, 1H), 7.02 (m, 1H), 7.36 
(m, 3H), 8.06 (m, 1H), 8.67 (dd, J = 2.4 Hz, 6.4 Hz, 1H), 10.57 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 24.0, 
28.9, 49.5, 58.6, 71.8, 104.8 (dd, J = 21.8 Hz, 26.2 Hz), 110.4 (dd, J = 4.4 Hz, 22.9 Hz), 115.5 (m), 117.6 
(d, J = 22.9 Hz), 121.2, 125.5 (d, J = 13.1 Hz), 127.9, 132.4 (m), 132.9 (d, J = 10.9 Hz), 133.2 (br m), 
143.0 (dd, J = 3.3 Hz, 10.9 Hz), 144.5, 152.6 (dd, J = 12.0 Hz, 248.5 Hz), 156.5 (dd, J = 9.8 Hz, 242.0 Hz) 
163.5 (d, J = 266.0 Hz), 179.0; max/cm-1 3114 (N-H), 1668 (C=O), 1606 (C=N), 1514, 1394, 1260, 1211 
(C-O), 1148; HRMS (ES) m/z = 466.1048 [M+H]+ found, C21H19F3N3O4S needs 466.1048; Rf = 0.33 (1:1 
ethyl acetate/ petroleum ether). 
 
(5-Chloro-2-fluorophenyl)(1H-1,2,4-triazol-5-yl)methanone 203 
Cl
O
F
N
N
H
N
 
To a solution of N-trityl protected ketone 205 (1.00 g, 2.14 mmol) in 1,4-dioxane (20 mL) was added 
10 % aqueous HCl (5 mL) and the resulting solution was stirred at 70 ᴼC for 4 hours. After cooling to 
room temperature, the mixture was made basic with saturated aqueous NaHCO3 solution (pH ~8), 
re-acidified with solid citric acid (pH 4) and extracted with ethyl acetate (3 x 20 mL). The combined 
organic extract was dried over MgSO4 and concentrated in vacuo. The crude mixture was 
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recrystallised from ethyl acetate/ petroleum ether mixture to give the product 203 as a colourless 
foam (0.35 g, 73 % yield): 1H NMR (400 MHz, DMSO) δ 7.44 (t, J = 9.3 Hz, 1H), 7.73 (m, 1H), 7.87 (m, 
1H), 8.75 (s, 1H), 14.91 (s, 1H); 13C NMR (126 MHz, DMSO) δ 118.2 (d, J = 24.0 Hz), 127.7 (d, J = 15.6 
Hz), 128.0 (d, J = 3.3 Hz), 130.5, 133.4 (d, J = 8.7 Hz), 146.3, 158.0 (d, J = 254.0 Hz), 158.3, 182.1; 
max/cm-1 1680 (C=O), 1489, 1431, 1240, 1197; HRMS (CI) m/z = 243.0449 [M+NH4]+ found, 
C9H9ClFN4Oneeds 243.0449; Rf = 0.12 (1:1 ethyl acetate/ petroleum ether). 
1-Trityl-1H-1,2,4-triazole 204211  
N N
N
Tr  
To a solution of 1,2,4-triazole (1.00 g, 14.49 mmol) and trityl chloride (5.66 g, 20.29 mmol) in THF (50 
mL) was added DBU (2.6 mL, 17.39 mmol) and the mixture was stirred at room temperature for 5 
hours. The resulting suspension was dissolved in DCM (80 mL) and washed with water (100 mL) and 
brine (50 mL). The organic extract was subsequently dried over MgSO4 and concentrated in vacuo. 
Purification of the resulting residue by flash column chromatography, eluting with 1:4 – 1:1 ethyl 
acetate/ petroleum ether gave N-trityl triazole 204 as a colourless solid (3.17 g, 91 % yield): 1H NMR 
(400 MHz, CDCl3) δ 7.15 (m 6H), 7.35 (m, 9H), 8.03 (s, 1H), 8.08 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
78.1, 128.0, 128.3, 129.9, 141.9, 145.7, 151.8; HRMS (CI) m/z = 311.1422 [M]+ found, C21H17N3 needs 
311.1422; Rf = 0.10 (1:4 ethyl acetate/ petroleum ether). 
(5-Chloro-2-fluorophenyl)(1-trityl-1H-1,2,4-triazol-5-yl)methanone 205 
Cl
O
F
N
N
N
Tr
 
To a solution of 1-trityl triazole 204 (1.50 g, 4.82 mmol) in THF (50 mL) at -78 ᴼC was added nBuLi 
(2.08 M in hexane, 3.00 mL, 6.27 mmol) and the mixture was stirred for 15 minutes. A solution of the 
ester 153 (1.09 g, 5.78 mmol) in THF (5 mL) was added and stirring was continued at -78 ᴼC for 30 
minutes. After warming to room temperature, the reaction mixture was washed with water (30 mL) 
and brine (15 mL), dried over MgSO4 and concentrated in vacuo. The residue was recrystallised from 
ethyl acetate/ petroleum ether mixture to give the N-trityl ketone 205 as a colourless solid (1.40 g, 
62 % yield): 1H NMR (400 MHz, CDCl3) δ 7.03 (m, 1H), 7.23 (m, 6H), 7.29 (m, 9H). 7.48 (m, 2H), 8.05 
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(s, 1H); 13C NMR (101 MHz, CDCl3) δ 80.4, 118.0 (d, J = 25.0 Hz), 125.6 (d, J = 12.1 Hz), 127.7, 128.1, 
129.7 (d, J = 2.6 Hz), 130.5, 130.7, 135.0 (d, J = 8.6 Hz), 141.7, 149.1, 152.6, 159.8 (d, J = 258.6 Hz), 
179.1; max/cm-1 1673 (C=O), 1600, 1479, 1443, 1256, 1224, 748; HRMS (CI) m/z = 467.1201 [M]+ 
found, C28H19ClFN3O needs 467.1201; Rf = 0.30 (1:4 ethyl acetate/ petroleum ether). 
1-(4-Chlorophenyl)-1H-1,2,4-triazole 207 
N
N
N
Cl
 
A mixture of phenyl-triazole ketone 203 (0.03 g, 0.13 mmol) and K2CO3 (0.03 g, 0.22 mmol) in DMF 
(2 mL) was irradiated in a microwave at 180 ᴼC for 20 minutes. After cooling to room temperature, 
the mixture was diluted with ethyl acetate (5 mL) and, washed with water (2 x 5 mL) and brine (3 x 5 
mL). The organic extract was dried over MgSO4 and concentrated in vacuo. Purification of the residue 
by flash column chromatography, eluting with 1:1 – 7:3 ethyl acetate/ petroleum ether gave the 1-
phenyl triazole 207 as a colourless solid (0.016 g, 68 % yield): 1H NMR (400 MHz, CDCl3) δ 7.52 (m, 
2H), 7.67 (m, 2H), 8.14 (s, 1H), 8.57 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 121.3, 130.0, 134.0, 135.5, 
140.8, 152.8; max/cm-1 3130, 1512, 1274, 1154, 1094, 823; MS (CI) m/z = 180 [M+H]+. 
(2-Fluorophenyl)(1H-1,2,4-triazol-5-yl)methanone 208 
F
N
N
N
HO
 
To a solution of 1-trityl triazole 204 (5.00 g, 16.08 mmol) in THF (100 mL) at -78 ᴼC was added nBuLi 
(2.06 M in hexane, 8.58 mL, 17.68 mmol) and the mixture was stirred for 15 minutes. This was 
followed by the dropwise addition of a solution of the ester 185 (2.46 ml, 19.29 mmol) in THF (10 
mL), maintaining the temperature below -70 ᴼC. Stirring was continued at -78 ᴼC for 30 minutes 
before warming to room temperature. The mixture was subsequently washed with water (30 mL) 
and brine (20 mL), dried over MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography, eluting with 1:5 – 1:1 ethyl acetate/ petroleum ether gave the corresponding N-
trityl protected ketone as a colourless solid (5.20 g, 75 % yield): 1H NMR (400 MHz, CDCl3) δ 7.05 (m, 
1H), 7.14 (t, J = 8.0 Hz, 1H), 7.26 (m, 15H), 7.55 (m, 2H), 8.05 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 
80.3, 116.5 (d, J = 20.7 Hz), 124.1 (br m), 124.4 (d, J = 9.8 Hz), 127.7, 128.0, 130.6, 131.2, 135.4 (d, J = 
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8.7 Hz), 141.9, 149.1, 153.3, 161.5 (d, J = 257.2 Hz), 180.5; HRMS (CI) m/z = 433.1590 [M]+ found, 
C28H20FN3O needs 433.1590; Rf = 0.21 (1:5 ethyl acetate/ petroleum ether). 
The resulting N-trityl protected ketone (0.56 g, 1.29 mmol) was dissolved in 1,4-dioxane (10 mL), 
treated with 10 % aqueous HCl (3 mL) and stirred at 70 ᴼC for 4 hours. After cooling to room 
temperature, the mixture was made basic with saturated aqueous NaHCO3 solution (pH ~8), re-
acidified with solid citric acid (pH ~5) and extracted with ethyl acetate (3 x 10 mL). The combined 
organic extract was dried over MgSO4 and concentrated in vacuo. Recrystallisation from ethyl 
acetate/ petroleum ether mixture gave the deprotected ketone 208 as a colourless solid (0.19 g, 77 
% yield): 1H NMR (400 MHz, DMSO) δ 7.37 (m, 2H), 7.70 (m, 1H), 7.79 (m, 1H), 8.75 (s, 1H), 14.85 (s, 
1H); 13C NMR (126 MHz, DMSO) δ 116.3 (d, J = 20.7 Hz), 124.4 (d, J =2.5 Hz), 126.4 (d, J = 13.1 Hz), 
131.2, 134.3 (d, J = 8.7 Hz), 146.3, 158.6, 160.1 (d, J = 251.8 Hz), 183.9; max/cm-1 1723 (C=O), 1624, 
1458, 1340, 1199, 1154; HRMS (CI) m/z = 192.0573 [M+H]+ found, C9H7FN3O needs 192.0573; Rf = 
0.15 (1:1 ethyl acetate/ petroleum ether). 
5-(2-(5-Chloro-2-fluorophenyl)-1,3-dioxolan-2-yl)-1H-1,2,4-triazole 209 
N
N
N
F
H
Cl
OO
 
To a suspension of the phenyl-triazole ketone 203 (0.52 g, 2.32 mmol) and ethylene glycol (1.29 mL, 
23.20 mmol) in toluene (20 mL) was added p-toluenesulfonic acid (0.05 g, 0.58 mmol) and the mixture 
was refluxed for 12 hours, collecting water with a Dean Stark trap. After cooling to room temperature, 
the mixture was washed with water (20 mL), dried over MgSO4 and concentration in vacuo. The crude 
residue was purified by flash column chromatography, eluting with 1:49 MeOH/ DCM to give the 
ketal 209 as a colourless solid (0.35 g, 50 % yield): 1H NMR (400 MHz, DMSO) δ 4.08 (m, 2H), 4.25 (m, 
2H), 7.23 (t, J = 9.3 Hz, 1H), 7.52 (m, 1H), 7.63 (m, 1H), 8.43 (s, 1H), 14.05 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 66.0, 102.9, 117.7 (d, J =  23.2 Hz), 127.6 (d, J = 4.0 Hz), 128.2 (m), 129.3 (m), 131.0 (d, J = 8.1 
Hz), 157.9, 158.7, 158.8 (d, J = 251.5 Hz); max/cm-1 3088 (N-H), 1480 (C=N), 1371, 1207 (O-C-O), 1133, 
1182; HRMS (ES) m/z = 270.0446 [M+H]+ found, C11H10ClFN3O2 needs 270.0446; Rf = 0.12 (1:1 ethyl 
acetate/ petroleum ether). 
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7-Chlorospiro[[1,2,4]triazolo[1,5-a]indole-9,2'-[1,3]dioxolane] 212 
N
N
N
O
O
Cl
 
To a solution of the ketal 209 (0.10 g, 0.37 mmol) in DMA (30 mL) was added Cs2CO3 (0.37 g, 1.12 
mmol) and the suspension was irradiated in a microwave at 180 ᴼC for 35 minutes. The mixture was 
allowed to cool to room temperature before diluting with ethyl acetate (50 mL) and washing with 
water (50 mL) and brine (3 x 80 mL). The combined organic extract was dried over MgSO4 and 
concentrated in vacuo. The resulting residue was purified by reverse phase prep HPLC, using a Waters 
600 controller binary pump; phenomenex Luna 5μ C18 (2), 100Å, 75 x 30 mm column and a waters 
2487 detector, measuring absorption at 254 nm. A mobile phase of 70 % aqueous formic acid (0.1 M) 
and 30 % acetonitrile with a flow rate of 9 mL/min and 50 minute run time were utilised. The cyclised 
product 212 was obtained as a colourless solid (0.032 g, 35 % yield): 1H NMR (400 MHz, CDCl3) δ 4.45 
(m, 2H), 4.57 (m, 2H), 7.46 (d, J = 8.3 Hz, 1H), 7.50 (dd, J = 2.0, 8.3 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1 H), 
8.07 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 66.0, 102.2, 112.4, 126.4, 131.7, 132.7, 135.5, 136.1, 156.1, 
160.2; HRMS (ES) m/z = 250.0383 [M+H]+ found, C11H9ClN3O2 needs 250.0383. 
Crystal structure was used to determine the regiochemistry of the ketal 212 as the regioisomer drawn 
above, and shown below in the image generated from crystal structure analysis. Crystals used for the 
study was prepared by dissolving the ketal 212 in ethyl acetate with slow solvent evaporation over 4 
days. All crystal data and structure refinement data can be found in the appendix.   
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The crystal structure of ketal-protected triazoleindolone 212 
5-(2-Fluorobenzyl)-1H-1,2,4-triazole 215a 
N
N
N
F
H
 
A solution of the phenyl-triazole ketone 208 (0.05 g, 0.22 mmol) in hydrazine monohydrate (1 mL) 
was irradiated in a microwave at 180 ᴼC for 1 hour. The mixture was allowed to cool to room 
temperature, diluted with ethyl acetate (5 mL) and washed with water (5 mL). The organic layer was 
dried over MgSO4 and concentrated in vacuo, followed by purification by flash column 
chromatography, eluting with 1:1 ethyl acetate/ petroleum ether to give the product 215a as a 
colourless solid (0.021 g, 55 %): 1H NMR (400 MHz, CDCl3) δ 4.24 (s, 2H), 7.15 (m, 3H), 7.35 (m, 2H), 
8.05 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 26.9, 115.6 (d, J = 22.5 Hz), 123.6 (d, J = 15.6 Hz), 124.5 (d, 
J = 3.5 Hz), 129.1 (d, J = 8.7 Hz), 131.1 (m), 147.8, 157.8, 161.0 (d, J = 246.2 Hz); MS (CI) m/z = 178 
[M+H]+; Rf = 0.12 (1:4 ethyl acetate/ petroleum ether).  
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7-Chloro-9-hydrazono-9H-[1,2,4]triazolo[4,3-a]indole 216 
N
N
N
N
Cl
NH2
 
A solution of the phenyl-triazole ketone 205 (0.05 g, 0.22 mmol) and KOH (0.04 g, 0.66 mmol) in 
hydrazine monohydrate (1 mL) was irradiated in a microwave at 180 ᴼC for 30 minutes. After cooling 
to room temperature, the mixture was diluted with water (1 mL) and extracted with DCM (2 x 5 mL). 
The aqueous layer was left to stand overnight and the resulting precipitated was collected by 
filtration. The precipitate was then washed with water (5 mL) and ethyl acetate (5 mL) to give the 
hydrazone 216 as a pale yellow solid (0.023 g, 48 % yield): 1H NMR (400 MHz, DMSO) δ 7.46 (dd, J = 
2.0 Hz, 8.8 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.48 (s, 1H), 13.67 (s, 2H); 13C NMR 
(101 MHz, CDCl3) δ 112.5, 120.4, 121.5, 125.8, 128.9, 134.8, 139.5, 147.5, 153.1; HRMS (ES) m/z = 
220.0390 [M+H]+ found, C9H7ClN5 needs 220.0390. 
(S)-(5-(2-((2,5-Difluorophenoxy)methyl)pyrrolidin-1-ylsulfonyl)-2-methoxyphenyl)(1-trityl-1H-1,2,4-
triazol-5-yl)methanone 222 
S
N
OO O
O
O
F
F
N
N
N
Tr
Me
 
To a solution of N-trityltriazole 204 (0.09 g, 0.29 mmol) in THF (3 mL) at -78 ᴼC, was added nBuLi (2.06 
M in hexane, 0.14 mL, 0.29 mmol) and the mixture was stirred for 10 minutes. A precooled solution 
of ester 187a (0.15 g, 0.35 mmol) in THF (0.5 mL) was added and stirring was continued at -78 ᴼC for 
15 minutes. This was followed by warming to room temperature and diluting with ethyl acetate (10 
mL), washing with water (5 mL) and brine (5 mL). Subsequent drying over MgSO4 and concentration 
in vacuo gave a residue which was purified by flash column chromatography, eluting with 1:4 – 2:3 
ethyl acetate/ petroleum ether to give ketone 222 as a colourless solid (0.13 g, 62 % yield): 1H NMR 
(400 MHz, DMSO) δ 1.7 (m, 2H), 2.03 (m, 2H), 3.07 (m, 1H), 3.51 (m, 1H), 3.81 (s, 3H), 3.92 (m, 2H), 
4.27 (m, 1H), 6.84 (m, 2H), 7.01 (m, 2H), 7.27 (m, 15H), 7.94 (m, 2H), 8.01 (s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 24.0, 28.9, 49.5, 56.2, 58.4, 71.8, 80.4, 104.9 (dd, J = 27.0 Hz, 22.1 Hz), 110.5 (m), 112.5, 
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115.5 (d, J = 10.8 Hz), 126.0, 127.7, 128.0, 129.3, 130.5, 130.9, 133.7, 141.9, 143.2 (m), 149.0, 152.2 
(m), 153.6, 156.3 (dd, J = 145 Hz, 9.6 Hz), 161.8, 180.9; max/cm-1 2923, 1682 (C=O), 1595, 1511 (C=N), 
1443, 1260 (C-O-C), 1140; HRMS (ES) m/z = 743.2110 [M+Na]+ found, C40H34F2N4O5S needs 743.2110; 
Rf = 0.24 (1:1 ethyl acetate/ petroleum ether).  
2-(1H-Imidazol-1-yl)benzonitrile 226212 
CN
N N
 
To a solution of imidazole (0.25 g, 3.68 mmol) and Cs2CO3 (3.00 g, 9.20 mmol) in anhydrous DMF (30 
mL) at room temperature, was added 2-fluorobenzonitrile (0.40 mL, 3.68 mmol) and the mixture was 
stirred at 100 ᴼC for 3 hours. After cooling to room temperature, the reaction mixture was diluted 
with ethyl acetate (30 mL), and washed with water (2 x 20 mL) and brine (3 x 60 mL). The combined 
organic extract was dried over MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography, eluting with ethyl acetate gave product 226 as a colourless solid (0.46 g, 74 % yield): 
1H NMR (400 MHz, CDCl3): 7.31 (br m, 1H), 7.40 (br m, 1H), 7.51 (br d, J = 7.5 Hz, 1H), 7.57 (br td, J = 
1.0 Hz, 7.5 Hz, 1H), 7.78 (br td, J = 1.6 Hz, 8.0 Hz 1H), 7.86 (br dd, J = 1.4 Hz, 7.8 Hz, 1H), 7.90 (s, 1H); 
13C NMR (101 MHz, CDCl3) δ 108.1, 115.9, 119.7, 125.7, 128.5, 130.8, 134.4, 134.6, 136.7, 139.4; 
max/cm-1 2230 (C≡N), 1600, 1506 (C=N), 1304, 1256; HRMS (CI) m/z = 170.0718 [M+H]+ found, 
C10H8N3 needs 170.0718. 
1-Phenyl-1H-imidazole 229202 
N
N  
A mixture of imidazole (1.08 g, 10.59 mmol), iodobenzene 225 (1.18 mL, 10.59 mmol), Cu(I) oxide 
(0.15 g, 1.06 mmol) and KOH (1.19 g, 21.18 mmol) in DMSO (20 mL) was stirred at 110 ᴼC for 24 hours. 
This was followed by cooling to room temperature and filtration through Celite®. The filtrate was 
diluted with ethyl acetate (40 mL), and washed with water (20 mL) and brine (3 x 60 mL), with 
subsequent drying over MgSO4 and concentration in vacuo. Purification by flash column 
chromatography, eluting with ethyl acetate gave the 1-phenylimidazole 229 as a pale yellow oil (1.22 
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g, 80 % yield): 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 1H), 7.32 (s, 1H), 7.40 (m, 3H), 7.51 (m, 2H), 7.89 
(s, 1H); 13C NMR (101 MHz, CDCl3) δ 118.3, 121.5, 127.5, 129.9, 130.4, 135.6, 137.4; max/cm-1 3355, 
3115, 1598, 1505 (C=N), 1303, 1247, 1056; HRMS (EI) m/z = 144.0687 [M]+ found, C9H8N2 needs 
144.0687; Rf = 0.20 (1:49 MeOH/ ethyl acetate). 
Methyl 1-phenyl-1H-imidazole-2-carboxylate 230 and Bis(1-phenyl-1H-imidazol-2-yl)methanone 
231 
N
N
OMe
O
      
N
N
O
N
N
 
To a solution of 1-phenylimidazole 229 (0.50 g, 3.47 mmol) in THF (7 mL) at -78 ᴼC was added nBuLi 
(1.6 M in hexane, 2.39 mL, 3.82 mmol). After stirring for 10 minutes, the resulting solution of 
deprotonated 1-phenylimidazole 229 was added to a precooled solution of methyl chloroformate 
(0.30 mL, 3.82 mmol) at -78 ᴼC, with stirring continued for 30 minutes before warming to room 
temperature. The mixture was washed with water (5 mL) and brine (5 mL), dried over MgSO4 and 
concentrated in vacuo. The obtained residue was purified by flash column chromatography, eluting 
with 0:1 – 1:49 MeOH/ ethyl acetate to give the ester 230 as a colourless solid (0.42 g, 60 % yield), 
and ketone 231 as a colourless solid (0.01 g, 9 % yield). 
Ester 230: 1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H), 7.23 (d, J = 1.0 Hz, 1H), 7.31 (d, J = 1.0 Hz, 1H), 
7.36 (m, 2H), 7.51 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 52.3, 126.1, 126.6, 129.0, 129.1, 130.0, 136.8, 
138.0, 158.8; HRMS (CI) m/z = 203.0821 [M+H]+ found, C11H11N2O2 needs 203.0812; Rf = 0.30 (ethyl 
acetate). 
Ketone 231: 1H NMR (400 MHz, CDCl3) δ 7.33 (m, 2H), 7.40 (m, 4H), 7.45 (br s, 1H); 13C NMR (101 
MHz, CDCl3) δ 125.3, 126.4, 128.5, 129.2, 130.8, 137.9, 143.3, 173.0; max/cm-1 3092, 1647 (C=O), 
1494, 1412 (C=N), 1309; HRMS, (EI) m/z = 314.1168 [M]+ found, C19H14N4O needs 314.1168. 
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4-Phenyl-4H-1,2,4-triazole 241206 
N
N N  
A mixture of aniline (0.44 g, 4.77 mmol) and azine salt 243 (1.00 g, 4.77 mmol) in benzene (10 mL) 
was heated to reflux for 5.5 hours, followed by cooling to room temperature and concentration in 
vacuo. The resulting residue was dissolved in 3:1 chloroform/ iso-propanol mixture (30 mL) and 
washed with water (10 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. 
Purification of the residue by flash column chromatography, eluting with ethyl acetate gave the 
product 241 as a colourless solid (0.50 g, 74 % yield): 1H NMR (400 MHz, CDCl3) δ 7.43 (m, 2H), 7.52 
(m, 1H), 7.59 (m, 2H), 8.51 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 122.3, 129.1, 130.4, 133.9, 141.5; 
max/cm-1 3120 (C=N), 1658, 1592, 1519 (C=N), 1222, 1093; HRMS (EI) m/z = 145.0640 [M]+ found, 
C8H7N3 needs 145.0640; Rf = 0.22 (ethyl acetate). 
N'-((Dimethylamino)methylene)-N,N-dimethylformohydrazonamide 243206 
N N NN
.2HCl
 
Thionyl chloride (9.53 mL, 133.00 mmol) was added, with stirring to anhydrous DMF (50 mL) at 0 ᴼC. 
The mixture was allowed to warm to room temperature and stirred for 24 hours. Then, aqueous 
hydrazine (1.67 mL, 33.00 mmol) was added and stirring was continued at room temperature for 2 
days. The resulting precipitate was collected by filtration and washed with DMF (5 mL) and diethyl 
ether (20 mL) to give the azine 243 as a colourless solid (2HCl salt, 6.03 g, 85 % yield, ~90 % purity): 
1H NMR (400 MHz, DMSO) δ 3.02 (s, 12H), 8.35 (s, 2H); 13C NMR (101 MHz, DMSO) δ 34.4, 163.5; 
max/cm-1 2939 – 2459 (-NH2+), 1702 (C=N), 1503, 1298; HRMS (ES) m/z = 143.1297 [M+H]+ found, 
C6H15N4 needs 143.1297.  
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Methyl 4-phenyl-4H-1,2,4-triazole-3-carboxylate 245213 and Methyl cyano(phenyl)carbamate 246 
N
N N
OMe
O
     
N O
OMe
N
 
To a solution of 1-phenyltriazole 241 (0.20 g, 1.38 mmol) in THF (3 mL) at -78 ᴼC was added nBuLi (1.6 
M in hexane, 0.86 mL, 1.38 mmol). After stirring for 15 minutes, methyl chloroformate (0.11 mL, 1.38 
mmol) was added and stirring was continued at -78 ᴼC for 30 minutes, before warming to room 
temperature. The mixture was diluted with ethyl acetate (10 mL) and washed with water (5 mL) and 
brine (5 mL). The organic extract was dried over MgSO4 and concentrated in vacuo. The resulting 
residue was purified by flash column chromatography, eluting with ethyl acetate to give ester 245 as 
colourless solid (0.07 g, 25 % yield) and carbamate 246 as a colourless solid (0.13 g, 54 % yield).  
Ester 245: 1H NMR (400 MHz, CDCl3) δ 3.96 (s, 3H), 7.37 (m, 2H), 7.58 (m, 3H), 8.38 (s, 1H); 13C NMR 
(101 MHz, CDCl3) δ 53.0, 125.9, 129.5, 130.1, 133.8, 145.0, 146.4, 157.5; max/cm-1 1729 (C=O), 1598, 
1510, 1471, 1268, 1146; HRMS (CI) m/z = 204.0766 [M+H]+ found, C10H10N3O2 needs 204.0768.  
Carbamate 246: 1H NMR (400 MHz, CDCl3) δ 4.01 (s, 3H), 7.48 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 
53.3, 126.5, 129.2, 130.3, 134.1, 147.5, 156.9; max/cm-1 2247 (C≡N), 1761 (C=O), 1493, 1493, 1257 
(C-O ester); HRMS (CI) m/z = 194.0930 [M+NH4]+ found, C9H8N2O2 needs 194.0930.   
UV-Vis Equilibria Studies 
10 mL of 1mM or 2 mM of ketone stock solutions in dry DMSO were prepared in flasks, degassed and 
stored under nitrogen. 2 mL of 300 mM and 600 mM of PMBSH solutions in dry DMSO were prepared 
in stoppered vials, degassed and stored under nitrogen. 
3 mL of 1 mM or 2 mM ketone stock solution was syringed into a stoppered cuvette under nitrogen. 
This was titrated with 10 μL aliquots of 300 mM PMBSH stock solution for 1 mM ketone solution or 
600 mM PMBSH solution for 2 mM ketone solutions. After each 10 μL aliquot injection, the cuvette 
was shaken to mix and allowed to stand for 15 minutes, before measuring and recording the UV-vis 
absorption.  
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General Radiochemistry  
Click Radiolabelling Procedure 
Part 1: To a Wheaton vial containing an aqueous solution of K2CO3 (50 µL, 1.00 mg), K222 (5.00 mg) 
and acetonitrile (600 µL), was added an aqueous solution of [18F]fluoride (50 -100 µL, < 20 mCi). The 
mixture was dried by azeotropic distillation using acetonitrile (3 x 600 µL). Then, a solution of 
tosylethylazide (1.5 µL) in acetonitrile (250 µL) was added to the vial and the resulting mixture was 
stirred at 80 oC for 15 minutes. The product [18F]fluoroethylazide 37 was then purified by distillation 
using a thermospray. 
Part 2: A buffered solution (sodium phosphate buffer, pH 6.0, 250 mM) of sodium L-ascorbate (25 
µL, pH 6.0, 2.53 mg, 12.79 µmol) was added to a Wheaton vial containing an aqueous solution of 
CuSO4 (25 µL, 0.51 mg, 2.06 µmol). Then, a solution of the relevant alkyne precursor 81 or 83 (1.00 – 
1.30 mg) in DMF or DMSO (50 µL) was added, followed by the addition of the distilled [18F]-2-
fluoroethylazide (< 20 mCi) in acetonitrile (30 – 100 µL). The mixture was stirred at room temperature 
or heated as appropriate. In reactions using BPDS ligand, a solution of BPDS (25 µL, 2.22 mg, 4.13 
µmol) in acetate buffer (250 mM, pH 5.0) was added to the Wheaton vial along with CuSO4 and 
sodium L-ascorbate solution. 
Reaction optimisation studies by analytical radio-HPLC: 10 µL samples of the reaction mixture were 
taken at time intervals, diluted with acetonitrile/water (1:1, 300 µL) and analysed by HPLC.  
Radio-product isolation and formulation by SPE: The reaction mixture was diluted with 
acetonitrile/water (1:1, 1.5 mL) and the resulting mixture was purified by prep radio-HPLC. The 
isolated HPLC fraction was diluted with water (5 mL) and loaded onto a SepPak C-18 cartridge, pre-
conditioned with ethanol (5 mL) and water (10 mL). The loaded cartridge was flushed with water (5 
mL) and the product was eluted with ethanol (4 x 100 µL fractions). 
Direct radiolabelling with [18F]fluoride  
To a Wheaton vial containing K222 (~ 7.0 mg), K2CO3 (0.05 mL aqueous solution, 1.0 mg) and 
acetonitrile (0.6 mL), was added an aqueous solution of [18F]fluoride (50 – 100 µL, < 20 mCi). The 
mixture was dried by azeotropic distillation using acetonitrile (3 x 0.6 mL). Subsequently, a solution 
of tosylate 84 (1.0 - 1.3 mg) in acetonitrile (0.2 mL) was added to the vial and the resulting mixture 
was heated at 110 - 120 oC for 15 minutes to give the intermediate [18F]97. Acetonitrile was then 
removed by distillation, followed by the addition of HCl (5M, 0.3 mL) and heating at 110 - 120 oC for 
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a further 20 minutes. The reaction mixture was then transferred into a vial containing aqueous PBS 
buffer (0.4 mL) and diluted with 3M aqueous NaOAc solution (0.6 mL). Then, the mixture was further 
diluted with water (10 mL) and loaded onto a SepPak C18 cartridge conditioned with ethanol (5 mL) 
and water (10 mL). The cartridge was washed with water (20 mL) and eluted with ethanol (0.6 mL). 
The crude mixture was subsequently diluted with water (0.6 mL) prior to HPLC prep purification to 
give the radio product [18F]62. 
Biological Characterisations 
a) Caspase Enzyme Inhibition Assayf  
The affinities of pyrimidoindolone 62 and isatin sulfonamide 22 for activated caspases 3 and 8 were 
measured by a fluorimetric in vitro caspase inhibition assay. Inhibition of recombinant human 
caspases was assessed by measuring the accumulation of a fluorogenic product, 7-amino-4-
methylcoumarin (7-AMC). The results are summarized in Table 3.12 (Chapter III). The data are the 
average for two runs, each done in duplicate at 9 concentrations ranging from 5 pM to 500 μM and 
at 4 time intervals (15 min, 30 min, 60 min and 90 min). The drug concentration required to inhibit 
each enzyme by 50 % (IC50) was obtained from nonlinear regression analysis of the inhibition profiles.  
b) In Vitro Cell Uptake of [18F]-Pyrimidoindolone 62 and Caspase Activation Assayg  
38C13 Cells were plated in triplicate in 12-well plates, 2 or 3 days before the experiments and treated 
with either 4-HC (3 µg/mL), PAC-1 (10 µM) or vehicle (0.1 % DMSO) for 24 hrs to induce apoptosis. 
On the day of the experiment, ∼10 µCi/well of [18F]-pyrimidoindolone 62 was added and allowed to 
accumulate into cells for 60 mins at 37 ᴼC. Cells were collected, washed, and re-suspended in 400 µL 
of PBS. Then 260 µL of each sample was transferred into counting tubes and [18F]fluoride radioactivity 
was immediately determined using a Packard Cobra II gamma counter (Perkin-Elmer, UK). BCA 
Protein assay (Pierce, UK) was performed for all samples and data were normalized and expressed as 
counts/mg of protein. 
                                                          
f Caspase enzyme inhibition assay was conducted by Dr. Quang-De Nguyen 
g In vitro cell uptake of [18F]-Pyrimidoindolone 62 and caspase activation assay were conducted by Dr. Quang-De 
Nguyen 
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c) In Vivo Biodistributionh and Metabolism Studies  
The radiation-induced murine ﬁbrosarcoma (RIF-1) tumour cells  were maintained in RPMI 1640 
medium (Invitrogen Ltd., Paisley, UK), supplemented with 10 % fetal calf serum (BioWhittaker Europe 
Ltd., Verviers, Belgium), 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 
µg/mL fungizone (Gibco, UK) at 37 ᴼC in a humidiﬁed incubator with 5 % CO2. All animal work was 
done by licensed investigators in accordance with the United Kingdom’s “Guidance on the Operation 
of Animals (Scientiﬁc Procedures) Act 1986” (HMSO, London, United Kingdom, 1990) and in full 
compliance with government regulations and guidelines on the welfare of animals in experimental 
neoplasia. Tumours were established in mice by subcutaneous injection of 5 × 105 cells on the back 
of male C3H/hej mice (Harlan, Bicester, Oxfordshire, UK). Tumour growth was monitored every two 
days using electronic calipers, and tumour volume, estimated using the equation (π/6) × L × W × D; 
(L) length, (W) width and (D) depth. Animals were selected for biodistribution studies of [18F]-
pyrimidoindolone 62 when the tumours reached ∼100 - 150 mm3. Mice were injected intravenously 
via the lateral vein with 0.08 - 0.13 mL of radioactivity dissolved in phosphate buffered saline. At 60 
minutes after injection, mice were sacriﬁced by exsanguination via cardiac puncture under general 
anaesthesia (isoﬂuorane inhalation). Aliquots of heparinized blood were rapidly centrifuged (2000 g 
for 5 mins) to obtain plasma. The radioactivity contained in tissues was determined by gamma 
counting on a Cobra II Auto-Gamma counter (Packard Instruments, Meriden, CTA) and expressed as 
a percentage of injected dose per gram of tissue (% ID/g). A minimum of two mice were used for each 
time point. All animals were treatment-naıve. 
HPLC Analysis of Metabolism. Plasma, liver, and urine samples from the animals were snap frozen in 
liquid nitrogen and kept in pre-weighed scintillation counting tubes on dry ice. Immediately prior to 
extraction, the samples were thawed and placed on ice. For extraction, ice cold acetonitrile (1.5 mL) 
was added to each sample. Each mixture was centrifuged (4 ᴼC, 3 min) and the resulting supernatant 
was evaporated in vacuo at 40 ᴼC. Liver samples were homogenized with ice cold acetonitrile (1.5 
mL) using an IKA Ultra-Turrax T-25 homogenizer prior to centrifugation. The residues, following rotary 
evaporation were then re-suspended in HPLC mobile phase (1.2 mL) and ﬁltered through a Minisart 
hydrophilic syringe ﬁlter (0.2 µm) (Sartorius, Goettingen, Germany). Urine samples were diluted with 
                                                          
h In vivo biodistribution studies were conducted by Dr Quang-De Nguyen 
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HPLC mobile phase and ﬁltered as above. The plasma, urine and liver samples (1 mL) were then 
analysed by radio-HPLC on an Agilent 1100 series HPLC system (Agilent Technologies, Stockport, UK) 
equipped with a γ-RAM model 3 gamma-detector (IN/US Systems Inc., Florida) and the Laura 
software. The stationary phase comprised of a of a Phenomenex C18 reverse-phase column (250 mm 
× 10 mm), using a mobile phase comprising of 0.1 M ammonium formate /ethanol (45:55) running in 
isocratic mode at a ﬂow rate of 3 mL/min.  
d) Transwell Assayi, 136 
Caco-2 cells were seeded on to cell culture chambers (transwells) for 21 days, with the media changed 
every other day. The transepithelial electric resistance was measured using an epithelial 
voltohmmeter equipped with an STX2 electrode (World Precision Instruments, Sarasota, Florida), and 
it was veriﬁed to be >300 Ω/cm2 prior to all experiments.  
The assay was started by replacing the culture medium with HBSS containing 1 μM of probe under 
study. The plates were placed on an orbital shaker (60 rpm) during the experiment. After 2 hrs, a 
volume of 10 μL of each chamber was collected for analysis by LCMS. The permeability of a test 
compound was deﬁned by the following equation: 
Papp = (dQ/dt)/ AC0  
Where A is the surface area of the transwell membrane; C0 is the molar drug concentration in the 
donor chamber at time, and dQ/dt is the rate of transfer of the compound to the receiver chamber, 
determined from the slope of the graph concentration (dQ) versus time (dt). 
It has been established that if a compound exerts a ratio between the secretion (permeability from 
the basal to the apical side (Papp B→A)) and the absorption (permeability from the apical to the basal 
side (Papp A→B)) of greater than 3, it can be considered as being actively efﬂuxed.140 ‘Normal’ 
diffusion, where the compound is at equilibrium between the apical and basal side gives a 
secretion/absorption ratio of approximately one.140 
At the end of the assay, the integrity of the monolayer was veriﬁed by measuring the amount of 
lucifer yellow, a ﬂuorophore which passes through the membrane, measured using a plate reader 
                                                          
i Transwell assay conducted by Dr Maciej Kaliszczak  
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(Wallac EnVision reader, PerkinElmer, Massachusetts) and veriﬁed to be < 2 % of the concentration 
in the donor chamber.214 The integrity of the monolayer was assessed post-drug transport as lucifer 
yellow may interfere with LCMS analysis. 
Statistical Analysis: The significance of comparison between two data sets for isatin 22 and 
pyrimidoindolone 62 was determined using Student's t test (Prism v5.0 software, Graph Pad), defined 
as significant (*, 0.01 < P < 0.05), very significant (**, 0.001 < P < 0.01), and extremely significant 
(***, P < 0.001). 
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Appendix 1: Gaussian Data Output from Computational Modelling of the 
Heterocycles 
52 53
Imidazoleindolone Traizoleindolone
57
Pyrimidoindolone
N
O
O
Me
41
Isatin
The heterocycles used for computational studies
N
N
O
N
N
N
O
N
N
O
58
Br-imidazoleindolone
N
N
O
Br
 
wB97xD 
 
Energies (Hartree) Energies (kJ/mol) 
H-bonding 
Distance (Å) Reactants TS Product G(TS) - G(React) ΔG 
G(TS) - 
G(Prod) 
41 -951.495666 -951.437916 -951.497073 151.622625 -3.6940785 155.3167 2.668 
57 -1243.465737 -1243.40365 -1243.462976 163.0094185 7.2490055 155.7604 2.334 
52 -1007.771542 -1007.709685 -1007.768559 162.4055535 7.8318665 154.5737 2.866 
53 -1023.804593 -1023.739291 -1023.804206 171.450401 1.0160685 170.4343 3.097 
58 -3579.080569 -3579.01554 -3579.076638 170.7336395 10.3208405 160.4128 2.854 
 
M062X 
 
Energies (Hartree) Energies (kJ/mol) 
H-bonding 
Distance (Å) Reactants TS Product G(TS) - G(React) ΔG 
G(TS) - 
G(Prod) 
41 -951.428277 -951.374542 -951.435412 141.0812425 -18.7329425 159.8142 2.506 
57 -1243.339854 -1243.286934 -1243.343562 138.94146 -9.735354 148.6768 2.315 
52 -1007.70608 -1007.647321 -1007.707874 154.2717545 -4.710147 158.9819 3.03 
53 -1023.74193 -1023.679979 -1023.746657 162.6523505 -12.4107385 175.0631 3.132 
58 -3579.062549 -3579.004253 -3579.066745 153.056148 -11.016598 164.0727 3.039 
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Appendix 2: UV-Vis Absorption Data 
 
Table 1: Changes in isatin 41 absorption at 426 nm: 2mM isatin titrated with aliquots of PMBSH of known 
concentrations 
[Thiol] / (mM) 
Isatin 41 Absorption  
n = 1 n=2 A (average) ΔA  
0 1.2 1.2087 1.206 0 
1.99 0.86 0.87667 0.87 0.336 
3.97 0.66 0.67126 0.666 0.54 
5.94 0.54 0.54875 0.542 0.664 
7.89 0.45 0.45838 0.453 0.753 
9.84 0.38 0.38956 0.385 0.821 
11.76 0.33 0.33992 0.336 0.87 
13.68 0.3 0.30033 0.299 0.907 
15.58 0.27 0.26859 0.269 0.937 
17.48 0.24 0.24589 0.245 0.961 
19.35 0.23 0.22517 0.226 0.98 
 
Table 2: Changes in imidazoleindolone 52 absorption at 392nm: 2mM imidazoleindolone titrated with 
aliquots of PMBSH of known concentrations 
[Thiol] / (mM) 
Imidazoleindolone 52 Absorption  
n = 1 n = 2 A (average) ΔA 
0 1.301 1.3007 1.30085 0 
3.97 1.2955 1.2896 1.29255 0.0083 
5.94 1.2951 1.288 1.288 0.01285 
7.89 1.2914 1.2853 1.285 0.01585 
9.84 1.2851 1.2807 1.2807 0.02015 
11.76 1.2804 1.2763 1.2763 0.02455 
13.68 1.2743 1.2719 1.2731 0.02775 
15.58 1.2693 1.2668 1.26805 0.0328 
17.48 1.2646 1.2635 1.26405 0.0368 
19.35 1.2586 1.2583 1.2584 0.04245 
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Table 3: Changes in pyrimidoindolone 57 absorption at 461 nm: 1mM ketone titrated with aliquots of 
PMBSH solutions of known concentrations 
[Thiol] / (mM) 
Pyrimidoindolone 57 Absorption 
n = 1 ΔA 
0 2.1384 0 
0.995 2.1235 0.0149 
1.985 2.1137 0.0247 
2.97 2.1008 0.0376 
3.945 2.0888 0.0496 
4.92 2.0779 0.0605 
5.88 2.0641 0.0743 
6.84 2.0512 0.0872 
7.79 2.0362 0.1022 
8.74 2.0144 0.124 
9.675 1.9988 0.1396 
 
Table 4: Changes in Br-imidazoleindolone 58 absorption at 394.7 nm: 2mM ketone titrated with aliquots of 
PMBSH and of known concentrations 
[Thiol] / (mM) 
Imidazoleindolone 58 Absorption 
n = 1 n = 2 A (average) ΔA 
0 1.1762 1.1832 1.1797 0 
1.99 1.1706 1.1672 1.1689 0.0108 
3.97 1.1611 1.1589 1.16 0.0197 
5.94 1.1505 1.1477 1.1491 0.0306 
7.89 1.1403 1.1383 1.1393 0.0404 
9.84 1.1289 1.128 1.12845 0.05125 
11.76 1.1205 1.1185 1.1195 0.0602 
13.68 1.1099 1.1091 1.1095 0.0702 
15.58 - 1.1009 1.1009 0.0788 
17.48 1.0924 1.0913 1.09185 0.08785 
19.35 1.0799 1.0817 1.0808 0.0989 
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Table 5: Changes in Br-imidazoleindolone 59 absorption at 400.8 nm: 2mM ketone titrated with aliquots of 
PMBSH solutions of known concentrations 
[Thiol] / (mM) Imidazoleindolone 59 Absorption 
 n = 1 ΔA 
0 1.54 0 
1.99 1.53 0.01 
3.97 1.5237 0.0163 
5.94 1.5168 0.0232 
7.89 1.506 0.034 
9.84 1.494 0.046 
11.76 1.4829 0.0571 
13.68 1.4701 0.0699 
15.58 1.4577 0.0823 
17.48 1.4455 0.0945 
19.35 1.4323 0.1077 
 
Table 6: Changes in sulfonamide-imidazoleindolone 60 absorption at 392.5 nm: 1mM ketone titrated with 
aliquots of PMBSH solutions of known concentrations 
[Thiol] / (mM) 
Imidazoleindolone 60 Absorption 
n = 1 ΔA 
0 0.7405 0 
0.995 0.73792 0.00258 
1.985 0.73557 0.00493 
2.97 0.73396 0.00654 
3.945 0.73157 0.00893 
4.92 0.72937 0.01113 
5.88 0.72745 0.01305 
6.84 0.7245 0.016 
7.79 0.72301 0.01749 
8.74 0.72097 0.01953 
9.675 0.71814 0.02236 
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Appendix 3: Crystal Data and Structure Refinement for the Ketal Protected 
Triazoleindolone 212j 
 
Figure 1: The determined regiochemistry of the ketal-protected triazoleindolone 212 
Initial tests were used to identify the atoms in the C(1)-based five membered-ring. The table below 
lists atoms 2 to 5 and each line specifies whether each atom was modelled as either carbon or 
nitrogen, with the resulting R-factor obtained from model refinement. The lower the R-factor, the 
more optimal the arrangement. 
Table 1: Modelling the favourable spatial distribution of the carbon and nitrogen atoms 
2 3 4 5 R-factor 
C C C C 7.56 
N C C C 6.96 
C N C C 7.05 
C C N C 8.23 
C C C N 7.19 
N N C N 5.62* 
N N N N 6.22 
                                                          
j The crystallography experiment was conducted by Dr Andrew J.P. White, Chemical Crystallography Laboratory, 
Department of Chemistry, Imperial College London. 
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The top line with all four atoms modelled as carbon serves as the baseline. The next four lines make 
it clear that the atoms at positions 2, 3 and 5 work better as nitrogen than carbon, and that the atom 
at position 4 works better as carbon than nitrogen. The penultimate line shows the clear 
improvement in the structure when all of the four atoms are modelled correctly, and the last line was 
a check that the four nitrogen model was not optimal. Hence, it was concluded that 2, 3 and 5 are 
nitrogen atoms and 4 is a carbon. Subsequently hydrogen atoms on C(4) and N(3) were located from 
difference electron density maps.  
 
Crystal Analysis Data  
Temperature 173 K 
Diffractometer, wavelength OD Xcalibur 3, 0.71073 Å 
Crystal system, space group Monoclinic, C2/c 
Unit cell dimensions a = 13.9404(6) Å  = 90° 
 b = 7.3853(3) Å  = 93.511(4)° 
 c = 20.7391(10) Å  = 90° 
Volume, Z 2131.17(16) Å3, 8 
Density (calculated) 1.556 Mg/m3 
Absorption coefficient 0.350 mm-1 
F(000) 1024 
Crystal colour / morphology Colourless tabular needles 
Crystal size 0.49 x 0.28 x 0.09 mm3 
 range for data collection 3.43 to 32.65° 
Index ranges -20<=h<=19, -5<=k<=11, -31<=l<=29 
Reflns collected / unique 11813 / 3618 [R(int) = 0.0276] 
Reflns observed [F>4(F)] 2831 
Absorption correction Analytical 
Max. and min. transmission 0.972 and 0.863 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3618 / 0 / 154 
Goodness-of-fit on F2 1.092 
Final R indices [F>4(F)] R1 = 0.0532, wR2 = 0.1122 
R indices (all data) R1 = 0.0723, wR2 = 0.1203 
Largest diff. peak, hole 0.354, -0.306 eÅ-3 
Mean and maximum shift/error 0.000 and 0.001 
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Table 2:  of Bond lengths [Å] and angles (°) for the ketal-protected triazoleindolone 212 
C(1)-N(5) 1.322(2) 
C(1)-N(2) 1.339(2) 
C(1)-C(6) 1.524(2) 
N(2)-N(3) 1.351(2) 
N(2)-C(12) 1.415(2) 
N(3)-C(4) 1.327(3) 
C(4)-N(5) 1.375(3) 
C(6)-O(7) 1.404(2) 
C(6)-O(10) 1.420(2) 
C(6)-C(11) 1.532(2) 
O(7)-C(8) 1.446(2) 
C(8)-C(9) 1.502(3) 
C(9)-O(10) 1.438(2) 
C(11)-C(16) 1.382(2) 
C(11)-C(12) 1.397(2) 
C(12)-C(13) 1.372(2) 
C(13)-C(14) 1.398(3) 
C(14)-C(15) 1.380(3) 
C(15)-C(16) 1.399(2) 
C(15)-Cl(1) 1.7411(18) 
 
N(5)-C(1)-N(2) 110.17(15) 
N(5)-C(1)-C(6) 139.86(16) 
N(2)-C(1)-C(6) 109.85(14) 
C(1)-N(2)-N(3) 111.69(14) 
C(1)-N(2)-C(12) 112.57(14) 
N(3)-N(2)-C(12) 135.22(15) 
C(4)-N(3)-N(2) 100.43(15) 
N(3)-C(4)-N(5) 116.30(17) 
C(1)-N(5)-C(4) 101.41(15) 
O(7)-C(6)-O(10) 107.08(13) 
O(7)-C(6)-C(1) 112.44(14) 
O(10)-C(6)-C(1) 111.99(14) 
O(7)-C(6)-C(11) 112.87(14) 
O(10)-C(6)-C(11) 112.49(13) 
C(1)-C(6)-C(11) 100.03(13) 
C(6)-O(7)-C(8) 103.55(14) 
O(7)-C(8)-C(9) 102.12(15) 
O(10)-C(9)-C(8) 103.75(15) 
C(6)-O(10)-C(9) 107.55(14) 
C(16)-C(11)-C(12) 119.91(15) 
C(16)-C(11)-C(6) 129.80(15) 
C(12)-C(11)-C(6) 110.28(14) 
C(13)-C(12)-C(11) 123.48(16) 
C(13)-C(12)-N(2) 129.42(16) 
C(11)-C(12)-N(2) 107.07(14) 
C(12)-C(13)-C(14) 116.68(16) 
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C(15)-C(14)-C(13) 120.29(16) 
C(14)-C(15)-C(16) 122.88(16) 
C(14)-C(15)-Cl(1) 118.46(13) 
C(16)-C(15)-Cl(1) 118.65(14) 
C(11)-C(16)-C(15) 116.76(16) 
 
